

# **Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation: The VENUS trial**

Miguel Valderrábano,<sup>1</sup> MD, Leif E. Peterson,<sup>1</sup> PhD, Vijay Swarup, MD,<sup>2</sup> Paul A. Schurmann,<sup>1,3</sup> MD, Akash Makkar,<sup>2</sup> MD, Rahul N Doshi,<sup>4</sup> MD, David DeLurgio,<sup>5</sup> MD, Charles A Athill,<sup>6</sup> MD, Kenneth A. Ellenbogen,<sup>7</sup> MD, Andrea Natale,<sup>8</sup> MD, Jayanthi Koneru,<sup>7</sup> MD, Amish S. Dave,<sup>1</sup> MD, PhD, Irakli Giorgberidze,<sup>3</sup> MD, Hamid Afshar,<sup>3</sup> MD, Michelle L. Guthrie,<sup>1</sup> RN, Raquel Bunge,<sup>1</sup> RN, Carlos A. Morillo,<sup>9</sup> MD, Neal S. Kleiman,<sup>1</sup> MD

<sup>1</sup>Houston Methodist DeBakey Heart and Vascular Center and Research Institute, Houston, TX

<sup>2</sup>Arizona Heart Rhythm Center, Phoenix, AZ

<sup>3</sup>Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX

<sup>4</sup>Keck-USC University Hospital, University of Southern California, Los Angeles, CA

<sup>5</sup>Emory St. Joseph's Hospital, Emory University, Atlanta, GA

<sup>6</sup>Sharp Memorial Hospital, San Diego, CA

<sup>7</sup>Virginia Commonwealth University School of Medicine, Richmond, VA

<sup>8</sup>Texas Cardiac Arrhythmia Institute, St David's Medical Center, Austin, TX

<sup>9</sup>Libin Cardiovascular Institute, University of Calgary, Calgary, Canada

## **SUPPLEMENTARY APPENDIX**

<b>Table of Contents</b>	<b>Page 1.</b>
<b>Original Protocol</b>	<b>Page 2.</b>
<b>Final Protocol (version 7)</b>	<b>Page 33.</b>
<b>Summary of Protocol Changes</b>	<b>Page 96.</b>
<b>Original Statistical Plan</b>	<b>Page 101.</b>
<b>Final Statistical Plan</b>	<b>Page 106.</b>
<b>Summary of Statistical Plan Changes</b>	<b>Page 139.</b>

# **Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation Clinical Protocol**

**July 2012  
Version 1.0**

Sponsor: The Methodist Hospital Research Institute  
6565 Fannin Street  
Houston, TX 77030

Principal Investigator: Miguel Valderrábano, MD

**Contents**

**1.0 Introduction & Significance** ..... 4

**2.0 Innovation**

    2.1 Targeting the intrinsic cardiac ganglia via the VOM ..... 6

    2.2 VOM ethanol infusion: technique ..... 7

    2.3 Unveiling of an LA venous plexus ..... 8

    2.4 VOM ethanol infusion: tissue ablation and left PV disconnection ..... 8

    2.5 VOM ethanol infusion: a novel technique for local vagal denervation ..... 8

    2.6 VOM ethanol infusion and perimitral flutter ..... 9

    2.7 Role of VOM in failed ablations ..... 9

**3.0 Trial Overview and Preliminary Data** ..... 9

**4.0 Clinical Protocol: Specific Aim 1**

    4.1 Inclusion/Exclusion Criteria ..... 10

    4.2 Primary and secondary endpoints ..... 10

    4.3 Study procedures ..... 10

        1. Initial assessment ..... 10

        2. Pre-procedural Imaging ..... 10

        3. Randomization ..... 10

        4. PVAI procedure ..... 11

        5. VOM procedure ..... 11

        6. Post ablation 3D voltage amplitude maps ..... 11

    4.4 Procedural data collection ..... 12

    4.5 Follow-up ..... 12

    4.6 Recurrences ..... 12

    4.7 Statistical Considerations ..... 13

**5.0 Study Administration**

    7.1 Patient recruitment ..... 18

    7.2 Core laboratories ..... 18

    7.3 Safety considerations ..... 18

    7.4 Adverse Event Reporting ..... 19

    7.5 Data safety monitoring board ..... 20

    7.6 Study administration ..... 21

**6.0 Timeline** ..... 18

**7.0 Literature Cited** ..... 19

## 1.0 INTRODUCTION

Atrial fibrillation (AF)\* is the most common sustained arrhythmia in adults, and is a leading cause of stroke, disability and increased mortality.<sup>1</sup> Catheter ablation has become an increasingly accepted form of rhythm control and –other than surgery- is the only treatment form that can potentially cure AF. The ablation procedural strategy –pulmonary vein (PV) antral isolation (PVAI)- is best suited for paroxysmal AF,<sup>2</sup> in which ectopic beats arising from the PVs were shown to initiate AF.<sup>3</sup> However, it is unclear whether this mechanistic rationale applies to persistent AF,<sup>4, 5</sup> in which the role of the cardiac autonomic system, particularly the intrinsic cardiac ganglia, is being increasingly recognized as a modulator of atrial physiology leading to AF.<sup>6, 7</sup> The success of PVAI is significantly lower in persistent AF.<sup>8</sup> Expanding the ablation lesions to include larger areas of the atrial anatomy –such as the left atrial (LA) roof, coronary sinus (CS), LA appendage, septum, posterior wall, superior vena cava, and others- has improved outcomes, but also led to increases in procedural complexity and duration, need of repeat procedures,<sup>9-12</sup> and complications such as atrial flutters, particularly perimitral flutter (PMF).<sup>13</sup> Little mechanistic evidence supports this approach, which does not specifically address the intrinsic cardiac ganglia. Given that persistent AF has far greater prevalence and is a greater cause of stroke, disability and mortality than paroxysmal AF,<sup>14</sup> strategies to improve outcomes of catheter ablation of persistent AF are much needed.

We have developed a technique to perform rapid ablation of targeted atrial tissues in AF using ethanol infusion in the vein of Marshall (VOM).<sup>15, 16</sup> A previous R21 project has generated sufficient human data to support the safety and mechanistic utility of this technique by showing: 1) Effective, rapid and safe tissue ablation of LA tissue neighboring the LA ridge and left inferior PV; 2) Facilitation of cure of PMF by ablating most of the mitral isthmus; and 3) Regional LA vagal denervation. The broad, long term objective is to improve the outcomes of catheter ablation of persistent AF using the VOM as a target and a route to deliver ablative therapies. Accordingly, the specific aims are:

## SIGNIFICANCE

### ***AF as a clinical and health care problem***

AF is the most common arrhythmia in the United States,<sup>1</sup> and is associated with significant morbidity and mortality, including up to 5-fold increased risk of stroke,<sup>17, 18</sup> 2-fold increased risk of dementia,<sup>19-21</sup> a 3-fold increased risk of heart failure<sup>18</sup> and a 40 to 90% increased risk of overall mortality.<sup>22</sup> Although the risk of stroke is comparable in persistent and paroxysmal AF,<sup>23</sup> the prevalence of persistent AF increases dramatically with increasing age,<sup>24, 25</sup> and thus is an overall more significant cause of morbidity and mortality. In the United States, there are currently an estimated 3.0 million adults with AF,<sup>26</sup> and this number is expected to double in the next 25 years.<sup>27</sup> Hospitalizations with a primary diagnosis of AF are close to half a million per year,<sup>28</sup> which generates a tremendous economic burden on the health care system. When compared to health care costs of non-AF control subjects, patients with AF have greater annual healthcare costs (up to \$8705 total annual incremental cost). On the basis of current prevalence data, it is estimated that AF leads to a national incremental health care cost of up to \$26 billion.<sup>29</sup>

### ***Inadequacy of pharmacological treatment options for persistent AF***

Management strategies are directed at heart rate control and stroke prevention –mere palliation- or at rhythm control. It has been shown that rhythm control strategies using antiarrhythmic drugs offer no benefit in elderly patients<sup>30</sup> or patients with heart failure.<sup>31</sup> Most of the lack of benefit of such rhythm control strategy is thought to be due to the adverse effects and suboptimal efficacy of antiarrhythmic drugs, that can potentially augment mortality.<sup>32</sup> Indeed, preservation of normal sinus rhythm is associated with decreased mortality.<sup>32</sup> Dronedarone, the only antiarrhythmic drug shown to improve outcomes in nonpermanent AF compared to placebo,<sup>33</sup> has been shown to double mortality, stroke and hospitalization for heart failure in the PALLAS study in patients with permanent AF (prematurely terminated: [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and [www.theheart.org/article/1264551.do](http://www.theheart.org/article/1264551.do)). Thus, antiarrhythmic drugs remain suboptimal at best for the treatment of AF.

### ***Shortcomings of catheter ablation of persistent AF***

*Weak mechanistic rationale.* Isolation of the PVs<sup>2</sup> and adjacent LA (PV antrum)<sup>34, 35</sup> is the accepted procedural

\* Abbreviations used: 3D: 3-dimensional; AF: atrial fibrillation; CFAE: complex fractionated atrial electrograms; CS: coronary sinus; LA: left atrium; PMF: perimitral flutter; PV: pulmonary vein; PVAI: PV antral isolation; RF: radiofrequency; VOM: vein of Marshall; VOM-PV: combined VOM ethanol infusion plus PVAI

endpoint, based on the mechanistic concept that atrial extrasystoles arising from the PVs initiate *paroxysmal* AF.<sup>3</sup> Other, non-PV triggers have been demonstrated.<sup>36</sup> The link between PV extrasystoles and AF is clear in paroxysmal AF, but not in persistent AF, in which the mechanisms of AF seem to be related more to a chronic atrial substrate than to acute triggers.<sup>4</sup> Indeed, intramural reentry in the posterior LA seems to be particularly relevant in chronic models of AF.<sup>37</sup> In persistent AF, the procedure has evolved, rather simplistically, to include additional lesions -besides isolation of the PVs,<sup>11, 38-40</sup> variably placed in the posterior wall,<sup>34</sup> LA roof,<sup>41, 42</sup> and towards the mitral annulus,<sup>43</sup> the superior vena cava,<sup>44</sup> left atrial appendage,<sup>45, 46</sup> and other areas where complex fractionated atrial electrograms (CFAE) may be mapped.<sup>13, 47</sup> This brute force approach of simply destroying more tissue has yielded additional success, but new procedural targets with solid mechanistic bases are needed.

*Suboptimal success and need for repeat procedures.* Despite the additional tissue destruction, ablation success in persistent AF is with much lower than in paroxysmal AF,<sup>48</sup> with single procedure success reported as low as 27%,<sup>40</sup> 36%,<sup>49</sup> or 49%,<sup>50</sup> but up to 61%<sup>13</sup> or 67%,<sup>51</sup> depending on study heterogeneities in: definitions of persistent AF and of recurrence of AF, the type of AF monitoring, and ablation technique and operator experience. In order to achieve overall acceptable success rates, (which can reach up to 79%-94%),<sup>13, 40, 51</sup> there is a consistent need for repeat procedures (sometimes up to 4) and the concomitant use of antiarrhythmic drugs. The rate of repeat procedures in experienced centers can reach up to 70 to 80%.<sup>9-12</sup>


*PMF after catheter ablation of persistent AF.* Clinical failures of a first ablation procedure are caused, in a significant portion of patients, by atrial flutters,<sup>52-54</sup> rather than recurrent AF, and recurrence as flutter portends a greater chance of success in a second procedure.<sup>55</sup> Such atrial flutters may be caused by perimitral reentry in up to 33-60% of the patients.<sup>52, 54-56</sup> Catheter ablation of PMF involves the creation of a linear lesion from the mitral annulus to the left inferior PV (the so-called mitral isthmus).<sup>43, 57</sup> Achieving a complete ablation (defined by bidirectional conduction block across the ablation line) can be very difficult,<sup>10, 43, 58</sup> with success rates reported as 32%,<sup>59</sup> 64%,<sup>60</sup> or 71%.<sup>61</sup> It sometimes requires ablation inside the CS,<sup>54, 56</sup> in close proximity to the circumflex coronary artery, which could be damaged.<sup>60</sup> Of note, incomplete ablation of the mitral isthmus is proarrhythmogenic,<sup>62, 63</sup> increasing the risk of recurrent flutter by up to 4 times.<sup>62</sup>

**2.0 INNOVATION**


The basis of this application is an entirely novel technique that was developed in our laboratory from its original conception, to its validation in animals,<sup>15</sup> to the demonstration of safety and feasibility in humans.<sup>16</sup> Ethanol is used in hypertrophic cardiomyopathy,<sup>64</sup> and in ventricular tachycardias that do not respond to conventional RF ablation.<sup>65</sup> When delivered in the VOM, we have shown that ethanol can help ablate neighboring atrial tissues, all of which are routinely targeted during conventional ablation.<sup>15</sup> Supported by an R21 grant that started in July 2010, significant human pilot data have been acquired that lend further support to the mechanistic rationale, safety, and potential clinical utility of this technique.

**2.1 Targeting the intrinsic cardiac ganglia via the VOM**

The role of autonomic regulation in AF is highly relevant.<sup>66</sup> The cardiac autonomic system (Figure 1) can be divided into *extrinsic cardiac nerves*—vagus nerves and sympathetic chain—, and an *intrinsic cardiac ganglia* (a complex atrial epicardial network of ganglionated plexi with vagal and sympathetic nerves, including the ligament of Marshall). The intrinsic cardiac ganglia contain parasympathetic ganglia and its sympathetic nerves are only postganglionic.<sup>67</sup> These ganglia are not simple relay stations, but process multiple inputs from vagal efferent neurons, extrinsic sympathetic neurons, vagal afferent neurons, and sensory neurons.<sup>67-73</sup> Acetylcholine release by postganglionic neurons exerts effects on myocytes via muscarinic receptors and *I<sub>KAch</sub>* channels, which shorten the action potential, allowing myocytes to sustain rapid activation rates (shorten refractoriness) and favoring the formation of rotors in AF.<sup>75</sup> Sympathetic innervation (norepinephrine) leads to enhanced automaticity, increased intracellular calcium and favors afterdepolarizations<sup>76-78</sup> that create extrasystoles that can initiate AF,<sup>77</sup> and destabilize rotors.<sup>75, 79</sup> Thus, a synergistic pro-AF effect can occur if both parasympathetic influences (shortening the action potential and refractoriness) and sympathetic influences (leading to extrasystoles via afterdepolarizations) activate simultaneously. Indeed, combined simultaneous sympathetic and parasympathetic discharges lead to AF.<sup>6</sup> Sympathovagal (stellate ganglion and vagus nerve) cryoablation of the *extrinsic cardiac nerves* eliminates paroxysmal AF episodes in a rapid atrial pacing model, but does not prevent the ultimate development of persistent AF.<sup>6</sup> The intrinsic cardiac autonomic system shows enhanced activity preceding AF, independent of the extrinsic system, that can play a role in developing persistent AF.<sup>7</sup> Translating this information into a modification of the ablation procedure to enhance its efficacy has proven difficult. Ablation of intrinsic autonomic ganglia has been proposed,<sup>80</sup> but the strategy has been RF ablation of the LA at locations where ganglia were identified as sites where bradycardic reflexes are triggered during high-frequency stimulation. Disappointingly, this approach has not been shown to add significant clinical benefit beyond PVAI.<sup>81-83</sup> Identification of vagal ganglia by finding bradycardic reflexes has not been shown to be more effective than simply using a standardized



**Figure 1.** Autonomic cardiac nerves. Inputs from the vagus (cholinergic nicotinic, ACh(N)), the sympathetic chain (using norepinephrine, NE) and from sensory neurons and interneurons (other neuromodulators, see text) are processed by intrinsic cardiac ganglia. Atrial myocytes receive output from postganglionic neurons via cholinergic muscarinic (ACh(M) receptors), and from sympathetic postganglionic adrenergic innervation.



**Figure 2.** Lateral LA and VOM. A, Cut open left atrium with left PVs and lateral ridge. Red dotted line indicates location of commonly placed ablation lesions. B, Microscopic view of the lateral ridge, showing the VOM (inset). C, Epicardial view of the lateral ridge, with VOM. Modified from ref. 87.



anatomic approach,<sup>84</sup> or to decrease AF inducibility.<sup>83</sup> Possible reasons for the failure of vagal ganglia RF ablation to impact procedural outcomes include: inaccurate ganglia localization, inadequate elimination of vagal innervation, given their epicardial location, and inadequate elimination of sympathetic innervation (not localizable by high-frequency stimulation).

The ligament of Marshall is the embryologic remnant of the left cardinal vein (superior vena cava), which, as it becomes atretic during development,<sup>85</sup> remains open as the VOM.<sup>86</sup> This vein drains in the CS and runs


posteriorly and superiorly in the epicardial surface of the LA, towards the anterior aspect of the left-sided PVs, as part of a thick pectinate muscle that separates the veins from the LA appendage (left atrial ridge).<sup>87</sup> See Figure 2. The VOM has been robustly shown to contain

parasympathetic<sup>88</sup> and sympathetic<sup>89</sup> innervation,<sup>90</sup> and is *part of the intrinsic cardiac ganglia*.<sup>91</sup> The ligament of Marshall has been solidly implicated in arrhythmogenesis. As a *source of ectopic rhythms*, Scherlag et al<sup>92</sup> demonstrated an ectopic rhythm arising from the ligament area upon left cardiac sympathetic nerve stimulation. Doshi et al


demonstrated the role of the ligament of Marshall in adrenergic atrial tachycardia.<sup>93</sup> Hwang et al demonstrated ectopic beats from the VOM leading to AF,<sup>86, 94</sup> as confirmed by others.<sup>36, 95-99</sup> Focal ectopy arising in the VOM triggering AF has been demonstrated clinically<sup>36, 86</sup> and in experimental models of *persistent* AF.<sup>100</sup> High-frequency stimulation in the ligament of Marshall (without exciting the atrial myocardium) leads to induction of AF, and this induction is inhibited by both esmolol and atropine, suggesting autonomic mediation.<sup>101</sup> The VOM is present and can be cannulated in ~85% of patients,<sup>94</sup> and our data confirm that it is a *direct vascular route to the intrinsic cardiac ganglia that could be therapeutically utilized*.

**2.2 VOM ethanol infusion: technique**

We have refined the technique over the past 3 years. We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a ~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly. Contrast injections through the sub-selector catheter help identify the VOM and direct the catheter tip to the VOM ostium. Then, an angioplasty wire is inserted into the VOM, over which an angioplasty balloon is advanced distally into the VOM. Contrast injections through the angioplasty balloon help delineate the size and branching patterns of the VOM. Ethanol injections are then delivered (up to four injections of 1 cc over 2 minutes each), each at different levels of the VOM –from distal in the VOM, where the first injection is delivered, the balloon is retracted ~1 cm after each injection until the balloon reaches the VOM ostium or 4 injections are given. Figure 3 shows an example. In our experience to date, we have been able to perform successful cannulation of the VOM and to complete the



**Figure 3.** VOM cannulation technique and LA venous plexus. **A**, Contrast injection in the CS lumen through the sub-selector catheter with its tip close to the VOM, showing the VOM take-off and branching patterns outlined in **B**. **C**, selective venogram via an angioplasty balloon in a VOM branch. Collaterals fill LA veins in the LA roof (outlined in **D**).



**Figure 4.** Tissue ablation by VOM ethanol infusion. **A**, Contrast injection in the CS showing the VOM take-off. **B**, VOM cannulation with angioplasty balloon. Contrast is injected prior to ethanol. A circular catheter is placed in the left inferior PV (LIPV). **C-D**, Voltage maps (scar in red, of 7 cm<sup>2</sup>) of the left atrium pre- and post-ethanol. **E**, Signals from the LIPV during ethanol infusion, showing elimination of PV potentials (LASSO).

protocol of ethanol infusion in 89 of a total of 106 patients (85%). Our success rates in the last half of the patients versus the first half have been higher (90% vs 73%,  $p < 0.05$ ), suggesting that success is not only determined by anatomical factors (eg, size and tortuosity of the VOM), but also by operator experience.

**2.3 Unveiling of an LA venous plexus**


Our initial experience has confirmed that the VOM is a true atrial vein, communicating via capillaries with the LA myocardium, rather than a simple residual lumen of the ligament of Marshall, and thus the VOM is a viable route to deliver therapeutic agents in the LA. Additionally, with occlusive VOM venograms, we have found a heretofore-undescribed epicardial atrial venous plexus filled via collaterals (Figure 3).

**2.4 VOM ethanol infusion: tissue ablation and left PV disconnection**


The obvious effect of ethanol infusion is rapid ablation of atrial tissues in the vicinity of the VOM. Such areas are standard targets of ablation in persistent AF, and encompass the lateral ridge of the left atrium (which due its thickness can be difficult to ablate, see Figure 2), extending variably to areas around the left PVs, and towards the mitral annulus, including a large portion of the mitral isthmus. In our total experience of up to 89 cases, ethanol infusion can lead to isolation of the left inferior PV in up to 74% of the cases, and isolation of the left superior PV in 44% and generates an area of ablated tissue of  $9.7 \pm 4.8 \text{ cm}^2$ . Figure 4 shows an example.

**2.5 VOM ethanol infusion: a novel technique for local vagal denervation in humans**

The location of the VOM coincides with that of the left dorsal pathway of vagal innervation to the intrinsic cardiac ganglia<sup>102</sup> (Figure 5). In our recent experience we have shown that high-frequency stimulation (30 Hz, 25 mA) in the VOM can induce vagal reflexes reaching the AV node (causing transient AV node conduction blockade) in 75% of patients ( $n=32$ ) and inducing AF in 100%. Such responses are completely abolished in all patients after VOM ethanol infusion (Figure 5). Of note, because AF is consistently induced during high-frequency stimulation –due to direct left atrial capture–, vagal responses are only assessable by the presence of AV nodal block. Of the vagal plexi of the atria, it is the right inferior PV plexus that directly connects with the AV node.<sup>103</sup> The VOM is remote from the AV node, so inducing AV conduction slowing by VOM high-frequency stimulation supports VOM-to-right inferior PV plexus-to-AV node connection, and thus *supports that the VOM is a vascular route to the intrinsic cardiac ganglia* (see Figure 5A). Vagal responses



**Figure 5.** Vagal denervation by VOM ethanol infusion. **A**, Vagal innervation (histochemical staining) of the LA. Dotted line is the location of the VOM, coinciding with the left dorsal (LD) tract of vagal nerves, connected with neural plexi (insets). From indicated reference. **B**, VOM cannulation with a quadripolar catheter to perform high-frequency stimulation, indicated by the blue arrow in **C** and **D**, Electrograms during high-frequency stimulation in the VOM during on-going AF. Pre-ethanol infusion (**C**), atrioventricular block with asystole of 4.1 s is induced. Such response is abolished after ethanol infusion (**D**).



**Figure 6.** PMF treated by VOM ethanol infusion. **A**, Example of PMF (counterclockwise, colors represent time). **B**, Conventional ablation sites (blue dots) in the mitral isthmus to treat PMF. **C-F**, Examples of ethanol-induced scar maps (voltage colorscale) and locations of RF ablation lesions (arrowheads), required to achieve bidirectional mitral block.




were abolished in all patients in whom such responses were elicited at baseline, and AF induction by VOM high-frequency elimination was eliminated in all patients. Thus, VOM ethanol infusion is an effective strategy to achieve regional denervation of the human LA.<sup>104</sup>

**2.6 VOM ethanol infusion and perimitral flutter**

Due to the frequent incidence of PMF, the difficulties in achieving perimitral bidirectional conduction block to treat it, and the potential risk of damaging the left circumflex coronary artery with RF ablation, there is a clinical need for new treatment strategies. We have evaluated the effect of VOM ethanol infusion on perimitral conduction in 43 patients (25 of which had PMF mapped prior to ethanol delivery). Although VOM ethanol infusion by itself only led to bidirectional perimitral block in 3 patients, this was easily achieved with minimal RF ablation in the most anterior aspect of the mitral isthmus ( $2.5 \pm 1.3$  min), anterior to the scar created by ethanol, in 98% of patients.<sup>105</sup> Figure 6 shows examples. Considering the low success rate reported by RF ablation (32%<sup>59</sup>, 64%<sup>60</sup> or 71%<sup>61</sup>) –including epicardial ablation in the CS–, and the potential iatrogenic induction of recurrent flutters when bidirectional perimitral block is not achieved due to incomplete ablation, this novel technique promises to make a significant difference in the treatment of PMF.

**2.7 Role of VOM in failed ablations**

We have assessed the role of VOM activity in patients presenting for a repeat ablation procedure after a failed PVAI, as part of our R21 project. In 58 patients with recurrent AF, the VOM was cannulated in 51 and VOM signals were present in all of them, indicating that a *conventional PVAI procedure does not ablate VOM activity*. This was the case even in cases in which extensive LA ablation had been performed in the index procedure. Figure 7 shows an example that illustrates that, even with extensive LA ablation (that caused most of the LA endocardium to be scarred –without detectable electrograms) the VOM remains electrically active. Thus, as a novel catheter ablation technique, our preliminary mechanistic data in humans supports that VOM ethanol infusion provides rapid tissue ablation of targeted areas, helps treat PMF and achieves regional LA vagal denervation. The VOM is not otherwise ablated by conventional PVAI.



**Figure 7.** Lack of VOM ablation by PVAI. A patient with recurrent AF after an extensive PVAI underwent VOM ethanol infusion. **A**, intracardiac signals from the CS, VOM and the endocardium adjacent to the VOM (LASSO). Pre-ethanol infusion, large signals are recorded from the VOM (red arrows) that are abolished post-ethanol (\*). **B**, 3D Voltage amplitude map of LA endocardium, showing scar (red) specifically on the endocardial side of the VOM. **C**, Fluoroscopic catheter position.

**3.0 TRIAL OVERVIEW AND PRELIMINARY DATA**

**Overview of the clinical trial**

Our hypothesis is that a combined procedure of VOM ethanol infusion plus conventional PVAI (VOM-PV) is superior to PVAI alone in the catheter ablation treatment of persistent AF. We will compare the two treatments in a randomized fashion in 2 subsets of patients: *de novo* ablation, and repeat ablation (Figure 8). Given the extent of tissue ablation required, we have chosen to use this technique in persistent AF, rather than in paroxysmal AF, in which less extensive tissue ablations may suffice. VOM ethanol infusion must be an add-on to the standard catheter ablation procedure, since it has no effect on other ablation targets such as the right PVs, septum, etc. Over our past experience we have established the safety of this procedure, uncovered novel mechanistic effects such as vagal denervation, and generated pilot data to support an improvement in outcomes.

**Preliminary outcomes data: results of our pilot experience**

We have compared our ablation outcomes in persistent AF patients treated with VOM-PV with those treated with PVAI. In 174 patients undergoing conventional PVAI, our single-procedure success rate at one year has been 45% (consistent with literature reports of 27%,<sup>45</sup> 36%,<sup>57</sup> or 49%<sup>58</sup>). In contrast, in 66 patients with persistent AF subjected to VOM-PV, our success rate has been 61%. These data will be used for sample size statistical calculations for Specific Aim #1.




Figure 8. Clinical trial design

#### 4.0 Clinical Protocol for Specific Aim #1. To assess the impact of VOM ethanol infusion in single-procedure success when added to de novo catheter ablation of persistent AF.

VOM triggers and innervation may play a role in persistent AF, not addressed by a standard PVAI. Our hypothesis is that VOM ethanol infusion will do so and lead to improved outcomes. This is a prospective, multi-center, randomized study comparing a combined procedure including VOM ethanol infusion plus PVAI (VOM-PV) with PVAI alone in patients with persistent AF. The trial design incorporates a plan for possible repeat procedures if AF recurs after the 3-month blanking period, as this is common in clinical practice.

##### **Inclusion/exclusion criteria.** Table 1 **Study procedures**

**1. Initial assessment.** These will include a history and physical exam, electrocardiogram (EKG), echocardiogram within one year prior to the procedure for evaluation of cardiac structure, and function, transesophageal echocardiogram within 48 hours pre- procedure to evaluate for thrombus, laboratory data. A quality of life (QOL) questionnaire, specifically developed for AF (AFEQT)<sup>113</sup> will be filled out by patients.

**2. Pre-procedural imaging.** Patients will undergo cardiac MRI with left atrial scar imaging, or a CT scan prior to catheter ablation per the standard of care. LA volume will be measured.

**3. Randomization.** Randomization (using PASS 2008, Kaysville, UT) should take place after confirmation that all inclusion/exclusion criteria are met and MRI or CT measurements of LA volume are obtained. Patients will be randomized in a 1.15:1 fashion (to account for an 85% technical feasibility of the VOM procedure) to receive either VOM-PV or the conventional PVAI. Randomization will be stratified per LA volume and AF duration. Patients will be blinded to the randomization outcome. See below in *statistical considerations*.

**4. PVAI procedure.** As part of a conventional catheter ablation of AF the following will be performed, all considered standard of care:

- Electrophysiological catheters will be inserted, including a CS catheter, a duodecapolar circumferential catheter, and an ablation catheter. The last two will be inserted in the LA via trans-septal punctures.
- Prior to ablation, a geometry of the LA will be obtained using a 3-dimensional (3D) mapping system (either of the two available, Carto or NavX). This will generate a computerized geometry of the LA, including baseline voltage amplitudes in different regions.

##### **Inclusion criteria**

- Patients between the ages of 21 and 85 years
- Diagnosed with symptomatic persistent AF
  - Documentation of history of AF for at least 6 months
  - AF not spontaneously converting to sinus rhythm, persisting for  $\geq 7$  days
  - Sinus rhythm after cardioversion is NOT an exclusion, provided that  $\geq 2$  episodes of persistent AF occurred in the previous 6 months
- Resistant or intolerant to at least one class I, II, or III AAD
- Patients deemed candidates for RF ablation of AF
- Able and willing to comply with pre-, post-, and follow-up requirements.

##### **Exclusion criteria**

- Patients with previous PVAI procedure or left heart ablation procedure.
- Left atrial thrombus.
- LA diameter greater than 65 mm on long axis parasternal view, or left atrial volume more than 200 cc by MRI or CT.
- Left ventricular ejection fraction  $< 30\%$ .
- Cardiac surgery within the previous 180 days.
- Expecting cardiac transplantation or other cardiac surgery within 180 days.
- Coronary PTCA/stenting within the previous 90 days.
- Documented history of a thrombo-embolic event within the previous 90 days.
- Diagnosed atrial myxoma.
- Significant restrictive, constrictive, or chronic obstructive pulmonary disease with chronic symptoms.
- Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment
- Women who are pregnant.
- Acute illness or active infection at time of index procedure documented by either pain, fever, drainage, positive culture and/or leukocytosis ( $WBC > 11,000 \text{ mm}^3$ ) for which antibiotics have been or will be prescribed.
- Creatinine  $> 2.5 \text{ mg/dl}$  (or  $> 221 \text{ } \mu\text{mol/L}$ , except for patients in dialysis).
- Unstable angina.
- Myocardial infarction within the previous 60 days.
- History of blood clotting or bleeding abnormalities.
- Contraindication to anticoagulation.
- Contraindication to computed tomography or MRI procedures.
- Life expectancy less than 1 year.
- Uncontrolled heart failure (NYHA class III or IV heart failure).
- Presence of an intramural thrombus, tumor, or other abnormality that precludes catheter introduction or positioning.
- Presence of a condition that precludes vascular access.
- INR greater than 3.5 within 24 hours of procedure.
- Cannot be removed from antiarrhythmic drugs for reasons other than AF.
- Unwilling or unable to provide informed consent.
- Current reported alcoholism.

**Table 1.** Inclusion and exclusion criteria.

- c. Lesion sets delivered by RF application will include, in a step-wise fashion, the following ablations, ***sequentially if AF persists after each step is completed:***
  - i. PVAI. RF should be applied 1 cm proximal to the PV ostia in a wide area circumferential pattern. Isolation will be verified by the absence of electrical activity from each PV and/or dissociated activity.
  - ii. The greater PV antra, including posterior wall and roof.
  - iii. Mitral isthmus: a line of RF ablation from the left inferior PV to the mitral annulus. Bidirectional block should be verified after completion by differential pacing.
  - iv. Areas of complex, fractionated potentials.
  - v. Sustained atrial flutters will be mapped and ablated as directed by the map and flutter location.
  - vi. Following step 4c, if AF persists after all the RF ablations, the patient will be cardioverted to restore sinus rhythm. Given the potential variability of the extent of ablations, maps of the lesion sets (see below) will be collected and maintained in an imaging core laboratory.

**5. VOM procedure.** In patients randomized to VOM-PV, ***prior to the conventional PVAI***, the following will be performed:

- a. A 7F sheath will be advanced in the CS via a right internal jugular vein access. Contrast injection in the CS will be performed via a sub-selector catheter (recommended 6F left internal mammary angiographic guide catheter) to identify the VOM. We will obtain a CS venogram and identify the location of the VOM. Cannulation of the VOM will be performed using the sub-selector catheter that can be torqued so that its tip is engaged in the ostium of the VOM. Contrast will be injected via the lumen of the sub-selector catheter to verify such engagement.
- b. If large enough, the VOM will be cannulated with an angioplasty wire (0.014") that will be advanced through the sub-selector catheter and into it. If the VOM is too small to accommodate the wire, venodilation with 200 µgm of nitroglycerine through the sub-selector catheter will be administered to facilitate VOM cannulation.



- c. An angioplasty balloon (2 mm diameter, 8 mm length, or 1.5 mm and 6 mm, respectively) will be advanced over the wire and positioned in the ostium of the VOM. The balloon will be inflated to occlude the vein. Contrast venograms of the VOM will be recorded in left and right anterior oblique projections. The angioplasty balloon will be then advanced as distally as possible in the VOM and the first ethanol injection will be performed there after balloon inflation. The balloon will be then deflated and retracted 1-2 cm for a repeat inflation and ethanol injection. Up to four, 1 cc injections (depending on the VOM length) of 98% ethanol will be delivered in the VOM by sequentially retracting the balloon up to the VOM ostium.
- d. The procedure will then continue with standard PVAI procedure as outlined in section 4.

**6. Post ablation 3D voltage amplitude maps** will be generated using either NavX or CARTO, to delineate the extent of the scar generated by ablation (PVAI group) or ablation plus VOM ethanol (VOM-PV group).

**Peri-procedural data collection.** See Table 2 and data collection forms in appendix.

**Post procedure follow-up and data collection**

**1. One month follow-up.** Follow up evaluation will include an EKG, and assessment for complications including history and physical exam. Routine medications, including AAD will be continued. Symptomatic AF or flutter will be treated with AAD or cardioversion as needed.

**2. Three-month follow-up.** Evaluation will include an EKG, and assessment for complications including history and physical exam. If the patient is in AF or flutter, a cardioversion will be performed electively within 2 weeks so that all patients are in sinus rhythm after the blanking period. AAD therapy will be discontinued in all patients.

**3. Six-month follow-up.** Follow up evaluation will include an EKG, and a history and physical exam. Patients will undergo a 4-week continuous EKG monitor (see *Core laboratories*, below). The purpose of this EKG monitor is to screen for recurrent AF that may prompt an early repeat procedure. Patients with clinical or EKG recurrences will undergo a repeat PVAI procedure (see below).

**4. Nine-month follow-up.** Follow up evaluation will include an EKG, and a history and physical exam.

**5. Twelve- and 15-month follow-up.** Follow up evaluation will include an EKG, and a history and physical exam. Additionally, patients will undergo a 4-week continuous EKG monitor to determine the primary endpoint. Patients will fill out the AFEQT<sub>113</sub> QOL questionnaire. Additionally, echocardiographic assessment of LA function (LA ejection fraction, strain<sub>114ab</sub>) will be performed.

**Definitions of Procedural Success or failure and Indications for Repeat Procedures:**

- 1. Success:** Freedom from symptomatic persistent AF or flutter, AND less than 1 min/day (0.07%) of AF or flutter on EKG monitor.
- 2. Clinical Success.** Patients that have freedom from symptomatic AF or flutter but on EKG monitor have AF or flutter exceeding 1 min/day but less than 1% AF or flutter burden. The rationale is to account for patients in which a repeat procedure would not be clinically indicated, yet AF/flutter would not be considered cured.
- 3. Repeat procedures.** The rationale behind allowing repeat procedures lies in several facts. First, Repeat procedures are a clinical reality in persistent AF, and a single-procedure success endpoint –which will be a secondary endpoint- is not relevant if a large number of patients need an additional procedure. Second, it is possible that VOM-PV on a first procedure may increase success of a second procedure –e. g. if the recurrences in VOM-PV group are as flutter instead of AF. Both represent a clinical failure of the procedure,

- 1. For all patients:**
  - a. Total procedure, RF ablation, and fluoroscopy times.
  - b. Occurrence of bidirectional block across the mitral isthmus line tested by differential pacing.
  - c. Pre-ablation 3D voltage maps.
  - d. Ablation lesion sets: 3D maps (Carto or NavX) , including ablated scar surface area, as measured by bipolar voltage less than 0.1 mV.
  - e. Any procedural complications.
- 2. In patients randomized to VOM ethanol infusion:**
  - a. Successful vs. unsuccessful cannulation with angioplasty wire and balloon.
  - b. VOM venograms in left anterior and right anterior oblique projections.
  - c. Extent of tissue ablation achieved by ethanol infusion, defined as areas with local electrogram voltage <0.1 mV on 3D mapping. (Pre-PVAI voltage map).
  - d. Added procedural and fluoroscopy time.
  - e. Effect on AF: termination, conversion into flutter or no change.
  - f. RF time to achieve block around the mitral annulus.
  - g. Complications related to VOM instrumentation.
  - h. Blood ethanol level measurement.
  - i. LA instrumentation time.
  - j. Ablation lesion sets: 3D maps (Carto or NavX) including total (RF plus ethanol) ablated scar surface area, as measured by bipolar voltage less than 0.1 mV
- 3. Post-procedure management**
  - a. EKG, troponin, CBC, creatinine in 48h or prior to discharge
  - b. Anticoagulation continued for at least 3 months
  - c. Phone call in 7 days

**Table 2.** Periprocedural data collection.

but a repeat procedure for flutter is more likely to succeed.<sup>65</sup> Thus, a repeat procedure consisting on a repeat conventional PVAI and flutter ablation if needed will be allowed if AF/flutter recurs between 3 and 9 months of the initial randomized procedure. This allows a minimum of 6 months of follow-up after a repeat procedure. See Figure 9. Although this may seem short, it is our clinical experience that the bulk of AF recurrences tend to occur shortly after the blanking period.<sup>115</sup> Thus, we expect a minority of patients to recur late in this window. A repeat procedure needed as late as 9 months implies that AF was successfully eliminated for that long, that the ablation had favorable anti-AF effects and that additional ablation needed may not be extensive, therefore long follow-up after the repeat procedure may not be required. Additionally, recurrences as flutter may occur later on, and given the greater success of flutter ablation, longer follow-ups are not needed. Indications for a repeat procedure include:

- a. Symptomatic, recurrent persistent AF or flutter, shown in 2 consecutive EKGs, at least one week apart.
- b. AF or flutter burden on electrocardiographic monitoring exceeding 1% of the time (14. 5 min/day).
- c. Symptomatic AF or flutter with burden greater than 1 min/day (0. 07%) but less than 1%.




Figure 9. Timeline of follow-ups and repeat procedures.

**Primary and secondary endpoints.**

**Primary endpoints:**

1. Freedom from symptomatic AF or flutter AND reduction of AF/flutter to less than 1 min/day in a continuous 4-week monitor between 12-15 months (1 or 2 procedures).
2. Safety: Acute procedural complications.

**Secondary Endpoints:**

1. Single vs 2-procedure success.
2. AF burden (% time) on continuous monitoring at 12 and 15 months.
3. Procedural parameters: total procedure, fluoroscopy, total RF ablation time (first procedure), and total extent of ablated LA tissue.
4. Clinical success: freedom from symptomatic AF/flutter but AF/flutter > 1 min/day < than 1% at 12 and 15 months.
5. Subacute procedural complications (within 45 days).
6. Recurrence as persistent or paroxysmal AF, or flutter after 1 or 2 procedures.
7. LA function on Doppler echocardiography (LA strain<sup>114ab</sup>) at 15 months.
8. Incidence and mechanisms of atrial flutters.
9. Cardiovascular hospitalizations and QOL.

**Statistical considerations**

**1. Power and sample size determination.** The primary outcome is freedom from symptomatic post-procedural AF or flutter at 12 and 15 months from the procedure and less than 1 min/day of AF or flutter on 4-week EKG monitor. PASS 2008 was used for determining group-specific sample size for testing two proportions. We observed (see pilot data) a response rate of  $p_1=45\%$  for  $n=174$  patients receiving PVAI and  $p_2=61\%$  for  $n=66$  patients receiving VOM-PV. The use of  $N_1=180$  in VOM-PV group and  $N_2=156$  in PVAI group (total  $N=336$ ) subjects achieves 80% power to detect the difference of 16% between  $p_1$  and  $p_2$  based on a stratified design (6 strata) using the two-sided ( $\alpha=0. 05$ ) Cochran-Mantel-Haenszel test. An 85% technical feasibility rate for VOM-PV treatment was considered in the sample size calculation ( $N_1=1.15 \times N_2$ ). Table 3 shows power calculations for different sample sizes.

	Sample Size Grp 1 N1	Sample Size Grp 2 N2	PropH1 Grp 1 or Trtmnt P1	Prop Grp 2 or Control P2	Diff if H0 D0	Diff if H1 D1	Target Alpha
Power	258	258	0.4483	0.6061	0.0000	-0.1578	0.0500
	209	209	0.4483	0.6061	0.0000	-0.1578	0.0500
	179	179	0.4483	0.6061	0.0000	-0.1578	0.0500
	156	156	0.4483	0.6061	0.0000	-0.1578	0.0500

Table 3. Power calculations.

**2. Sample size modification due to attrition.** The attrition rate in this population is very low (around 2%), thus, the overall planned enrollment will remain  $N=336$ .

**3. Subject randomization.** Patients will be randomized to treatment groups by the study coordinator using a pre-generated randomization list generated with PASS 2008 software. Stratified block-randomization (to ensure balance of strata –AF duration and LA volume- across treatments) will be performed in an attempt to remove treatment preference based on risk, prognostic factors, and subject choice.<sup>116-118</sup> The  $N=336$  planned enrollees will be block-randomized into the 2 treatment groups (PVAI or VOM-PV), with stratification by AF duration (6m-2y, 2y+) and LA volume (normal or mild enlargement- up to 75 ml/m<sup>2</sup>-,

moderate -76-89 ml/m<sup>2</sup>-, or severe enlargement -90+ ml/m<sup>2</sup>)<sup>119</sup> yielding 6 strata.

4. **Data quality.** All study data will be evaluated on a 2-week basis by the study staff at the data coordinating center (see below). Meetings will consist of review of enrollment progress, recruitment sample size summaries, review of potential problems, holes reports for existing data (missing data), progress with data collection, and summary statistics of subjects enrolled.
5. **Statistical analysis.** All major treatment comparisons between the two randomized groups in this study will be performed according to the principle of “intention-to-treat”, that is, subjects will be analyzed according to the treatment arm to which patients were randomized, regardless of compliance to assigned treatment. Summary statistics (age, race, gender, BMI, smoking, AF duration, medical history coronary artery disease, diabetes mellitus, hypertension, chronic obstructive pulmonary disease, sleep apnea, prior stroke), will be determined by treatment arm. The difference between treatment arms will be compared by Chi-square or Fisher’s exact test for categorical variables and t-test or Wilcoxon Rank Sum test for continuous variables. The Cochran-Mantel-Haenzel stratified odds ratio test will be used to determine whether or not  $H_0: p_1 = p_2$  should be rejected while controlling for the AF duration (6m-2y, 2y+) and LA volume (normal or mild, moderate, or severe enlargement) strata. In spite of the smaller sample sizes, we will nevertheless employ logistic regression modeling ( $y=0$  for success  $y=1$  for failure) to assess confounding effects of age, race, gender, and AF duration and LA size categories.
6. **Use of propensity scores in multivariate models.** An ideal goal for observational etiological studies is to allocate randomly subjects into different treatment groups in order to guarantee on average that there are no systematic differences in covariates between groups.<sup>120</sup> After randomization, there is nevertheless a possibility for observing large differences in confounders which may lead to bias in results. The propensity score provides a scalar summary of covariate information and is defined as the propensity (probability) that a subject’s covariate profile represents subjects truly assigned to a given treatment group. Propensity scores based on significantly different confounder variables can be used to create a quasi-randomized experiment with adjustment to the treatment effect. We will assess the role of propensity scores in prediction models in order to reduce the effects of baseline factors that may be significantly different among subjects in different treatment groups. Firstly, we will identify baseline covariates which are significantly different across treatment groups (using t-tests with skew-zero transformed covariates or Mann-Whitney tests). Significant covariates will be incorporated into a logistic regression model ( $y=0$  PVAI, 1-VOM-PV) to generate subject-specific logits, which are normally-distributed.<sup>121, 122</sup> Treatment-subject-specific logits will then be used for matching subjects across the treatment groups in order to construct a sample of subjects with balanced covariates. We suspect that propensity matching will not be required to tackle the problem of extreme confounder differences, but will nevertheless evaluate the effect of propensity matching prior to logistic regression to determine treatment effect possibly adjusted for age.

## 5.0 Study Organization.

### **Patient recruitment, procedures and follow-up**

Patients will be recruited from Cardiac Electrophysiology consultation services at participating sites. Houston sites will include Methodist Hospital, Ben Taub General Hospital (BTGH) and the Michael E. DeBakey VA Medical Center (MDVA). The PI has a large AF ablation practice at Methodist, where ~30 patients/year have been enrolled in prior VOM studies. A faculty appointment at Baylor and privileges at BTGH and MDVA will ensure the PI access to their patient population. Patients will be identified and followed up (blinded to the treatment) by local investigators (Amish Dave, MD, PhD at Methodist, Irakli Giorgberidze, MD at MDVA, Hamid Afshar, MD at BTGH). At St David's Dr Natale will perform the procedures and Dr Di Biase (blinded) will follow patients. Enrollment goals (101 patients per year in all sites combined) can be easily achieved given these sites' ablation volume. See letters of support (Dr Natale, Dr Giorgberidze, and Dr Afshar).

### **Data coordinating center (DCC)**

A DCC has been set up at the Dan L. Duncan Institute for Clinical and Translational Research at Baylor College of Medicine. Coordinators at each site will use a web-based data entry and collection system, which is capable of image collection (including maps) and FISMA-compliant. Uma Ramamurthy, PhD, with extensive experience in clinical trials, will be the trial data manager, will oversee data collection, integrity and quality. Neal S. Kleiman, MD, a co-investigator with extensive experience handling large data sets (as leader of the nation-wide EVENT myocardial infarction registry) has been recruited to independently lead data analysis. He will meet quarterly with DCC and lead blinded data analysis of the proposed endpoints, and SAEs. Data will be reported to the DSMB with pre-specified criteria for stopping the trial if safety and futility boundaries are reached. See below in "Protection of Human Subjects".

### **Interim analyses**

The DCC will analyze safety and efficacy data with pre-specified boundaries for study termination. Adverse events and endpoints will be analyzed every 50 patients enrolled. Termination will occur if excess mortality (analyzed using Poisson's regression), or a 30% increased rate of serious adverse events, or a 30% difference in primary endpoints.

### **Scientific advisory board**

This will oversee the conduct of the trial by quarterly reviewing enrollment status, protocol violations, and reports of the DSMB. Modifications of the protocol, study termination, consideration of additional sites and other major trial decisions will be made by the advisory board. See Figure 11.

### **Blinding**

Patients, personnel involved in data analysis, and physicians following patients after the randomized procedure will be blinded to the treatment provided. Upon enrollment, the operators (MV and AN) will be informed of the randomization outcome. After the procedure is performed, data will be collected and analyzed with treatments "A" or "B" as the only identifier. The DSMB will receive the data identification for their assessment. Primary endpoints -absence of symptoms and freedom from AF- will be adjudicated *in an independent and blinded manner* by the physicians following the patients (different from the operators performing the procedure) and by the external EKG monitoring laboratory, respectively.

### **Core laboratories: Echocardiography, and EKG monitoring**

Electrocardiographic monitoring will be performed by continuous 4-week monitors as described. We have secured a commitment from MEDICALgorithmics to provide with storage of *continuous data* (i. e. all the heart beats) for the 4-week monitoring time that will allow precise determination of the AF burden (percentage of time in AF). *Data will be reviewed by technicians unaware of the treatment mode, thus AF occurrence and AF burden quantification will be blinded.* Additionally, analysis such as heart rate variability may be performed: If VOM ethanol causes effective vagal denervation, and vagal innervation modulates dynamics of heart rate variability<sup>123</sup> then we expect differences between the two treatment groups. The core echocardiographic laboratory will be lead by Dr Nagueh, a national leader in echocardiography with particular expertise in LA function.<sup>114b</sup> LA volumes, ejection fraction and strain will be collected as described and reviewed and analyzed in the echocardiography core laboratory at Methodist Hospital.<sup>114ab</sup>

### **Safety considerations**

Ethanol infusion for the treatment of hypertrophic cardiomyopathy has been used for more than a decade.<sup>124</sup> Complications derive from collateral damage (i. e. AV block) or spillage of ethanol in unintended arterial branches.<sup>124</sup> VOM infusion is retrograde, and spilled ethanol drains via the CS into the right atrium to be diluted



to non-damaging concentrations. Ethanol passage into the systemic circulation via the LA, albeit seemingly dangerous, is necessary for its ablative effects in the atrial myocardium. In order to achieve rapid dilution and avoid systemic effects, a slow infusion rate is critical. Mixed blood ethanol have been undetectable. VOM venograms performed after VOM ethanol infusion can show varying degrees of myocardial staining, but macroscopic extravasation into the epicardial space has not occurred. Adverse events of the VOM procedure included one CS dissection, which had no clinical consequences. Two patients developed subacute pericardial effusion 4 and 6 weeks after the procedure, respectively. The role of VOM ethanol is unclear, since this complication is also well described in conventional ablation.<sup>56</sup> No systemic effects were detected at the doses tested (total 4 ml). This is an FDA Investigational New Drug (IND # 105083) project, which will continue. Added procedure and fluoroscopy times in our previous experience average 45 and 8 minutes, respectively. Reported fluoroscopy times of conventional ablation can be up to 100-120 minutes,<sup>125, 126</sup> so 8 minutes do not represent a major fluoroscopy time increase. Given that VOM ethanol may lead to ablation of otherwise targeted tissue (including LIPV isolation),<sup>1</sup> and facilitate perimitral block,<sup>3</sup> it may reduce the need of RF ablation in these areas. Thus VOM ethanol may potentially save procedure and fluoroscopy times downstream.

### **Adverse Event Reporting**

The adverse event reporting period for this trial begins at the time the investigator gains venous access and continue through the 12 month follow-up visit or withdrawal from the study. Events will be reported per institution specific IRB policy.

Only AE's related to the catheter ablation procedure, ethanol ablation, and disease process will be captured.

### **Screen Failures**

Subjects will be deemed screen failures when they do not meet all inclusion/ exclusion criteria and do not receive an ethanol injection in the vein of Marshall. Adverse events that occur for subjects prior to the intervention, will be documented in the study record and will not be reported to the IRB or sponsor (TMHRI) unless unexpected or the PI determines the event should be reported to the IRB as non-study intervention related event. Subjects who are deemed screen failures and experience an event that meets the general SAE criteria will be followed until resolution of the event and those events will be reported to TMHRI as the sponsor of the IND, and to the IRB per institutional policies for reporting SAE's.

### **Adverse Events (AE's)**

Patients may experience certain clinical events that are attributable to the ablation procedure or the disease process of the patient. ***The following list of AE's are expected based on previous clinical and research experience and data.***

- Atrial Arrhythmias
- Chest pain or Angina
- Standard of care cardioversions for arrhythmias
- Headache
- Minor bleeding
- Hypertension or hypotension
- Vasovagal reactions
- self-limiting pericarditis attributable to the ablation procedure defined as pleuritic chest discomfort with or without pericardial rub
- pacemaker implantation for nodal dysfunction rhythms (sick sinus syndrome, sinus bradycardia, sinus arrest or AV blocks) that resulted in symptomatic bradycardia (unrelated to the ablation procedure or related to pre-existing disease state)
- Incision site pain/soreness
- Incision site infection
- Inadvertent AV block: Second or third degree heart block
- Palpitations

- Pulmonary edema
- ECG changes that did not require additional hospitalization
- Pericarditis
- Anxiety
- Hematoma

### **Serious Adverse Events (SAE)**

An adverse event that meets one or more of the following criteria/outcomes will be classified as serious: These events will be treated accordingly and reported per local & federal regulations and institutional policies & requirements.

- Results in a life-threatening illness or injury.
- Results in permanent impairment of a body structure or a body function.
- Requires inpatient hospitalization  $\geq 24$  hours (other than the ablation procedure) or prolongation of existing hospitalization.
- Requires a medical or surgical intervention to prevent permanent impairment to body structure.
- Death

SAE's will be reported in accordance with institutional policy.

### **Data Safety and Monitoring Plan**

We will use the Weill-Cornell Data, Safety and Monitoring Board (DSMB). This is an external, pre-constituted board that provides oversight to the IRBs at Cornell and affiliated institutions. The Methodist Hospital has had a close affiliation with Weill Cornell Medical College that serves as a framework for Cornell's DSMB oversight of projects conducted at Methodist. The DSMB (see Research Plan) will also have 3 *ad hoc* electrophysiologists appointed for their expertise in catheter ablation of AF and the role of the VOM (Peng-Sheng Chen, MD, Francis Marchlinski, MD and David A. Cesario, MD, PhD) that will serve as consultants. Additionally, the DSMB will have Charles G. Minard, PhD, as a dedicated statistician. Dr Minard is part of the Baylor College of Medicine Dan L. Duncan Institute for Clinical and Translational Research (described above), where the DCC will be constituted, but will not be involved in data analysis. All members of the DSMB will be physicians who are not listed on the protocol as sub-investigators. See the DSMB charter in the appendix.

There are known risks to the conventional pulmonary vein ablation procedure, and they remain present for every patient undergoing ablation of AF. Additional risks specific to the Vein of Marshall procedure are listed in the consent and expected outcomes are fully explained to each consented subject. An adverse event is defined as any unfavorable clinical event which impacts or has the potential to impact the health or safety of a clinical study participant caused by or associated with a study intervention. Should an adverse event occur the PI will notify the IRB within seven working days of gaining knowledge of the event and the event will be captured on an appropriate data collection or case report form (CRF). A serious adverse event includes death, life threatening adverse experiences, hospitalization or prolongation of hospitalization, disability or incapacitation, overdose, congenital anomalies and any other serious events that may jeopardize the subject or require medical or surgical intervention to prevent one of the outcomes listed in this definition. All serious adverse events will be reported to the Institution Review Board within 72 hours of PI gaining knowledge of the event and will be classified as expected or unexpected and possibly, probably, definitely, or not related to the study procedure. A report will also be submitted to the FDA according to the applicable Federal Regulations. Unexpected serious adverse events deemed related, probably or possibly related to the VOM study procedure will warrant a hold on the study until further review and approval by the IRB and DSMB.

All data will be de-identified and only the research personnel will have access to subjects protected health information; all source documents will be kept onsite and stored with the principal investigator. The CRFs for this Study will be created by the PI as hard copy (paper) and as electronic CRFs. If electronic CRFs are used, the source document will be the electronic CRF, with appropriate password controls. The forms are designed to record observations and other data pertinent to the Study on each participant enrolled in the Study. The CRFs will be completed by the Investigator and/or designated staff. All data will be entered into a computer and

VEIN OF MARSHALL ETHANOL INFUSION FOR PERSISTENT ATRIAL FIBRILLATION CLINICAL PROTOCOL

stored in a secure database, accessible to approved personnel only. All hardcopies will be stored in a secure location and will be only accessible to approved personnel.

Standard safety precautions will be taken to minimize risk. The Principal Investigator of the study is very familiar with the risks of catheter ablation procedures and is experienced in its resolution and treatment.


**Data Reporting**

The DCC will perform data analysis quarterly. Dr Uma Ramamurthy will be the data manager and coordinator and Dr Neal S Kleiman will oversee the clinical aspects of the data analysis. Outcomes, adverse events, protocol violations will be analyzed in a fashion blinded to the treatment provided (i.e. treatments A or B). Statistical analysis will be provided by Dr Leif Peterson. Quarterly reports will be supplied to the DSMB, which will receive un-blinded data in order to properly ascertain adverse events attributable to the VOM procedure. The DSMB reports will subsequently be provided to the IRB and the FDA as part of the IND oversight process.

**Interim analyses**

The DCC will quarterly analyze safety and efficacy data with pre-specified boundaries for study termination. Additionally, adverse events and endpoints will be analyzed every 50 patients enrolled. Termination will occur if the VOM-PV group has: excess mortality (analyzed using Poisson’s regression), or a 30% increased rate of serious adverse events, a 40% increase in fluoroscopy time, or a 30% difference in primary endpoints.

**Study administration**



Clinical trial organization.

## **Study Organization and Administration**

### **COORDINATION LEVEL**

The Methodist Hospital Research Institute (TMHRI) will serve as the coordinating center for this study, led by the project PI, Dr. Miguel Valderrábano. Dr. Valderrábano will have general and scientific oversight of the project. A trial administrator-manager (Bhoomieka Patel) at TMHRI will oversee day-to-day operations of the clinical study as it relates to participant enrollment, clinical site administration, and data administration. Dr. Valderrábano will manage all clinical sites, which includes overseeing the quality of clinical measurements obtained in the study and ensuring adherence to the protocol. Additionally, he will be responsible for patient recruitment, which includes site start-up activities and training for all site personnel.

### **Statistical Core**

The primary functions of the individuals in the statistical core laboratory, led by Leif Peterson, PhD, will be to contribute to data analysis and to create systems for randomization. Data from the Data Coordinating Center (see below) will be available for blinded statistical analysis for interim analysis, applicable DSMB or FDA reports, and prior to publications or presentations.

### **Data management: Data Coordinating Center**

We will use the Dan L. Duncan Institute for Clinical and Translational Research (ICTR) as our Data Coordinating center. The ICTR, established in 2011 is located in the Jewish Wing of Baylor College of Medicine (BCM). The ICTR supports and promotes translational and clinical research across BCM and its partner institutions in the Texas Medical Center, including the BCM clinics, the Michael DeBakey VA Hospital, Ben Taub Hospital, Texas Children's Hospital, Methodist Hospital, Rice University, the University of Houston School of Pharmacy and the University of Texas Health Science Center. The ICTR provides BCM investigators with ready access to a robust infrastructure to encourage and support high-quality, multidisciplinary, clinical and translational research. Services available to investigators include regulatory and administrative assistance with all aspects of protocol development, implementation and analysis; research nursing and coordination services, quality assurance and quality control services, and ready availability to biostatistical and clinical trial informatics services. The research informatics team provides ready access to secure, compliant, web-based applications for all aspects of clinical trial management. The ICTR also supports clinical research units where subjects enrolled on clinical trials can be seen for study specific procedures and follow-up. The ICTR is constructing a multi-purpose web portal to integrate and maintain the institutional knowledge required to conduct clinical and translational research. This Virtual Institute for Clinical and Translational Research (VICTR) will be launched in the 3rd quarter of 2012.

In addition to infrastructure support, the ICTR oversees internal pilot funding programs at BCM that are designed to support translational research with high potential for further peer-review funding and clinical development. The ICTR is also committed to education and training a broad spectrum of individuals in clinical, translational and collaborative research in order to improve and accelerate discoveries that will improve human health and healthcare practice at the local, national and global levels.

The Data Coordinating Center for this multi-site clinical trial will reside at the Dan L. Duncan Institute for Clinical and Translational Research (ICTR) at Baylor College of Medicine. The Research Informatics team in the ICTR, led by Dr. Uma Ramamurthy, has extensive experience for 13+ years in setting up databases and data management for multi-center clinical trials funded by NCI and NHLBI. This team consists of several software developers and systems engineers. Each member in this team has one or more graduate degrees in computer science/engineering, and senior members of the team have 8-10 years of software/systems development experience in health informatics, biomedical and clinical trials research. The Research Informatics team develops web-based, secure database applications, software applications and tools tailored to meet the needs of researchers at the Texas Medical Center (TMC). The database systems are platform independent, and focused on ease of use and being compliant with required regulatory requirements. They utilize Microsoft SQL Server for the database backend and .Net/Java for the web-based frontends for the



database applications. Other software tools and applications developed by the team are in C++, C# and Java programming languages. This team's goal is to stay current with technology and ensure that the researchers at TMC have state of the art informatics and flexible systems that provide informatics support to accomplish their research mission and objectives.

The Research Informatics team in the ICTR will design, develop and maintain the secure, web-based electronic database systems for this trial. The proposed electronic data management system is a secure, web-based system which will require the participants to have an internet-accessible computer/tablet with an Internet browser. This electronic data management system will have logical checks and audit logs built into the system to ensure data correctness and data integrity. All automated alerts and notifications requested by the project team will be implemented in this electronic data management system. This system will also have reports and queries that are requested by the project team and the DSMB to monitor and manage the study. Also provided will be backend access to statistical software like SAS, R, SPIus, SPSS, etc. with ODBC data connectivity to facilitate data analyses. At various time points in the study, as requested by the study team, snapshots and locking of the database will occur, and clean data sets will be provided to the study team for review and data analyses.

Dr Uma Ramamurty at the DCC will be responsible for the integrity of data collection –blinded to the specific treatment provided (Treatments "A" or "B"). Statistical analysis will be provided by Dr Peterson's team, who will have access to the DCC data. Dr Neal S Kleiman will be responsible for overseeing data analysis from the clinical standpoint.

#### *Data flow*

The Investigator at each investigative site is responsible for the completion and timely web-based submission of case report forms (CRFs) for each patient according to visit requirements as detailed in the Schedule of Events. **Within 2 weeks of the study visit**, CRFs will be submitted via a webpage to the DCC in the ICTR. All electronic data will be stored as a HIPAA-compliant limited data set in a password-protected database. Research nurses at each site will be responsible for entering the data in the system. The DCC provides nursing support for the two Baylor sites (Michael E. DeBakey VA Medical Center and Ben Taub Harris County Hospital).

#### *Data collection and record-keeping*

A Case Report Form (CRF) will be completed for each subject enrolled into the clinical study (see appendix for sample CRFs). The investigator will review, approve and sign/date each completed CRF; the investigator's signature serving as attestation of the investigator's responsibility for ensuring that all clinical and laboratory data entered on the CRF are complete, accurate and authentic.

*Source Data* are the clinical findings and observations, laboratory and test data, and other information contained in *Source Documents*. *Source Documents* are the original records (and certified copies of original records); including, but not limited to, hospital medical records, physician or office charts, physician or nursing notes, subject diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, x-rays, etc. When applicable, information recorded on the CRF shall match the *Source Data* recorded on the *Source Documents*.

#### *Record storage*

The investigator will maintain records in accordance with [Good Clinical Practice guidelines](#). Case report forms will not contain any subject identifiers and will be labeled with only subject ID numbers. Case report forms will be filed in a locked filing cabinet in the study coordinator's locked office. Any records, such as consent forms, that contain direct subject identifiers (e.g., name, social security number) will be stored in a separate locked filing cabinet in the study coordinator's office. Only the study coordinator and the Investigator will have access to this information.

#### *Missing data processing plan*

Critical data fields are those variables necessary for final study analysis. They will be agreed upon by the PI and the Clinical Data Manager, and detailed within the Data Management Plan. For those critical fields that are

discrepant or not completed on the case report form (CRF), a query will be issued to the investigative site. Missing or overdue patient CRFs will also be queried.

### **Study Monitoring**

The principal investigator will be responsible for monitoring the ongoing safety of participants in the trial. The study sponsor (The Methodist Hospital Research Institute) will assign a clinical study monitor (June Rodriguez) to monitor the clinical trial. Monitoring visits will begin as soon as subjects are consented and enrolled and will continue until all subjects have been taken off of the clinical trial and the trial has been terminated. Monitoring visits will include review of informed consent process, eligibility, adherence to the clinical protocol, and adverse events.

The clinical trial administrator will oversee all aspects of clinical monitoring for the study, which will be conducted by personnel in the monitoring department of TMHRI on no less than a semi-annual basis. The clinical monitors are qualified by training and experience to oversee the progress of the study and will ensure that the Investigators and their staff understand and adhere to both the regulatory requirements and the study protocol. Monitoring procedures for this clinical study include pre-study communication to review data forms and other study documents, periodic on-site monitoring visits, and a final monitoring visit. Clinical monitors will present data to the study administrator and PI throughout the study with reports detailing protocol adherence, appropriate informed consent practice, accurate completion of all CRF's and data queries.

The study will be monitored on the following basis, in all sites:

1. The first 3 subjects at each site will be monitored at 100% source data verification level.
2. After the first 3 subjects, if there are no issues warranting otherwise, only 20% of the remaining subjects enrolled on the study at each site will be monitored at 100% source data verification level
3. If after the first 3 subjects at each site, there are issues which require additional training, or if the site requires or requests closer monitoring, the 100% source data verification will continue until such time is determined to be reduced to a lower percentage.

### **CONDUCT LEVEL: Clinical Trial Sites**

The organization of this trial is centralized at TMHRI, which will act as a coordinating center for other clinical sites. Commitments from additional sites- Texas Cardiac Arrhythmia Institute, Austin, Michael E. DeBakey VA Medical Center, and Ben Taub Harris County Medical Center- have been obtained to enroll patients and receive reimbursement on a per-patient basis. Sites will be trained on the protocol prior to initiation to minimize protocol deviations, avoid breaches of blinding procedures and other violations. Sites will be structured with 3 levels of personnel: operators (Dr Valderrábano at the Methodist Hospital, Michael E. DeBakey VA Medical Center, and Ben Taub Harris County Hospital; and Dr Natale at St David's in Austin); blinded clinicians (listed in the chart) that would follow the patients and evaluate adverse events and clinical primary endpoints; and research nurses. Site funding will operate on a payment-per-patient basis, as described in the letters of support.

### **OVERSIGHT LEVEL**

#### **Data Safety Monitoring Board**

See details above. Briefly, we will use the Weill-Cornell Medical College DSMB, which has been constituted through an affiliation with Methodist hospital to provide DSMB services to clinical studies performed in both institutions. See DSMB charter in the appendix. Three additional electrophysiology consultants and a statistician have been added to provide insights into the specific clinical scenarios that can occur in AF ablation. The board will receive unblended quarterly reports from the DCC with safety and efficacy data.

## VEIN OF MARSHALL ETHANOL INFUSION FOR PERSISTENT ATRIAL FIBRILLATION CLINICAL PROTOCOL

Predetermined criteria for early termination of the trial are proposed, to be considered by the DSMB which will make the final determinations.

### Scientific advisory board

Constituted by outside experts in clinical research (Christie Ballantyne, MD), autonomic nervous system and evidence-based medicine research (Carlos Morillo, MD) or the use of ethanol ablation (Nassir Lakkis, MD), plus the two investigators performing the VOM procedure, it will have the following functions:

1. Overseeing the operational conduct of the study, including adherence to the study protocol. The board will assist in facilitating resolution of problems that may arise concerning these issues.
2. Reviewing and rendering advice concerning potential changes to the protocol. Such changes would require approval by the DSMB.
3. Recommending publication policies, as well as overseeing the publications and presentations review process. This includes reviewing scientific reports, analysis, ancillary study proposals, and publications resulting from data that are obtained during the study; review and approval of any revisions to the publication guidelines for the study; and determination of data analyses, not currently included in the protocol, for the purpose of furthering scientific understanding in the field.
4. Reviewing recommendations from the DSMB and providing advice and guidance regarding potential study issues.

### 6.0 TIMELINE

	Year 1	Year 2	Year 3	Year 4	Year 5
Specific Aim #1	Enrollment	Enrollment	Enrollment	Enrollment	Follow-up

## 9.0 LITERATURE CITED

1. Dave AS, Baez-Escudero JL, Sasaridis C, Hong TE, Rami T, Valderrabano M. Role of the vein of marshall in atrial fibrillation recurrences after catheter ablation: Therapeutic effect of ethanol infusion. *Journal of cardiovascular electrophysiology*. 2012;23 (6) :583-591.
2. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ, Jr. , Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 hrs/ehra/ecas expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: A report of the heart rhythm society (hrs) task force on catheter and surgical ablation of atrial fibrillation. Developed in partnership with the european heart rhythm association (ehra) , a registered branch of the european society of cardiology (esc) and the european cardiac arrhythmia society (ecas) ; and in collaboration with the american college of cardiology (acc) , american heart association (aha) , the asia pacific heart rhythm society (aphrs) , and the society of thoracic surgeons (sts). Endorsed by the governing bodies of the american college of cardiology foundation, the american heart association, the european cardiac arrhythmia society, the european heart rhythm association, the society of thoracic surgeons, the asia pacific heart rhythm society, and the heart rhythm society. *Heart Rhythm*. 2012;9 (4) :632-696 e621.
3. Baez-Escudero JL, Morales PF, Dave AS, Sasaridis CM, Kim YH, Okishige K, Valderrabano M. Ethanol infusion in the vein of marshall facilitates mitral isthmus ablation. *Heart Rhythm*. 2012 In press.
- 3b. Morales PF, Dave AS, Sasaridis CM, Valderrabano M. Anatomical variations of the vein of Marshall and its implications to atrial fibrillation ablation. *Heart Rhythm*. 2012;9(5): S78.
4. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TS, Van Wagener DR, Waldo AL, Wyse DG. Prevention of atrial fibrillation: Report from a national heart, lung, and blood institute workshop. *Circulation*. 2009;119 (4) :606-618.
5. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ, Jr. , Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ. Hrs/ehra/ecas expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up. A report of the heart rhythm society (hrs) task force on catheter and surgical ablation of atrial fibrillation developed in partnership with the european heart rhythm association (ehra) and the european cardiac arrhythmia society (ecas) ; in collaboration with the american college of cardiology (acc) , american heart association (aha) , and the society of thoracic surgeons (sts). Endorsed and approved by the governing bodies of the american college of cardiology, the american heart association, the european cardiac arrhythmia society, the european heart rhythm association, the society of thoracic surgeons, and the heart rhythm society. *Europace*. 2007;9 (6) :335-379.
6. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *The New England journal of medicine*. 1998;339 (10) :659-666.
7. Katritsis D, Merchant FM, Mela T, Singh JP, Heist EK, Armondas AA. Catheter ablation of atrial fibrillation the search for substrate-driven end points. *Journal of the American College of Cardiology*. 2010;55 (21) :2293-2298.
8. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Turov A, Shirokova N, Karaskov A. Ablation of paroxysmal and persistent atrial fibrillation: 1-year follow-up through continuous subcutaneous monitoring. *Journal of cardiovascular electrophysiology*. 2011;22 (4) :369-375.
9. Tan AY, Zhou S, Ogawa M, Song J, Chu M, Li H, Fishbein MC, Lin SF, Chen LS, Chen PS. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. *Circulation*. 2008;118 (9) :916-925.



10. Choi EK, Shen MJ, Han S, Kim D, Hwang S, Sayfo S, Piccirillo G, Frick K, Fishbein MC, Hwang C, Lin SF, Chen PS. Intrinsic cardiac nerve activity and paroxysmal atrial tachyarrhythmia in ambulatory dogs. *Circulation*. 2010;121 (24) :2615-2623.
11. Oral H, Knight BP, Tada H, Ozaydin M, Chugh A, Hassan S, Scharf C, Lai SW, Greenstein R, Pelosi F, Jr. , Strickberger SA, Morady F. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. *Circulation*. 2002;105 (9) :1077-1081.
12. O'Neill MD, Wright M, Knecht S, Jais P, Hocini M, Takahashi Y, Jonsson A, Sacher F, Matsuo S, Lim KT, Arantes L, Derval N, Lellouche N, Nault I, Bordachar P, Clementy J, Haissaguerre M. Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint. *Eur Heart J*. 2009;30 (9) :1105-1112.
13. Knecht S, Hocini M, Wright M, Lellouche N, O'Neill MD, Matsuo S, Nault I, Chauhan VS, Makati KJ, Bevilacqua M, Lim KT, Sacher F, Deplagne A, Derval N, Bordachar P, Jais P, Clementy J, Haissaguerre M. Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation. *Eur Heart J*. 2008;29 (19) :2359-2366.
14. Rostock T, Steven D, Hoffmann B, Servatius H, Drewitz I, Sydow K, Mullerleile K, Ventura R, Wegscheider K, Meinertz T, Willems S. Chronic atrial fibrillation is a biatrial arrhythmia: Data from catheter ablation of chronic atrial fibrillation aiming arrhythmia termination using a sequential ablation approach. *Circ Arrhythm Electrophysiol*. 2008;1 (5) :344-353.
15. Oral H, Chugh A, Good E, Wimmer A, Dey S, Gadeela N, Sankaran S, Crawford T, Sarrazin JF, Kuhne M, Chalfoun N, Wells D, Frederick M, Fortino J, Benloucif-Moore S, Jongnarangsin K, Pelosi F, Jr. , Bogun F, Morady F. Radiofrequency catheter ablation of chronic atrial fibrillation guided by complex electrograms. *Circulation*. 2007;115 (20) :2606-2612.
16. Elayi CS, Verma A, Di Biase L, Ching CK, Patel D, Barrett C, Martin D, Rong B, Fahmy TS, Khaykin Y, Hongo R, Hao S, Pelargonio G, Dello Russo A, Casella M, Santarelli P, Potenza D, Fanelli R, Massaro R, Arruda M, Schweikert RA, Natale A. Ablation for longstanding permanent atrial fibrillation: Results from a randomized study comparing three different strategies. *Heart Rhythm*. 2008;5 (12) :1658-1664.
17. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jr. , Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. Acc/aha/esc 2006 guidelines for the management of patients with atrial fibrillation: A report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) : Developed in collaboration with the european heart rhythm association and the heart rhythm society. *Circulation*. 2006;114 (7) :e257-354.
18. Valderrabano M, Chen HR, Sidhu J, Rao L, Ling Y, Khoury DS. Retrograde ethanol infusion in the vein of marshall: Regional left atrial ablation, vagal denervation and feasibility in humans. *Circ Arrhythm Electrophysiol*. 2009;2 (1) :50-56.
19. Valderrabano M, Liu X, Sasaridis C, Sidhu J, Little S, Khoury DS. Ethanol infusion in the vein of marshall: Adjunctive effects during ablation of atrial fibrillation. *Heart Rhythm*. 2009;6 (11) :1552-1558.
20. Baez-Escudero JLD, A. S. ;Sasaridis, C. M. ; Valderrabano, M. Regional vagal denervation of the human left atrium following ethanol infusion in the vein of marshall *Heart Rhythm*. 2011;8:s77.
21. Wolf PA, Dawber TR, Thomas HE, Jr. , Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The framingham study. *Neurology*. 1978;28 (10) :973-977.
22. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the manitoba follow-up study. *Am J Med*. 1995;98 (5) :476-484.
23. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The rotterdam study. *Stroke*. 1997;28 (2) :316-321.
24. Miyasaka Y, Barnes ME, Petersen RC, Cha SS, Bailey KR, Gersh BJ, Casaclang-Verzosa G, Abhayaratna WP, Seward JB, Iwasaka T, Tsang TS. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: Data from a community-based cohort. *Eur Heart J*. 2007;28 (16) :1962-1967.

25. Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: A systematic review and meta-analysis. *Neurology*. 2011;76 (10) :914-922.
26. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The framingham heart study. *Circulation*. 1998;98 (10) :946-952.
27. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators. *Journal of the American College of Cardiology*. 2000;35 (1) :183-187.
28. Goudevenos JA, Vakalis JN, Giogiakas V, Lathridou P, Katsouras C, Michalis LK, Sideris DA. An epidemiological study of symptomatic paroxysmal atrial fibrillation in northwest greece. *Europace*. 1999;1 (4) :226-233.
29. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (atria) study. *Jama*. 2001;285 (18) :2370-2375.
30. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the united states. *Am J Cardiol*. 2009;104 (11) :1534-1539.
31. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in olmsted county, minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation*. 2006;114 (2) :119-125.
32. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y. Heart disease and stroke statistics--2009 update: A report from the american heart association statistics committee and stroke statistics subcommittee. *Circulation*. 2009;119 (3) :e21-181.
33. Kim MH, Johnston SS, Chu B-C, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the united states. *Circ Cardiovasc Qual Outcomes*. 2011;4 (3) :313-320.
34. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. *The New England journal of medicine*. 2002;347 (23) :1825-1833.
35. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL. Rhythm control versus rate control for atrial fibrillation and heart failure. *The New England journal of medicine*. 2008;358 (25) :2667-2677.
36. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG. Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (affirm) study. *Circulation*. 2004;109 (12) :1509-1513.
37. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. *The New England journal of medicine*. 2009;360 (7) :668-678.
38. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH. Dronedarone in high-risk permanent atrial fibrillation. *The New England journal of medicine*. 2011;365 (24) :2268-2276.
39. Verma A, Marrouche NF, Natale A. Pulmonary vein antrum isolation: Intracardiac echocardiography-guided technique. *Journal of cardiovascular electrophysiology*. 2004;15 (11) :1335-1340.

40. Arentz T, Weber R, Burkle G, Herrera C, Blum T, Stockinger J, Minners J, Neumann FJ, Kalusche D. Small or large isolation areas around the pulmonary veins for the treatment of atrial fibrillation? Results from a prospective randomized study. *Circulation*. 2007;115 (24) :3057-3063.
41. Lin WS, Tai CT, Hsieh MH, Tsai CF, Lin YK, Tsao HM, Huang JL, Yu WC, Yang SP, Ding YA, Chang MS, Chen SA. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. *Circulation*. 2003;107 (25) :3176-3183.
42. Tanaka K, Zlochiver S, Vikstrom KL, Yamazaki M, Moreno J, Klos M, Zaitsev AV, Vaidyanathan R, Auerbach DS, Landas S, Guiraudon G, Jalife J, Berenfeld O, Kalifa J. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. *Circ Res*. 2007;101 (8) :839-847.
43. Haissaguerre M, Hocini M, Sanders P, Sacher F, Rotter M, Takahashi Y, Rostock T, Hsu LF, Bordachar P, Reuter S, Roudaut R, Clementy J, Jais P. Catheter ablation of long-lasting persistent atrial fibrillation: Clinical outcome and mechanisms of subsequent arrhythmias. *Journal of cardiovascular electrophysiology*. 2005;16 (11) :1138-1147.
44. Rostock T, Drewitz I, Steven D, Hoffmann BA, Salukhe TV, Bock K, Servatius H, Aydin MA, Meinertz T, Willems S. Characterization, mapping, and catheter ablation of recurrent atrial tachycardias after stepwise ablation of long-lasting persistent atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2010;3 (2) :160-169.
45. Rostock T, Salukhe TV, Steven D, Drewitz I, Hoffmann BA, Bock K, Servatius H, Mullerleile K, Sultan A, Gosau N, Meinertz T, Wegscheider K, Willems S. Long-term single- and multiple-procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation. *Heart Rhythm*. 2011;8 (9) :1391-1397.
46. Hocini M, Jais P, Sanders P, Takahashi Y, Rotter M, Rostock T, Hsu LF, Sacher F, Reuter S, Clementy J, Haissaguerre M. Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: A prospective randomized study. *Circulation*. 2005;112 (24) :3688-3696.
47. Takahashi Y, O'Neill MD, Hocini M, Reant P, Jonsson A, Jais P, Sanders P, Rostock T, Rotter M, Sacher F, Laffite S, Roudaut R, Clementy J, Haissaguerre M. Effects of stepwise ablation of chronic atrial fibrillation on atrial electrical and mechanical properties. *Journal of the American College of Cardiology*. 2007;49 (12) :1306-1314.
48. Jais P, Hocini M, Hsu LF, Sanders P, Scavee C, Weerasooriya R, Macle L, Raybaud F, Garrigue S, Shah DC, Le Metayer P, Clementy J, Haissaguerre M. Technique and results of linear ablation at the mitral isthmus. *Circulation*. 2004;110 (19) :2996-3002.
49. Arruda M, Mlcochova H, Prasad SK, Kilicaslan F, Saliba W, Patel D, Fahmy T, Morales LS, Schweikert R, Martin D, Burkhardt D, Cummings J, Bhargava M, Dresing T, Wazni O, Kanj M, Natale A. Electrical isolation of the superior vena cava: An adjunctive strategy to pulmonary vein antrum isolation improving the outcome of af ablation. *Journal of cardiovascular electrophysiology*. 2007;18 (12) :1261-1266.
50. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Mohanty S, Horton R, Gallinghouse GJ, Bailey SM, Zagrodzky JD, Santangeli P, Hao S, Hongo R, Beheiry S, Themistoclakis S, Bonso A, Rossillo A, Corrado A, Raviele A, Al-Ahmad A, Wang P, Cummings JE, Schweikert RA, Pelargonio G, Dello Russo A, Casella M, Santarelli P, Lewis WR, Natale A. Left atrial appendage: An underrecognized trigger site of atrial fibrillation. *Circulation*. 2010;122 (2) :109-118.
51. Hocini M, Shah AJ, Nault I, Sanders P, Wright M, Narayan SM, Takahashi Y, Jais P, Matsuo S, Knecht S, Sacher F, Lim KT, Clementy J, Haissaguerre M. Localized reentry within the left atrial appendage: Arrhythmogenic role in patients undergoing ablation of persistent atrial fibrillation. *Heart Rhythm*. 2011.
52. Elayi CS, L DIB, Bai R, Burkhardt JD, Mohanty P, Sanchez J, Santangeli P, Hongo R, Gallinghouse GJ, Horton R, Bailey S, Zagrodzky J, Beheiry S, Natale A. Identifying the relationship between the non-pv triggers and the critical cfae sites post-pvai to curtail the extent of atrial ablation in longstanding persistent af. *Journal of cardiovascular electrophysiology*. 2011.
53. Narayan SM, Krummen DE, Rappel WJ. Clinical mapping approach to diagnose electrical rotors and focal impulse sources for human atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2012;23 (5) :447-454.
54. Yamazaki M, Vaquero LM, Hou L, Campbell K, Zlochiver S, Klos M, Mironov S, Berenfeld O, Honjo H, Kodama I, Jalife J, Kalifa J. Mechanisms of stretch-induced atrial fibrillation in the presence and the



- absence of adrenergic stimulation: Interplay between rotors and focal discharges. *Heart Rhythm*. 2009;6 (7) :1009-1017.
55. Valderrabano M. Atrial fibrillation: The mother rotor and its rebellious offspring take turns sustaining the family. *Heart Rhythm*. 2009;6 (7) :1018-1019.
  56. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2010;3 (1) :32-38.
  57. Earley MJ, Abrams DJ, Staniforth AD, Sporton SC, Schilling RJ. Catheter ablation of permanent atrial fibrillation: Medium term results. *Heart*. 2006;92 (2) :233-238.
  58. Mulder AA, Wijffels MC, Wever EF, Boersma LV. Pulmonary vein isolation and left atrial complex-fractionated atrial electrograms ablation for persistent atrial fibrillation with phased radio frequency energy and multi-electrode catheters: Efficacy and safety during 12 months follow-up. *Europace*. 2011.
  59. Bhargava M, Di Biase L, Mohanty P, Prasad S, Martin DO, Williams-Andrews M, Wazni OM, Burkhardt JD, Cummings JE, Khaykin Y, Verma A, Hao S, Beheiry S, Hongo R, Rossillo A, Raviele A, Bonso A, Themistoclakis S, Stewart K, Saliba WJ, Schweikert RA, Natale A. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: Results from a multicenter study. *Heart Rhythm*. 2009;6 (10) :1403-1412.
  60. Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen J, Crijns HJ. Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. *Journal of the American College of Cardiology*. 2012;60 (1) :54-61.
  61. Gersak B, Pernat A, Robic B, Sinkovec M. Low rate of atrial fibrillation recurrence verified by implantable loop recorder monitoring following a convergent epicardial and endocardial ablation of atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2012.
  62. Deisenhofer I, Estner H, Zrenner B, Schreieck J, Weyerbrock S, Hessling G, Scharf K, Karch MR, Schmitt C. Left atrial tachycardia after circumferential pulmonary vein ablation for atrial fibrillation: Incidence, electrophysiological characteristics, and results of radiofrequency ablation. *Europace*. 2006;8 (8) :573-582.
  63. Haissaguerre M, Sanders P, Hocini M, Takahashi Y, Rotter M, Sacher F, Rostock T, Hsu LF, Bordachar P, Reuter S, Roudaut R, Clementy J, Jais P. Catheter ablation of long-lasting persistent atrial fibrillation: Critical structures for termination. *Journal of cardiovascular electrophysiology*. 2005;16 (11) :1125-1137.
  64. Chugh A, Oral H, Good E, Han J, Tamirisa K, Lemola K, Elmouchi D, Tschopp D, Reich S, Igic P, Bogun F, Pelosi F, Jr. , Morady F. Catheter ablation of atypical atrial flutter and atrial tachycardia within the coronary sinus after left atrial ablation for atrial fibrillation. *Journal of the American College of Cardiology*. 2005;46 (1) :83-91.
  65. Ammar S, Hessling G, Reents T, Fichtner S, Wu J, Zhu P, Kathan S, Estner HL, Jilek C, Kolb C, Haller B, Deisenhofer I. Arrhythmia type after persistent atrial fibrillation ablation predicts success of the repeat procedure. *Circ Arrhythm Electrophysiol*. 2011.
  66. Chugh A, Oral H, Lemola K, Hall B, Cheung P, Good E, Tamirisa K, Han J, Bogun F, Pelosi F, Jr. , Morady F. Prevalence, mechanisms, and clinical significance of macroreentrant atrial tachycardia during and following left atrial ablation for atrial fibrillation. *Heart Rhythm*. 2005;2 (5) :464-471.
  67. Pappone C, Manguso F, Vicedomini G, Gugliotta F, Santinelli O, Ferro A, Gulletta S, Sala S, Sora N, Paglino G, Augello G, Agricola E, Zangrillo A, Alfieri O, Santinelli V. Prevention of iatrogenic atrial tachycardia after ablation of atrial fibrillation: A prospective randomized study comparing circumferential pulmonary vein ablation with a modified approach. *Circulation*. 2004;110 (19) :3036-3042.
  68. Knecht S, Wright M, Sacher F, Lim KT, Matsuo S, O'Neill MD, Hocini M, Jais P, Clementy J, Haissaguerre M. Relationship between perimitral and peritricuspid conduction times. *Heart Rhythm*. 2008;5 (3) :400-405.
  69. Pak HN, Oh YS, Lim HE, Kim YH, Hwang C. Comparison of voltage map-guided left atrial anterior wall ablation versus left lateral mitral isthmus ablation in patients with persistent atrial fibrillation. *Heart Rhythm*. 2011;8 (2) :199-206.



70. Yokokawa M, Sundaram B, Garg A, Stojanovska J, Oral H, Morady F, Chugh A. Impact of mitral isthmus anatomy on the likelihood of achieving linear block in patients undergoing catheter ablation of persistent atrial fibrillation. *Heart Rhythm*. 2011;8 (9) :1404-1410.
71. Mountantonakis S, Frankel DS, Hutchinson MD, Dixit S, Riley M, Callans DJ, Garcia F, Lin D, Tzou W, Bala R, Marchlinski FE, Gerstenfeld EP. Feasibility of catheter ablation of mitral annular flutter in patients with prior mitral valve surgery. *Heart Rhythm*. 2011;8 (6) :809-814.
72. Anousheh R, Sawhney NS, Panutich M, Tate C, Chen WC, Feld GK. Effect of mitral isthmus block on development of atrial tachycardia following ablation for atrial fibrillation. *Pacing Clin Electrophysiol*. 2011;33 (4) :460-468.
73. Matsuo S, Yamane T, Hioki M, Ito K, Tanigawa S, Yamashita S, Inada K, Date T, Yoshimura M. Recurrent atrial arrhythmia in patients with atrial fibrillation following pulmonary vein isolation. *Journal of cardiovascular electrophysiology*. 2011;22 (9) :1080-1082.
74. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. *Circulation*. 1997;95 (8) :2075-2081.
75. Sacher F, Sobieszczyk P, Tedrow U, Eisenhauer AC, Field ME, Selwyn A, Raymond JM, Koplan B, Epstein LM, Stevenson WG. Transcoronary ethanol ventricular tachycardia ablation in the modern electrophysiology era. *Heart Rhythm*. 2008;5 (1) :62-68.
76. Chen PS. Douglas p. Zipes lecture. Neural mechanisms of atrial fibrillation. *Heart Rhythm*. 2006;3 (11) :1373-1377.
77. Ardell JL. Structure and function of mammalian intrinsic cardiac neurons. In: Armour JAA, J. L. , ed. *Neurocardiology*. New York: Oxford University Press; 1994:95-114.
78. Ardell JL. Intrathoracic neuronal regulation of cardiac function. In: Armour JAA, J. L. , ed. *Basic and clinical neurocardiology*. New York: Oxford University Press; 2004:118-152.
79. Pauza DH, Skripkiene G, Skripka V, Pauziene N, Stropus R. Morphological study of neurons in the nerve plexus on heart base of rats and guinea pigs. *J Auton Nerv Syst*. 1997;62 (1-2) :1-12.
80. Pauza DH, Skripka V, Pauziene N, Stropus R. Morphology, distribution, and variability of the epicardiac neural ganglionated subplexuses in the human heart. *Anat Rec*. 2000;259 (4) :353-382.
81. Smith FM. Extrinsic inputs to intrinsic neurons in the porcine heart in vitro. *Am J Physiol*. 1999;276 (2 Pt 2) :R455-467.
82. Adams DJC, J. Electrophysiological properties of intrinsic cardiac neurons. In: Armour JAA, J. L. , ed. *Basic and clinical neurocardiology*. New York: Oxford University Press; 2004:1-60.
83. Parsons RL. Mammalian cardiac ganglia as local integration centers: Histochemical and electrophysiological evidence. In: Dun NJM, B. H. ;Pilowsky, P. M. , ed. *Neural mechanisms of cardiovascular regulation*. Boston: Kluwer Academic Publishers; 2004:335-356.
84. Lin J, Scherlag BJ, Zhou J, Lu Z, Patterson E, Jackman WM, Lazzara R, Po SS. Autonomic mechanism to explain complex fractionated atrial electrograms (cfae). *Journal of cardiovascular electrophysiology*. 2007;18 (11) :1197-1205.
85. Patterson E, Jackman WM, Beckman KJ, Lazzara R, Lockwood D, Scherlag BJ, Wu R, Po S. Spontaneous pulmonary vein firing in man: Relationship to tachycardia-pause early afterdepolarizations and triggered arrhythmia in canine pulmonary veins in vitro. *Journal of cardiovascular electrophysiology*. 2007;18 (10) :1067-1075.
86. Chen PS, Chou CC, Tan AY, Zhou S, Fishbein MC, Hwang C, Karagueuzian HS, Lin SF. The mechanisms of atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2006;17 Suppl 3:S2-7.
87. Schauerte P, Scherlag BJ, Pitha J, Scherlag MA, Reynolds D, Lazzara R, Jackman WM. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. *Circulation*. 2000;102 (22) :2774-2780.
88. Scanavacca M, Pisani CF, Hachul D, Lara S, Hardy C, Darrieux F, Trombetta I, Negrao CE, Sosa E. Selective atrial vagal denervation guided by evoked vagal reflex to treat patients with paroxysmal atrial fibrillation. *Circulation*. 2006;114 (9) :876-885.
89. Katritsis D, Giazitzoglou E, Sougiannis D, Goumas N, Paxinos G, Camm AJ. Anatomic approach for ganglionic plexi ablation in patients with paroxysmal atrial fibrillation. *Am J Cardiol*. 2008;102 (3) :330-334.

90. Danik S, Neuzil P, d'Avila A, Malchano ZJ, Kralovec S, Ruskin JN, Reddy VY. Evaluation of catheter ablation of periatrial ganglionic plexi in patients with atrial fibrillation. *Am J Cardiol.* 2008;102 (5) :578-583.
91. Pokushalov E, Romanov A, Shugayev P, Artyomenko S, Shirokova N, Turov A, Katritsis DG. Selective ganglionated plexi ablation for paroxysmal atrial fibrillation. *Heart Rhythm.* 2009;6 (9) :1257-1264.
92. Marshall J. On the development of the great anterior veins in man and mammalia: Including an account of certain remnants of foetal structure found in the adult, a comparative view of these great veins in the different mammalia, and an analysis of their occasional peculiarities in the human subject. *Philos Trans R Soc Lond.* 1850;140:133-169.
93. Hwang C, Wu TJ, Doshi RN, Peter CT, Chen PS. Vein of marshall cannulation for the analysis of electrical activity in patients with focal atrial fibrillation. *Circulation.* 2000;101 (13) :1503-1505.
94. Cabrera JA, Ho SY, Climent V, Sanchez-Quintana D. The architecture of the left lateral atrial wall: A particular anatomic region with implications for ablation of atrial fibrillation. *Eur Heart J.* 2008;29 (3) :356-362.
95. Ulphani JS, Arora R, Cain JH, Villuendas R, Shen S, Gordon D, Inderyas F, Harvey LA, Morris A, Goldberger JJ, Kadish AH. The ligament of marshall as a parasympathetic conduit. *American journal of physiology.* 2007;293 (3) :H1629-1635.
96. Kim DT, Lai AC, Hwang C, Fan LT, Karagueuzian HS, Chen PS, Fishbein MC. The ligament of marshall: A structural analysis in human hearts with implications for atrial arrhythmias. *Journal of the American College of Cardiology.* 2000;36 (4) :1324-1327.
97. Makino M, Inoue S, Matsuyama TA, Ogawa G, Sakai T, Kobayashi Y, Katagiri T, Ota H. Diverse myocardial extension and autonomic innervation on ligament of marshall in humans. *Journal of cardiovascular electrophysiology.* 2006;17 (6) :594-599.
98. Lin J, Scherlag BJ, Niu G, Lu Z, Patterson E, Liu S, Lazzara R, Jackman WM, Po SS. Autonomic elements within the ligament of marshall and inferior left ganglionated plexus mediate functions of the atrial neural network. *Journal of cardiovascular electrophysiology.* 2009;20 (3) :318-324.
99. Scherlag BJ, Yeh BK, Robinson MJ. Inferior interatrial pathway in the dog. *Circ Res.* 1972;31 (1) :18-35.
100. Doshi RN, Wu TJ, Yashima M, Kim YH, Ong JJ, Cao JM, Hwang C, Yashar P, Fishbein MC, Karagueuzian HS, Chen PS. Relation between ligament of marshall and adrenergic atrial tachyarrhythmia. *Circulation.* 1999;100 (8) :876-883.
101. Lin J, Scherlag BJ, Lu Z, Zhang Y, Liu S, Patterson E, Jackman WM, Lazzara R, Po SS. Inducibility of atrial and ventricular arrhythmias along the ligament of marshall: Role of autonomic factors. *Journal of cardiovascular electrophysiology.* 2008;19 (9) :955-962.
102. Han S, Joung B, Scanavacca M, Sosa E, Chen PS, Hwang C. Electrophysiological characteristics of the marshall bundle in humans. *Heart Rhythm.* 2010;7 (6) :786-793.
103. Hwang C, Karagueuzian HS, Chen PS. Idiopathic paroxysmal atrial fibrillation induced by a focal discharge mechanism in the left superior pulmonary vein: Possible roles of the ligament of marshall. *Journal of cardiovascular electrophysiology.* 1999;10 (5) :636-648.
104. Katritsis D, Ioannidis JP, Anagnostopoulos CE, Sarris GE, Giazitzoglou E, Korovesis S, Camm AJ. Identification and catheter ablation of extracardiac and intracardiac components of ligament of marshall tissue for treatment of paroxysmal atrial fibrillation. *Journal of cardiovascular electrophysiology.* 2001;12 (7) :750-758.
105. Polymeropoulos KP, Rodriguez LM, Timmermans C, Wellens HJ. Images in cardiovascular medicine. Radiofrequency ablation of a focal atrial tachycardia originating from the marshall ligament as a trigger for atrial fibrillation. *Circulation.* 2002;105 (17) :2112-2113.
106. Katritsis D, Giazitzoglou E, Korovesis S, Paxinos G, Anagnostopoulos CE, Camm AJ. Epicardial foci of atrial arrhythmias apparently originating in the left pulmonary veins. *Journal of cardiovascular electrophysiology.* 2002;13 (4) :319-323.
107. Kurotobi T, Ito H, Inoue K, Iwakura K, Kawano S, Okamura A, Date M, Fujii K. Marshall vein as arrhythmogenic source in patients with atrial fibrillation: Correlation between its anatomy and electrophysiological findings. *Journal of cardiovascular electrophysiology.* 2006;17 (10) :1062-1067.

108. Wu TJ, Ong JJ, Chang CM, Doshi RN, Yashima M, Huang HL, Fishbein MC, Ting CT, Karagueuzian HS, Chen PS. Pulmonary veins and ligament of marshall as sources of rapid activations in a canine model of sustained atrial fibrillation. *Circulation*. 2001;103 (8) :1157-1163.
109. Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M, Sandoval E, Calvo N, Brugada J, Kelder J, Wijffels M, Mont L. Atrial fibrillation catheter ablation versus surgical ablation treatment (fast) : A 2-center randomized clinical trial. *Circulation*. 2011;125 (1) :23-30.
110. Vaitkevicius R, Saburkina I, Rysevaite K, Vaitkeviciene I, Pauziene N, Zaliunas R, Schauerte P, Jalife J, Pauza DH. Nerve supply of the human pulmonary veins: An anatomical study. *Heart Rhythm*. 2009;6 (2) :221-228.
111. Mischke K, Zarse M, Schmid M, Gemein C, Hatam N, Spillner J, Dohmen G, Rana O, Saygili E, Knackstedt C, Weis J, Pauza D, Bianchi S, Schauerte P. Chronic augmentation of the parasympathetic tone to the atrioventricular node: A nonthoracotomy neurostimulation technique for ventricular rate control during atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2010;21 (2) :193-199.
112. Baez-Escudero JLD, A. S. ;Sasaridis, C. M. ; Valderrabano, M. Ethanol injection in the vein of marshall facilitates bidirectional mitral isthmus block. *Europace*. 2011;13:Abstract 830.
113. Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development and validation of the atrial fibrillation effect on quality-of-life (afeqt) questionnaire in patients with atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2011;4 (1) :15-25.
- 114a. Munger TM, Dong YX, Masaki M, Oh JK, Mankad SV, Borlaug BA, Asirvatham SJ, Shen WK, Lee HC, Bielinski SJ, Hodge DO, Herges RM, Buescher TL, Wu JH, Ma C, Zhang Y, Chen PS, Packer DL, Cha YM. Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation. *Journal of the American College of Cardiology*. 2012.
- 114b. Kurt M, Wang J, Torre-Amione G, Nagueh S. Left atrial function in diastolic heart failure. *Circ Cardiovasc Imaging*. 2009;2:10-5.
115. Leong-Sit P, Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, Bala R, Dixit S, Riley M, Hutchinson MD, Cooper J, Russo AM, Verdino R, Gerstenfeld EP. Antiarrhythmics after ablation of atrial fibrillation (5a study) : Six-month follow-up study. *Circ Arrhythm Electrophysiol*. 2011;4 (1) :11-14.
116. Piantadosi S. *Clinical trials - a methodological perspective*. New Jersey: Wiley & Sons; 2005.
117. Pocock S. *Clinical trials - a practical approach*. New York: Wiley & Sons; 1983.
118. Rosenberger WFL, J. M. *Randomization in clinical trials - theory and practice*. New York: Wiley & Sons; 2002.
119. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. *J Cardiovasc Magn Reson*. 2005;7 (5) :775-782.
120. Rubin DB. On principles for modeling propensity scores in medical research. *Pharmacoepidemiol Drug Saf*. 2004;13 (12) :855-857.
121. Peterson LEA, S;Divakaran, V. ;Deswal, A. ;Bozkurt, B. ; Mann, D. L. *Improved propensity matching for heart failure using neural gas and self-organizing maps. Proceedings of the international joint conference on neural networks (ijcnn'09)*. . Piscataway (NJ) : IEEE Press; 2009.
122. Chylack LT, Jr. , Peterson LE, Feiveson AH, Wear ML, Manuel FK, Tung WH, Hardy DS, Marak LJ, Cucinotta FA. Nasa study of cataract in astronauts (nasca). Report 1: Cross-sectional study of the relationship of exposure to space radiation and risk of lens opacity. *Radiat Res*. 2009;172 (1) :10-20.
123. Malik M, Camm AJ. Heart rate variability: From facts to fancies. *Journal of the American College of Cardiology*. 1993;22 (2) :566-568.
124. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, Hodge DO, Schaff HV, Holmes DR, Jr. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. *Circulation*. 2008;118 (2) :131-139.
125. Dixit S, Marchlinski FE, Lin D, Callans DJ, Bala R, Riley MP, Garcia FC, Hutchinson MD, Ratcliffe SJ, Cooper JM, Verdino RJ, Patel VV, Zado ES, Cash NR, Killian T, Tomson TT, Gerstenfeld EP. Randomized ablation strategies for the treatment of persistent atrial fibrillation: Rasta study. *Circ Arrhythm Electrophysiol*. 2012;5 (2) :287-294.
126. Chao TF, Tsao HM, Lin YJ, Tsai CF, Lin WS, Chang SL, Lo LW, Hu YF, Tuan TC, Suenari K, Li CH, Hartono B, Chang HY, Ambrose K, Wu TJ, Chen SA. Clinical outcome of catheter ablation in patients

with nonparoxysmal atrial fibrillation: Results of 3-year follow-up. *Circ Arrhythm Electrophysiol.* 2012;5 (3) :514-520.



CLINICAL PROTOCOL

**VEIN OF MARSHALL ETHANOL INFUSION FOR  
PERSISTENT ATRIAL FIBRILLATION**

(IND 115,060)

(A MULTICENTER TRIAL)

**Version 7.2**

**February 15, 2016**

Clinical Trials.gov NCT 01898221

NIH-NHLBI R01HL115003-02

IND Sponsor

Houston Methodist Research Institute (HMRI)

6565 Fannin Street

Houston, TX 77030

Principal Investigator

Miguel Valderrábano, MD

Houston Methodist Hospital, Houston TX

Coordinating site

Houston Methodist Research Institute (HMRI)

Houston TX

## CONTENTS

### PROTOCOL SYNOPSIS 4

<b>1.0</b>	<b>INTRODUCTION .....</b>	<b>7</b>
<b>2.0</b>	<b>SIGNIFICANCE .....</b>	<b>7</b>
2.1	<i>AF as a clinical and health care problem .....</i>	<i>7</i>
2.2	<i>Inadequacy of pharmacological treatment options for persistent AF.....</i>	<i>8</i>
2.3	<i>Shortcomings of catheter ablation of persistent AF .....</i>	<i>8</i>
<b>3.0</b>	<b>INNOVATION 9</b>	
3.1	<i>Targeting the intrinsic cardiac ganglia via the VOM.....</i>	<i>9</i>
3.2	<i>VOM ethanol infusion: technique .....</i>	<i>11</i>
3.3	<i>Unveiling of an LA venous plexus .....</i>	<i>12</i>
3.4	<i>VOM ethanol infusion: tissue ablation and left PV disconnection .....</i>	<i>12</i>
3.5	<i>VOM ethanol infusion: a novel technique for local vagal denervation in humans .....</i>	<i>13</i>
3.6	<i>VOM ethanol infusion and perimitral flutter (PMF).....</i>	<i>14</i>
3.7	<i>Role of VOM in failed ablations.....</i>	<i>15</i>
<b>4.0</b>	<b>TRIAL OVERVIEW AND PRELIMINARY DATA.....</b>	<b>16</b>
4.1	<i>HYPOTHESIS.....</i>	<i>16</i>
4.2	<i>Preliminary outcomes data: results of our pilot experience .....</i>	<i>18</i>
4.3	<i>Three Month Blanking Period .....</i>	<i>18</i>
<b>5.0</b>	<b>MATERIALS AND METHODS.....</b>	<b>18</b>
5.1	<i>Specific Aims .....</i>	<i>18</i>
5.2	<i>Study Endpoints.....</i>	<i>18</i>
5.3	<i>Inclusion and exclusion criteria.....</i>	<i>19</i>
5.4	<i>Informed Consent Process .....</i>	<i>20</i>
5.5	<i>Study Procedures .....</i>	<i>20</i>
5.6	<i>Post-Procedural Data Collection: .....</i>	<i>23</i>
5.7	<i>VENUS: Definitions of Procedural Success or Failure and Indications for Repeat Procedures.....</i>	<i>24</i>
5.8	<i>MARS: Definitions of Procedural Success or Failure and Indications for Repeat Procedures.....</i>	<i>27</i>
<b>6.0</b>	<b>STATISTICAL CONSIDERATIONS .....</b>	<b>27</b>

<b>7.0</b>	<b>STUDY ORGANIZATION.....</b>	<b>38</b>
7.1	<i>SCHEDULE OF EVENTS.....</i>	38
7.2	<i>Patient Recruitment, Procedures And Follow-Up.....</i>	40
7.3	<i>Clinical Research Nurses/Coordinators.....</i>	40
7.4	<i>Data Coordinating Center (DCC).....</i>	40
7.5	<i>Study Drug.....</i>	41
7.6	<i>Blinding.....</i>	41
7.7	<i>Core laboratories: Echocardiography, and EKG monitoring.....</i>	42
7.8	<i>Safety considerations.....</i>	42
<b>8.0</b>	<b>STUDY ADMINISTRATION &amp; OVERSIGHT.....</b>	<b>45</b>
8.1	<i>PI Oversight.....</i>	45
8.2	<i>Coordinating Center.....</i>	45
8.3	<i>Scientific Advisory Board.....</i>	45
8.4	<i>DATA SAFETY MONITORING BOARD (DSMB).....</i>	46
<b>9.0</b>	<b>TRIAL MANAGEMENT.....</b>	<b>46</b>
9.1	<i>Statistical Management.....</i>	46
9.2	<i>Data Management.....</i>	46
9.3	<i>STUDY MONITORING.....</i>	47
9.4	<i>PROJECT MANAGEMENT.....</i>	48
<b>10.0</b>	<b>GUIDE TO ACRONYMS / DEFINITIONS.....</b>	<b>49</b>
<b>11.0</b>	<b>Classes of Anti-Arrhythmic Drugs (Vaughn-Williams Classification)<sup>127</sup>.....</b>	<b>50</b>
<b>12.0</b>	<b>LITERATURE CITED.....</b>	<b>51</b>

## PROTOCOL SYNOPSIS

Title	Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
IND Sponsor	Houston Methodist Research Institute (HMRI) 6565 Fannin Street Houston, TX 77030
Name of Product	Dehydrated Alcohol Injection, USP
Clinical Phase	III
Patient Population	Patients with documented, persistent atrial fibrillation (AF that persists beyond 7 days) that have failed to respond to at least one class of antiarrhythmic drugs (due to failure or intolerance), and who are otherwise deemed candidates for radiofrequency ablation of AF.
Objectives	<b>VENUS-AF. Vein of Marshall Ethanol iNfusion in Untreated perSistent Atrial Fibrillation: <i>To assess the role of VOM ethanol infusion in catheter ablation of persistent AF.</i></b>
Trial Design	Subjects who meet inclusion criteria will be randomized to either a conventional PVAI or PVAI with VOM procedure. Subjects will return for follow-up evaluations at 1, 3, 6, 9, and 12 months. One-month continuous cardiac event monitoring will be performed at 6 months and at 12 months. Studies performed at follow-up visits may include EKG, physical exam, QOL questionnaires, echocardiography, laboratory studies, anticoagulation therapy, and management of adverse events and AF recurrences. Patient and co-investigator performing follow-up of electrocardiographic data will be blinded to the type of procedure. Operator is not blinded.
Sample Size	405 total subjects, VENUS: 180 (VOM-PV) + 156 (PVAI) = 336
Primary Endpoints	<b><i>De Novo (VENUS-AF)</i></b> <b>Efficacy:</b> Freedom from symptomatic AF or atrial tachycardia (AT) AND reduction of AF/AT to less than 30 seconds in a continuous monitor at 6 and 12 months after a single procedure. <b>Safety:</b> Acute procedural complications and total mortality



<p>Secondary Endpoints <b><i>De Novo (VENUS-AF)</i></b></p>	<ol style="list-style-type: none"> <li>1. Freedom from AF/AT after &gt;1 procedure.</li> <li>2. Freedom from AF/AT on antiarrhythmic drugs.</li> <li>3. AF burden (% time) on continuous monitoring at 6 and 12 months.</li> <li>4. Procedural parameters: total procedure, fluoroscopy, total RF ablation time (first procedure), and total extent of ablated LA tissue.</li> <li>5. Clinical/partial success: less than 25% AF burden on a continuous event monitor at 6 and 12 months from ablation procedure.</li> <li>6. Sub-acute procedural complications (within 30 days).</li> <li>7. Recurrence as persistent or paroxysmal AF, or flutter after 1 or 2 procedures.</li> <li>8. LA function on Doppler echocardiography (LA strain<sup>114ab</sup>) at 12 months.</li> <li>9. Incidence and mechanisms of atrial flutters.</li> <li>10. Cardiovascular hospitalizations and</li> <li>11. QOL as determined by AFEQT questionnaire.</li> </ol>
<p><b>Inclusion Criteria</b></p>	<p><b><i>VENUS-AF</i></b></p> <ol style="list-style-type: none"> <li>1. Patients between the ages of 21 and 85 years undergoing their first ablation of AF.</li> <li>2. Diagnosed with symptomatic persistent or long-standing persistent AF, defined as: <ul style="list-style-type: none"> <li>▪ AF not spontaneously converting to sinus rhythm, persisting for &gt;7 days</li> </ul> </li> <li>3. Resistant or intolerant to at least one class I, II, or III antiarrhythmic drug (AAD)</li> <li>4. Patients deemed candidates for RF ablation of AF</li> <li>5. Able and willing to comply with pre-, post-, and follow-up requirements.</li> </ol>

<p><b>Exclusion Criteria-</b></p> <p><b>VENUS-AF</b></p>	<ol style="list-style-type: none"> <li>1. Left atrial thrombus by pre-procedural imaging.</li> <li>2. LA diameter greater than 65 mm on long axis parasternal view, or left atrial volume more than 200 cc.</li> <li>3. Left ventricular ejection fraction &lt; 30%.</li> <li>4. Cardiac surgery within the previous 180 days.</li> <li>5. Expecting cardiac transplantation or other cardiac surgery within 180 days.</li> <li>6. Coronary PTCA/stenting within the previous 90 days.</li> <li>7. Documented history of a thrombo-embolic event within the previous 90 days.</li> <li>8. Diagnosed atrial myxoma.</li> <li>9. Significant restrictive, constrictive, or chronic obstructive pulmonary disease with chronic symptoms.</li> <li>10. Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment</li> <li>11. Women who are pregnant or who plan to become pregnant during the study.</li> <li>12. Acute illness or active infection at time of index procedure documented by pain, fever, drainage, positive culture and/or leukocytosis (WBC &gt; 11.000 per mm<sup>3</sup>) for which antibiotics have been or will be prescribed.</li> <li>13. Creatinine &gt; 2.5 mg/dl (or &gt; 221 µmol/L, except for patients in dialysis).</li> <li>14. Unstable angina.</li> <li>15. Myocardial infarction within the previous 60 days.</li> <li>16. History of blood clotting or bleeding abnormalities.</li> <li>17. Contraindication to anticoagulation.</li> <li>18. Life expectancy less than 1 year.</li> <li>19. Uncontrolled heart failure</li> <li>20. Presence of an intramural thrombus, tumor, or other abnormality that precludes catheter introduction or positioning.</li> <li>21. Presence of a condition that precludes vascular access.</li> <li>22. INR greater than 3.5 within 24 hours of procedure- for patients taking warfarin.</li> <li>23. Cannot be removed from antiarrhythmic drugs for reasons other than AF.</li> <li>24. Unwilling or unable to provide informed consent.</li> </ol>
--	--

## 1.0 INTRODUCTION

Atrial fibrillation (AF)\* is the most common sustained arrhythmia in adults, and is a leading cause of stroke, disability and increased mortality.<sup>1</sup> Catheter ablation has become an increasingly accepted form of rhythm control and –other than surgery- is the only treatment form that can potentially cure AF. The ablation procedural strategy –pulmonary vein (PV) antral isolation (PVAI)- is best suited for paroxysmal AF,<sup>2</sup> in which ectopic beats arising from the PVs were shown to initiate AF.<sup>3</sup> However, it is unclear whether this mechanistic rationale applies to persistent AF,<sup>4, 5</sup> in which the role of the cardiac autonomic system, particularly the intrinsic cardiac ganglia, is being increasingly recognized as a modulator of atrial physiology leading to AF.<sup>6, 7</sup> The success of PVAI is significantly lower in persistent AF.<sup>8</sup> Expanding the ablation lesions to include larger areas of the atrial anatomy -such as the left atrial (LA) roof, coronary sinus (CS), LA appendage, septum, posterior wall, superior vena cava, and others- has improved outcomes, but also led to increases in procedural complexity and duration, need of repeat procedures,<sup>9-12</sup> and complications such as atrial flutters, particularly perimitral flutter (PMF).<sup>13</sup> Little mechanistic evidence supports this approach, which does not specifically address the intrinsic cardiac ganglia. Given that persistent AF has far greater prevalence and is a greater cause of stroke, disability and mortality than paroxysmal AF,<sup>14</sup> strategies to improve outcomes of catheter ablation of persistent AF are much needed.

We have developed a technique to perform rapid ablation of targeted atrial tissues in AF using ethanol infusion in the vein of Marshall (VOM).<sup>15, 16</sup> A previous R21 project has generated sufficient human data to support the safety –no safety issues were identified- and mechanistic utility of this technique by showing: 1) Effective, rapid and safe tissue ablation of LA tissue neighboring the LA ridge and left inferior PV; 2) Facilitation of cure of PMF by ablating most of the mitral isthmus; and 3) Regional LA vagal denervation. The broad, long term objective is to improve the outcomes of catheter ablation of persistent AF using the VOM as a target and a route to deliver ablative therapies.

## 2.0 SIGNIFICANCE

### 2.1 AF AS A CLINICAL AND HEALTH CARE PROBLEM

AF is the most common arrhythmia in the United States,<sup>1</sup> and is associated with significant morbidity and mortality, including up to 5-fold increased risk of stroke,<sup>17, 18</sup> 2-fold increased risk of dementia,<sup>19-21</sup> a 3-fold increased risk of heart failure<sup>18</sup> and a 40 to 90% increased risk of overall mortality.<sup>22</sup> Although the risk of stroke is comparable in persistent and paroxysmal AF,<sup>23</sup> the prevalence of persistent AF increases dramatically with increasing age,<sup>24, 25</sup> and thus is an overall more significant cause of morbidity and mortality. In the United States, there are currently an estimated 3.0 million adults with AF,<sup>26</sup> and this number is expected to double in the

---

\* Abbreviations used: 3D: 3-dimensional; AF: atrial fibrillation; CFAE: complex fractionated atrial electrograms; CS: coronary sinus; LA: left atrium; PMF: perimitral flutter; PV: pulmonary vein; PVAI: PV antral isolation; RF: radiofrequency; VOM: vein of Marshall; VOM-PV: combined VOM ethanol infusion plus PVAI

next 25 years.<sup>27</sup> Hospitalizations with a primary diagnosis of AF are close to half a million per year,<sup>28</sup> which generates a tremendous economic burden on the health care system. When compared to health care costs of non-AF control subjects, patients with AF have greater annual healthcare costs (up to \$8,705 total annual incremental cost). On the basis of current prevalence data, it is estimated that AF leads to a national incremental health care cost of up to \$26 billion.<sup>29</sup>

## 2.2 INADEQUACY OF PHARMACOLOGICAL TREATMENT OPTIONS FOR PERSISTENT AF

Management strategies are directed at heart rate control and stroke prevention –mere palliation– or at rhythm control. It has been shown that rhythm control strategies using antiarrhythmic drugs offer no benefit in elderly patients<sup>30</sup> or patients with heart failure.<sup>31</sup> Most of the lack of benefit of such rhythm control strategy is thought to be due to the adverse effects and suboptimal efficacy of antiarrhythmic drugs, that can potentially augment mortality.<sup>32</sup> Indeed, preservation of normal sinus rhythm is associated with decreased mortality.<sup>32</sup> Dronedarone, the only antiarrhythmic drug shown to improve outcomes in nonpermanent AF compared to placebo,<sup>33</sup> has been shown to double mortality, stroke and hospitalization for heart failure in the PALLAS study in patients with permanent AF (prematurely terminated: [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and [www.theheart.org/article/1264551.do](http://www.theheart.org/article/1264551.do)). Thus, antiarrhythmic drugs remain suboptimal at best for the treatment of AF.

## 2.3 SHORTCOMINGS OF CATHETER ABLATION OF PERSISTENT AF

**Weak mechanistic rationale.** Isolation of the PVs<sup>2</sup> and adjacent LA (PV antrum)<sup>34, 35</sup> is the accepted procedural endpoint, based on the mechanistic concept that atrial extrasystoles arising from the PVs initiate *paroxysmal* AF.<sup>3</sup> Other, non-PV triggers have been demonstrated.<sup>36</sup> The link between PV extrasystoles and AF is clear in paroxysmal AF, but not in persistent AF, in which the mechanisms of AF seem to be related more to a chronic atrial substrate than to acute triggers.<sup>4</sup> Indeed, intramural reentry in the posterior LA seems to be particularly relevant in chronic models of AF.<sup>37</sup> In persistent AF, the procedure has evolved, rather simplistically, to include additional lesions –besides isolation of the PVs,<sup>11, 38-40</sup> variably placed in the posterior wall,<sup>34</sup> LA roof,<sup>41, 42</sup> and towards the mitral annulus,<sup>43</sup> the superior vena cava,<sup>44</sup> left atrial appendage,<sup>45, 46</sup> and other areas where complex fractionated atrial electrograms (CFAE) may be mapped.<sup>13, 47</sup> This brute force approach of simply destroying more tissue has yielded additional success, but new procedural targets with solid mechanistic bases are needed.

**Suboptimal success and need for repeat procedures.** Despite the additional tissue destruction, ablation success in persistent AF is with much lower than in paroxysmal AF,<sup>48</sup> with single procedure success reported as low as 27%,<sup>40</sup> 36%,<sup>49</sup> or 49%,<sup>50</sup> but up to 61%<sup>13</sup> or 67%,<sup>51</sup> depending on study heterogeneities in: definitions of persistent AF and of recurrence of AF, the type of AF monitoring, and ablation technique and operator experience. In order to achieve overall acceptable success rates, (which can reach up to 79%-94%),<sup>13, 40, 51</sup> there is a consistent need for repeat procedures (sometimes up to 4) and the concomitant use of antiarrhythmic drugs. The rate of repeat procedures in experienced centers can reach up to 70 to 80%.<sup>9-12</sup>

**PMF after catheter ablation of persistent AF.** Clinical failures of a first ablation procedure are

caused, in a significant portion of patients, by atrial flutters,<sup>52-54</sup> rather than recurrent AF, and recurrence as flutter portends a greater chance of success in a second procedure.<sup>55</sup> Such atrial flutters may be caused by perimitral reentry in up to 33-60% of the patients.<sup>52, 54-56</sup> Catheter ablation of PMF involves the creation of a linear lesion from the mitral annulus to the left inferior PV (the so-called mitral isthmus).<sup>43, 57</sup> Achieving a complete ablation (defined by bidirectional conduction block across the ablation line) can be very difficult,<sup>10, 43, 58</sup> with success rates reported as 32%,<sup>59</sup> 64%,<sup>60</sup> or 71%.<sup>61</sup> It sometimes requires ablation inside the CS,<sup>54, 56</sup> in close proximity to the circumflex coronary artery, which could be damaged.<sup>60</sup> Of note, incomplete ablation of the mitral isthmus is proarrhythmogenic,<sup>62, 63</sup> increasing the risk of recurrent flutter by up to 4 times.<sup>62</sup>

### 3.0 INNOVATION


The basis of this application is an entirely novel technique that was developed in our laboratory from its original conception, to its validation in animals,<sup>15</sup> to the demonstration of safety and feasibility in humans.<sup>16</sup> Ethanol is used in hypertrophic cardiomyopathy,<sup>64</sup> and in ventricular tachycardias that do not respond to conventional RF ablation.<sup>65</sup> When delivered in the VOM, we have shown that ethanol can help ablate neighboring atrial tissues, all of which are routinely targeted during conventional ablation.<sup>15</sup> Supported by an R21 grant that started in July 2010, significant human pilot data have been acquired that lend further support to the mechanistic rationale, safety, and potential clinical utility of this technique.

#### 3.1 TARGETING THE INTRINSIC CARDIAC GANGLIA VIA THE VOM

The role of autonomic regulation in AF is highly relevant.<sup>66</sup> The cardiac autonomic system ([Figure 1](#)) can be divided into *extrinsic cardiac nerves* –vagus nerves and sympathetic chain-, and an *intrinsic cardiac ganglia* (a complex atrial epicardial network of ganglionated plexi with vagal and sympathetic nerves, including the ligament of Marshall). The intrinsic cardiac ganglia contain parasympathetic ganglia and its sympathetic nerves are only postganglionic.<sup>67</sup> These ganglia are not simple relay stations, but process multiple inputs from vagal efferent neurons, extrinsic sympathetic neurons, vagal afferent neurons, and sensory neurons.<sup>67-73</sup> Acetylcholine release by postganglionic neurons exerts effects on myocytes via muscarinic receptors and  $I_{K_{ACh}}$  channels, which shorten the action potential, allowing myocytes to sustain rapid activation rates (shorten refractoriness) and favoring the formation of rotors in AF.<sup>75</sup> Sympathetic innervation (norepinephrine) leads to enhanced automaticity, increased intracellular calcium and favors afterdepolarizations<sup>76-78</sup> that create extrasystoles that can initiate AF,<sup>77</sup> and destabilize rotors.<sup>75, 79</sup> Thus, a synergistic pro-AF effect can occur if both parasympathetic influences (shortening the action potential and refractoriness) and sympathetic influences (leading to extrasystoles via after depolarizations) activate simultaneously. Indeed, combined simultaneous sympathetic and parasympathetic discharges lead to AF.<sup>6</sup> Sympathovagal (stellate ganglion and vagus nerve) cryoablation of the *extrinsic cardiac nerves* eliminates paroxysmal AF episodes in a rapid atrial pacing model, but does not prevent the ultimate development of persistent AF.<sup>6</sup> The intrinsic cardiac autonomic system shows enhanced activity preceding AF, independent of the extrinsic system, that can play a role in developing persistent AF.<sup>7</sup>



Figure 1. Lateral LA and VOM



**A**, Cut open left atrium with left PVs and lateral ridge. Red dotted line indicates location of commonly placed ablation lesions. **B**, Microscopic view of the lateral ridge, showing the VOM (inset). **C**, Epicardial view of the lateral ridge, with VOM. Modified from ref. 87.

Translating this information into a modification of the ablation procedure to enhance its efficacy has proven difficult. Ablation of intrinsic autonomic ganglia has been proposed,<sup>80</sup> but the strategy has been RF ablation of the LA at locations where ganglia were identified as sites where bradycardic reflexes are triggered during high-frequency stimulation. Disappointingly, this approach has not been shown to add significant clinical benefit beyond PVAI.<sup>81-83</sup> Identification of vagal ganglia by finding bradycardic reflexes has not been shown to be more effective than simply using a standardized anatomic approach,<sup>84</sup> or to decrease AF inducibility.<sup>83</sup> Possible reasons for the failure of vagal ganglia RF ablation to impact procedural outcomes include: inaccurate ganglia localization, inadequate elimination of vagal innervation, given their epicardial location, and inadequate elimination of sympathetic innervation (not localizable by high-frequency stimulation).

The ligament of Marshall is the embryologic remnant of the left cardinal vein (superior vena cava), which, as it becomes atretic during development,<sup>85</sup> remains open as the VOM.<sup>86</sup> This vein drains in the CS and runs posteriorly and superiorly in the epicardial surface of the LA, towards the anterior aspect of the left-sided PVs, as part of a thick pectinate muscle that separates the veins from the LA appendage (left atrial ridge).<sup>87</sup> (See Figure 2). The VOM has been robustly shown to contain parasympathetic<sup>88</sup> and sympathetic<sup>89</sup> innervation,<sup>90</sup> and is *part of the intrinsic cardiac ganglia*.<sup>91</sup> The ligament of Marshall has been solidly implicated in arrhythmogenesis. As a source of ectopic rhythms, Scherlag, et al<sup>92</sup> demonstrated an ectopic rhythm arising from the ligament area upon left cardiac sympathetic nerve stimulation. Doshi, *et.al.* demonstrated the role of the ligament of Marshall in adrenergic atrial tachycardia.<sup>93</sup> Hwang *et al* demonstrated ectopic beats from the VOM leading to AF,<sup>86, 94</sup> as confirmed by others.<sup>36, 95-99</sup>

Focal ectopy arising in the VOM triggering AF has been demonstrated clinically<sup>36, 86</sup> and in experimental models of *persistent* AF.<sup>100</sup>




Figure 2. **Autonomic cardiac nerves**


Inputs from the vagus (cholinergic nicotinic, Ach(N)), the sympathetic chain (using norepinephrine, NE) and from sensory neurons and interneurons (other neuromodulators, see text) are processed by intrinsic cardiac ganglia. Atrial myocytes receive output from postganglionic neurons via cholinergic muscarinic (Ach (M) receptors), and from sympathetic postganglionic adrenergic innervation.

High-frequency stimulation in the ligament of Marshall (without exciting the atrial myocardium) leads to induction of AF, and this induction is inhibited by both esmolol and atropine, suggesting autonomic mediation.<sup>101</sup> The VOM is present and can be cannulated in ~85% of patients,<sup>94</sup> and our data confirm that it is a *direct vascular route to the intrinsic cardiac ganglia that could be therapeutically utilized*.

### 3.2 VOM ETHANOL INFUSION: TECHNIQUE

We have refined the technique over the past 3 years. We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a ~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly. Contrast injections through the sub-selector catheter help identify the VOM and direct the catheter tip to the VOM ostium. Then, an angioplasty wire is inserted into the VOM, over which an angioplasty balloon is advanced distally into the VOM. Contrast injections through the angioplasty balloon help delineate the size and branching patterns of the VOM. Ethanol injections are then delivered (up to four injections of 1 cc over 2 minutes each), each at different levels of the VOM –from distal in the VOM, where the first injection is delivered, the balloon is retracted ~1 cm after each injection until the balloon reaches the VOM ostium or 4 injections are given. [Figure 3](#) shows an example.

**Figure 3. VOM cannulation technique and LA venous plexus.**



**A**, Contrast injection in the CS lumen through the sub-selector catheter with its tip close to the VOM, showing the VOM take-off and branching patterns outlined in **B**. **C**, selective venogram via an angioplasty balloon in a VOM branch. Collaterals fill LA veins in the LA roof (outlined in **D**).

In our experience to date, we have been able to perform successful cannulation of the VOM and to complete the protocol of ethanol infusion in 89 of a total of 106 patients (85%). Our success rates in the last half of the patients versus the first half have been higher (90% vs. 73%,  $p < 0.05$ ), suggesting that success is not only determined by anatomical factors (e.g., size and tortuosity of the VOM), but also by operator experience.


### 3.3 UNVEILING OF AN LA VENOUS PLEXUS

Our initial experience has confirmed that the VOM is a true atrial vein, communicating via capillaries with the LA myocardium, rather than a simple residual lumen of the ligament of Marshall, and thus the VOM is a viable route to deliver therapeutic agents in the LA. Additionally, with occlusive VOM venograms, we have found a heretofore-undescribed epicardial atrial venous plexus filled via collaterals.

### 3.4 VOM ETHANOL INFUSION: TISSUE ABLATION AND LEFT PV DISCONNECTION

The obvious effect of ethanol infusion is rapid ablation of atrial tissues in the vicinity of the VOM. Such areas are standard targets of ablation in persistent AF, and encompass the lateral ridge of the left atrium (which due its thickness can be difficult to ablate, see Figure 2), extending variably to areas around the left PVs, and towards the mitral annulus, including a large portion of the mitral isthmus. In our total experience of up to 89 cases, ethanol infusion can lead to isolation of the left inferior PV in up to 74% of the cases, and isolation of the left superior PV in 44% and generates an area of ablated tissue of  $9.7 \pm 4.8 \text{ cm}^2$ . [Figure 4](#) shows an example.

Figure 4. Tissue ablation by VOM ethanol infusion




### 3.5 VOM ETHANOL INFUSION: A NOVEL TECHNIQUE FOR LOCAL VAGAL DENERVATION IN HUMANS

The location of the VOM coincides with that of the left dorsal pathway of vagal innervation to the intrinsic cardiac ganglia<sup>102</sup> (Figure 5). In our recent experience we have shown that high-frequency stimulation (30 Hz, 25 mA) in the VOM can induce vagal reflexes reaching the AV node (causing transient AV node conduction blockade) in 75% of patients (n=32) and inducing AF in 100%. Such responses are completely abolished in all patients after VOM ethanol infusion (Figure 5). Of note, because AF is consistently induced during high-frequency stimulation –due to direct left atrial capture–, vagal responses are only assessable by the presence of AV nodal block. Of the vagal plexi of the atria, it is the right inferior PV plexus that directly connects with the AV node.<sup>103</sup> The VOM is remote from the AV node, so inducing AV conduction slowing by VOM high-frequency stimulation supports VOM-to-right inferior PV plexus-to-AV node connection, and thus *supports that the VOM is a vascular route to the intrinsic cardiac ganglia* (see Figure 5A). Vagal responses were abolished in all patients in whom such responses were elicited at baseline, and AF induction by VOM high-frequency elimination was eliminated in all patients. Thus, VOM ethanol infusion is an effective strategy to achieve regional denervation of the human LA.<sup>104</sup>



**Figure 5. Vagal denervation by VOM ethanol infusion**




A, Vagal innervation (histochemical staining) of the LA. Dotted line is the location of the VOM, coinciding with the left dorsal (LD) tract of vagal nerves, connected with neural plexi (insets). From indicated reference. B, VOM cannulation with a quadripolar catheter to perform high-frequency stimulation, indicated by the blue arrow in C and D, Electrograms during high-frequency stimulation in the VOM during on-going AF. Pre-ethanol infusion (C), atrioventricular block with asystole of 4.1 s is induced. Such response is abolished after ethanol infusion (D).

**3.6 VOM ETHANOL INFUSION AND PERIMITRAL FLUTTER (PMF)**

Due to the frequent incidence of PMF, the difficulties in achieving perimitral bidirectional conduction block to treat it, and the potential risk of damaging the left circumflex coronary artery with RF ablation, there is a clinical need for new treatment strategies. We have evaluated the effect of VOM ethanol infusion on perimitral conduction in 43 patients (25 of which had PMF mapped prior to ethanol delivery). Although VOM ethanol infusion by itself only led to bidirectional perimitral block in 3 patients, this was easily achieved with minimal RF ablation in the most anterior aspect of the mitral isthmus ( $2.5 \pm 1.3$  min), anterior to the scar created by ethanol, in 98% of patients.<sup>105</sup> Figure 6 shows examples. Considering the low success rate reported by RF ablation (32%<sup>59</sup>, 64%<sup>60</sup> or 71%<sup>61</sup>) –including epicardial ablation in the CS–, and the potential iatrogenic induction of recurrent flutters when bidirectional perimitral block is not achieved due to incomplete ablation, this novel technique promises to make a significant difference in the treatment of PMF.



**Figure 6. PMF treated by VOM ethanol infusion**




A, Example of PMF (counterclockwise, colors represent time). B, Conventional ablation sites (blue dots) in the mitral isthmus to treat PMF. C-F, Examples of ethanol-induced scar maps (voltage color scale) and locations of RF ablation lesions (arrowheads), required to achieve bidirectional mitral block.

### 3.7 ROLE OF VOM IN FAILED ABLATIONS

We have assessed the role of VOM activity in patients presenting for a repeat ablation procedure after a failed PVAI, as part of our R21 project. In 58 patients with recurrent AF, the VOM was cannulated in 51 and VOM signals were present in all of them, indicating that a *conventional PVAI procedure does not ablate VOM activity*. This was the case even in cases in which extensive LA ablation had been performed in the index procedure. [Figure 7](#) shows an example that illustrates that, even with extensive LA ablation (that caused most of the LA endocardium to be scarred –without detectable electrograms) the VOM remains electrically active.

*Thus, as a novel catheter ablation technique, our preliminary mechanistic data in humans supports that VOM ethanol infusion provides rapid tissue ablation of targeted areas, helps treat PMF and achieves regional LA vagal denervation. The VOM is not otherwise ablated by conventional PVAI.*

**Figure 7. Lack of VOM ablation by PVAI**




## 4.0 TRIAL OVERVIEW AND PRELIMINARY DATA

### 4.1 HYPOTHESIS

Our hypothesis is that a combined procedure of VOM ethanol infusion plus conventional PVAI (VOM-PV) is superior to PVAI alone in the catheter ablation treatment of persistent AF. We will compare the two treatments in a randomized fashion in 2 subsets of patients: *de novo* ablation, and repeat ablation in patients with persistent AF (Figure 8). Given the extent of tissue ablation required, we have chosen to use this technique in persistent AF, rather than in paroxysmal AF, in which less extensive tissue ablations may suffice. VOM ethanol infusion must be an add-on to the standard catheter ablation procedure, since it has no effect on other ablation targets such as the right PVs, septum, etc. Over our past experience we have established the safety of this procedure, uncovered novel mechanistic effects such as vagal denervation, and generated pilot data to support an improvement in outcomes.

Figure 8. Clinical Trial Design.



#### 4.2 PRELIMINARY OUTCOMES DATA: RESULTS OF OUR PILOT EXPERIENCE

We have compared our ablation outcomes in persistent AF patients treated with VOM-PV with those treated with PVAI. In 174 patients undergoing conventional PVAI, our single-procedure success rate at one year has been 45% (consistent with literature reports of 27%,<sup>45</sup> 36%,<sup>57</sup> or 49%<sup>58</sup>). In contrast, in 66 patients with persistent AF subjected to VOM-PV, our success rate has been 61%. These data will be used for sample size statistical calculations for VENUS-AF, which enrolls a patient population undergoing their first AF ablation.

#### 4.3 THREE MONTH BLANKING PERIOD

This protocol uses a three month “blinking period” as a period of time following an atrial fibrillation procedure in which atrial fibrillation episodes can occur as part of the body’s healing response. Any atrial fib/flutter activity during that blinking period is not counted in the study’s results and is not used in determining success or failure of the procedure as it is a common and expected outcome.

1. For all patients:
  - a. Total procedure, RF ablation, and fluoroscopy times.
  - b. RF time and success of bidirectional block across the mitral isthmus line tested by differential pacing.
  - c. Pre-ablation 3D voltage maps.
  - d. Ablation lesion sets: 3D maps (Carto or NavX), including ablated scar surface area, as measured by bipolar voltage less than 0.1 mV.
  - e. Any procedural complications.
2. In patients randomized to VOM ethanol infusion:
  - a. Successful vs. unsuccessful cannulation with angioplasty wire and balloon.
  - b. Extent of tissue ablation achieved by ethanol infusion, defined as areas with local electrogram voltage <0.1 mV on 3D mapping. (Pre-PVAI voltage map).
  - c. Added procedural and fluoroscopy time.
  - d. Effect on AF: termination, conversion into flutter or no change.
  - e. RF time to achieve block around the mitral annulus.
  - f. Complications related to VOM instrumentation.
  - g. Blood ethanol level measurement.
  - h. LA instrumentation time.
  - i. Ablation lesion sets: 3D maps (Carto or NavX) including total (RF plus ethanol) ablated scar surface area, as measured by bipolar voltage less than 0.1 mV
  - j. Periprocedural data collection.

## 5.0 MATERIALS AND METHODS

### 5.1 SPECIFIC AIMS

***Aim for VENUS is to assess the impact of VOM ethanol infusion in single-procedure success when added to de novo catheter ablation of persistent AF.***

VOM triggers and innervation may play a role in persistent AF, and are not addressed by a standard PVAI. Our hypothesis is that VOM ethanol infusion will do so and lead to improved outcomes. This is a prospective, multi-center, randomized study comparing a combined procedure including VOM ethanol infusion plus PVAI (VOM-PV) with PVAI alone in patients with persistent AF. The trial design incorporates a plan for possible repeat procedures if AF recurs after the 3-month blinking period, as this is common in clinical practice.

### 5.2 STUDY ENDPOINTS

### **Primary endpoints:**

1. Primary Efficacy Endpoint Freedom from AT/AF clinical recurrence on follow-up visits AND less than 30 seconds of AT/AF on a 1 month continuous electrocardiographic monitor at 6 and 12 months.
2. Primary Safety Endpoint - Acute procedural complications and total mortality.

### **Secondary Endpoints**

1. Freedom from AF/AT after >1 procedure.
2. Freedom from AF/AT on antiarrhythmic drugs.
3. AF burden (% time) on continuous monitoring at 6 and 12 months.
4. Procedural parameters: total procedure, fluoroscopy, total RF ablation time (first procedure), and total extent of ablated LA tissue.
5. Clinical/partial success: less than 25% AF burden on a continuous event monitor at 6 and 12 months from ablation procedure.
6. Sub-acute procedural complications (within 30 days).
7. Recurrence as persistent or paroxysmal AF, or flutter after 1 or 2 procedures.
8. LA function on Doppler echocardiography (LA strain<sup>114ab</sup>) at 12 months.
9. Incidence and mechanisms of atrial flutters.
10. Cardiovascular hospitalizations and
11. QOL as determined by AFEQT questionnaire.

## 5.3 INCLUSION AND EXCLUSION CRITERIA

### **Inclusion criteria**

1. Patients between the ages of 21 and 85 years
2. Ablation History  
Patients for **VENUS** must meet the following:
  - Diagnosed with symptomatic not previously ablated persistent AF,
  - AF not spontaneously converting to sinus rhythm, persisting for  $\geq 7$  days
3. Resistant or intolerant to at least one class I, II, or III AAD
4. Patients deemed candidates for RF ablation of AF
5. Able and willing to comply with pre-, post-, and follow-up requirements.

### **Exclusion criteria**

1. Left atrial thrombus.  
LAA thrombus can be determined by pre-procedural imaging: CT, TEE, or MRI. Documentation by exception (i.e. no LAA thrombus on imaging reports) is permitted for determination of eligibility.
2. LA diameter greater than 65 mm on long axis parasternal view, or left atrial volume more than 200 cc.
3. Left ventricular ejection fraction < 30%.
4. Cardiac surgery within the previous 90 days.
5. Expecting cardiac transplantation or other cardiac surgery within 180 days.
6. Coronary PTCA/stenting within the previous 90 days.



7. Documented history of a thrombi-embolic event within the previous 90 days.
8. Diagnosed atrial myxoma.
9. Significant restrictive, constrictive, or chronic obstructive pulmonary disease with chronic symptoms.
10. Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment
11. Women who are pregnant or who plan to become pregnant during the study.
12. Acute illness or active infection at time of index procedure documented by either pain, fever, drainage, positive culture and/or leukocytosis (WBC > 11k/ mm<sup>3</sup>) for which antibiotics have been or will be prescribed.
13. Creatinine > 2.5 mg/dl (or > 221 µmol/L, except for patients in dialysis).
14. Unstable angina.
15. Myocardial infarction within the previous 60 days.
16. History of blood clotting or bleeding abnormalities.
17. Contraindication to anticoagulation.
18. Life expectancy less than 1 year.
19. Uncontrolled heart failure.
20. Presence of an intramural thrombus, tumor, or other abnormality that precludes catheter introduction or positioning.
21. Presence of a condition that precludes vascular access.
22. INR greater than 3.5 within 24 hours of procedure – for patients taking warfarin.
23. Cannot be removed from antiarrhythmic drugs for reasons other than AF.
24. Unwilling or unable to provide informed consent.

#### 5.4 INFORMED CONSENT PROCESS

The informed consent should be signed by the potential subject ***prior to any study-specific procedures taking place.***

An appropriately trained study team member will conduct the informed consent process with potential subjects in the approved manner for the institution, to include (at a minimum) the following procedures: ensuring the use of the most currently IRB approved document, allowing the potential subject sufficient time to read the consent and ask questions of the study staff, and ensure subjects have a clear understanding of the voluntary nature of their consent and the expectations for their commitment. The process above should be documented in the study record, apart from a copy being placed into the study file.

#### 5.5 STUDY PROCEDURES **SCREENING/BASELINE**

##### **1. Initial assessment.**

After signing informed consent, the following data will be collected; a significant medical history and recent targeted physical exam, electrocardiogram (EKG), echocardiogram within one year prior to the procedure for evaluation of cardiac

structure, and function, and laboratory tests. In addition, a review of medications that patient is taking (limited to AAD and anticoagulants), and a quality of life (QOL) questionnaire especially developed for AF (AFEQT)<sup>113</sup> will be filled out by patients.

Screening assessments performed pre-consent signature that are completed under standard of care can be included as viable source documents for patient study inclusion/exclusion and may be collected to screen potential study patients.

## **2. Pre-procedural imaging.**

Imaging prior to enrollment is required to rule out structural heart disease and, as needed, to rule out the presence of LA appendage thrombus. *Ruling out LAA thrombus can be performed by the following: TEE, CT, or MRI within 48 hours of the procedure; at least one month of oral anticoagulation prior to the procedure; or documented prior procedures of LAA occlusion or ligation.* For ruling out structural heart disease, either a cardiac MRI, CT or transthoracic echocardiogram within 1 year prior to participation in the study is sufficient. Documentation by exception (i.e. no LAA thrombus documented on imaging report) is permitted for determination of eligibility. Left atrial diameter and estimated left atrial volume will be obtained from any of these diagnostic modalities. There is no specific requirement for a pre-ablation CT or MR, since anatomical details of the LA can be obtained intra-procedurally with current mapping systems.

## **3 Randomization.**

Randomization should take place after confirmation that all inclusion/exclusion criteria are met and measurements of LA volume are obtained. Patients will be randomized in a 1.15:1 fashion (to account for an 85% technical feasibility of the VOM procedure) to receive either VOM-PV or the conventional PVAI. Patients will be blinded to the randomization outcome.

## **PROCEDURE/DAY 0:**

### **1 PVAI procedure**

As part of a conventional catheter ablation of AF the following will be performed, all considered standard of care:

- a) Electrophysiological catheters will be inserted, including a CS catheter, a duodecapolar circumferential catheter, and an ablation catheter. The last two will be inserted in the LA via trans-septal punctures.
- b) Prior to ablation, geometry of the LA will be obtained using a 3-dimensional (3D) mapping system (any of the commercially available systems). This will generate a computerized geometry of the LA, including baseline voltage amplitudes in different regions. LA scar surface area (bipolar voltage less than 0.1 mV) will be collected.

- c) Lesion sets delivered by RF application will include, in a step-wise fashion, the following ablations, starting with PVAI and added sequentially per the operator's judgment if AF persists after each step is completed:
- i) PVAI. RF should be applied 1 cm proximal to the PV ostia in a wide area circumferential pattern. Isolation will be verified by the absence of electrical activity from each PV and/or dissociated activity.
  - ii) The greater PV antra, including posterior wall and roof.
  - iii) Mitral isthmus: a line of RF ablation from the left inferior PV to the mitral annulus. Bidirectional block should be verified after completion by differential pacing.
  - iv) Areas of complex, fractionated potentials.
  - v) Sustained atrial flutters will be mapped and ablated as directed by the map and flutter location.
  - vi) Following step 4c, if AF persists after all the RF ablations, the patient will be cardioverted to restore sinus rhythm. Given the potential variability of the extent of ablations, maps of the lesion sets (see below) will be collected and maintained in an imaging core laboratory.

## **2 VOM procedure**

In patients randomized to VOM-PV, **prior to the conventional PVAI**, the following will be performed:

- a) A 7F-9F sheath will be advanced in the CS via a right internal jugular vein access. Femoral vein access is also appropriate to cannulate the CS. Contrast injection in the CS will be performed via a sub-selector catheter (recommended 6F left internal mammary angiographic guide catheter) to identify the VOM. We will obtain a CS venogram and identify the location of the VOM. Cannulation of the VOM will be performed using the sub-selector catheter that can be torqued so that its tip is engaged in the ostium of the VOM. Contrast will be injected via the lumen of the sub-selector catheter to verify such engagement.
- b) If large enough, the VOM will be cannulated with an angioplasty wire (0.014") that will be advanced through the sub-selector catheter and into it. If the VOM is too small to accommodate the wire, venodilation with 200 µgm of nitroglycerine through the sub-selector catheter will be administered to facilitate VOM cannulation.
- c) An angioplasty balloon (1.5 -2 mm diameter, 6-8 mm length) will be advanced over the wire and positioned in the ostium of the VOM. The balloon will be inflated to occlude the vein. Contrast venograms of the VOM will be recorded in left and right anterior oblique projections. The angioplasty balloon will be then advanced as distally as possible in the VOM and the first ethanol injection will be

performed there after balloon inflation. The balloon will be then deflated and retracted 1-2 cm for a repeat inflation and ethanol injection. Up to four, 1 cc injections (depending on the VOM length) of 98% ethanol will be delivered in the VOM by sequentially retracting the balloon up to the VOM ostium.

- d) The procedure will then continue with standard PVAI procedure as outlined in section 4.

### **3 Bipolar voltage amplitude maps to be performed:**

Using an electro-anatomical mapping system, the extent of the scar –measured as bipolar voltage <0.1 mV- will be recorded:

- a. At baseline after gaining trans-septal access to the LA in both randomization groups.
- b. After ethanol infusion, if randomized to VOM-PV.
- c. After completion of the PVAI ablation lesions, in both randomization groups.

#### **5.6 POST-PROCEDURAL DATA COLLECTION:**

*Patients may receive follow-up standard of care procedures (ECG, physical exam, review of medical history and concomitant medications) at the study site or at a provider of their choice. If an investigator at a study site does not perform the visit, the study staff will have the patient sign a Release of Medical Information and request the applicable medical records from the patient's provider. All ECG tracings must be reviewed and interpreted by a study investigator. The AFEQT questionnaire may be conducted by telephone call with the patient.*

- 1. Seven day telephone follow-up (+/- 3 days)** should be conducted by study coordinator to assess patient for symptoms of procedure related or disease related complications.
- 2. Thirty-day (30D) follow-up (+/- 10 days).** Follow up evaluation will include an EKG, assessment for complications including a targeted physical exam and a review of adverse events and concomitant medications (limited to AAD and anticoagulants) will be documented. Routine medications, including AAD may be continued. Symptomatic AF or flutter should be treated with AAD or cardioversion as needed but will not be recorded for endpoint assessment.
- 3. Three-month (90D) follow-up (+/- 30 days).** Evaluation will include an EKG, and assessment for complications, targeted physical exam and a review of adverse events and concomitant medications (limited to AAD and anticoagulants) will be documented. If the patient is in AF or flutter, a cardioversion will be performed electively within 2 weeks so that all patients are in sinus rhythm after the 3 month blanking period. AAD therapy will be discontinued in all patients at this time if they are clinically stable and in sinus rhythm.
- 4. Six-month (180D) follow-up up (+/- 60 days).** Follow up evaluation will include an EKG, and physical exam. Additionally, patients will fill out the AFEQT<sub>113</sub> QOL questionnaire and will undergo a 3-4 week continuous EKG monitor (4 weeks if tolerated by patient) (see *Core laboratories*, below). Subjects who have a miniaturized, implantable rhythm recording device (such as Medtronic LinQ and others) or an implanted

pacemaker/defibrillator may have the continuous rhythm data obtained from that device, and may forego the portable recorder. The purpose of this EKG monitor (4 weeks if tolerated by patient) is to screen for recurrent AF that may prompt an early repeat procedure. Patients that have clinical or EKG recurrences will undergo a PVAI procedure (see below and Figure 8).

5. **Nine-month follow-up (+/- 30 days).** Follow up evaluation will include an EKG and physical exam. Patients that have clinical or EKG recurrences will undergo a repeat PVAI procedure. The timing of a repeat procedure will be encouraged to be within 6 months of randomization.
6. **Twelve-month follow-up (+/- 60 days).** Follow up evaluation will include an EKG, and physical exam. Additionally, patients will fill out the AFEQT<sub>113</sub> QOL questionnaire and undergo a continuous EKG monitor (4 weeks if tolerated by patient) to determine the primary efficacy endpoint.

Subjects who have a miniaturized, implantable rhythm recording device (such as Medtronic LinQ and others) or an implantable pacemaker/defibrillator may have the continuous rhythm data obtained from that device, and may forego the portable recorder.

Patients will fill out the AFEQT<sub>113</sub> QOL questionnaire. Additionally, echocardiographic assessment of LA function (LA ejection fraction, strain<sup>114ab</sup>) will be performed by a central reader at Houston Methodist Hospital.

–

## 5.7 VENUS: DEFINITIONS OF PROCEDURAL SUCCESS OR FAILURE AND INDICATIONS FOR REPEAT PROCEDURES

1. **Success:** Freedom from AT/AF clinical recurrence on follow-up visits AND less than 30 seconds of AT/AF on a 1 month continuous electrocardiographic monitor.
2. **Clinical Success.** Freedom from AT/AF clinical recurrence on follow-up visits but documented AF or flutter up to 25% of the time on a 1-month continuous electrocardiographic monitor. The rationale is to account for patients in whom a repeat procedure would not be clinically indicated, yet AF/AT would not be considered cured.
3. **Repeat procedures. A repeat procedure will constitute an effectiveness failure for the purpose of the primary efficacy endpoint.** However, repeat procedures and their outcomes will be recorded for secondary outcome analysis. First, repeat procedures are a clinical reality in persistent AF, and a single-procedure success endpoint –does not capture it. Second, it is possible that VOM-PV on a first procedure may increase success of a second procedure –e. g. if the recurrences in VOM-PV group are as AT instead of AF. Both represent a clinical failure of the procedure, but a repeat procedure for AT is more likely to succeed.<sup>65</sup> Repeat procedures will be encouraged to be timed within the first 6 months of the randomization procedure. Although this may seem short, it is our clinical experience that the bulk of AF recurrences tend to occur shortly after the



blanking period.<sup>115</sup> Thus, we expect a minority of patients to recur late in this window.

Indications for a repeat procedure include:

- a. Procedure failure: Symptomatic, recurrent persistent AF or flutter detected clinically during the scheduled follow-up visits.
- b. Less than partial/clinical success: AF or flutter burden on electrocardiographic monitoring exceeding 25% regardless of symptoms. Monitoring will be performed at 6 months post randomization procedure.
- c. Symptomatic AF or flutter detected on electrocardiographic monitoring regardless of AF or flutter burden. Monitoring will be performed at 6 months post randomization procedure.

Data to be collected during a repeat procedure will include

- a. Documentation of PV isolation: number and location of reconnected PV at the baseline of the repeat procedure.
- b. Perimitral conduction: presence or absence of perimitral block.
- c. Mechanisms of atrial flutter, if present.
- d. Documentation of other RF ablation sites
- e. Documentation of RF time, time to perimitral block (if not already achieved), fluoroscopy time, LA instrumentation time, and procedure time.
- f. Baseline and Final LA voltage map (using any commercially available electroanatomical mapping systems). Measurement of baseline and Final LA scar surface area.

#### **4. Effectiveness (Treatment) Failures**

Effectiveness failures towards the primary endpoint will include the following (see Figure 8):

- a. Clinical recurrence of AF or AT after 3-months.
- b. Documented AF or AT of 30 seconds or more on EKG monitor at obtained at 6 and 12 months.
- c. Requirement of a repeat ablation procedure for recurrent AT-AF.
- d. Death.

VENUS patients who have a recurrence after 3 months post randomization will have a repeat procedure (PVAI). Patients will be deemed to be effectiveness failure for the primary efficacy endpoint of the trial after repeat procedures. Still, subjects will:

- a. Remain in the study for the purpose of all secondary endpoints: these include quality of life, AF burden on event monitoring, success after multiple procedures.
- b. Undergo all clinically necessary procedures and treatments, including prescription of antiarrhythmic therapy and additional procedures needed to control atrial fibrillation or flutter. A crossover VOM procedure will be offered to those randomized to PVAI after 2 in-study procedures.
- c. Data on such additional procedures or treatment will be collected in the Electronic Data Capture system (EDC).

- d. An additional secondary endpoint will be created: total number of procedures performed and requirement of antiarrhythmic drugs.

#### **5. VENUS: Cross-over of patients initially randomized to PVAI only.**

If a VENUS patient is originally randomized to conventional PVAI and experiences a treatment failure after a repeat procedure he or she may undergo an additional conventional PVAI ablation procedure during the study. Crossover to VOM ethanol will only be allowed after 2 procedures are performed in the setting of study participation. This is allowed because certain recurrent flutters are particularly suited to respond to VOM ethanol. The primary and secondary endpoints will be computed following their original randomization group.

#### Indications for a repeat procedure include:

- a. Procedure failure: Symptomatic, recurrent persistent AF or flutter detected clinically during the scheduled follow-up visits.
- b. Less than partial/clinical success: AF or flutter burden on electrocardiographic monitoring exceeding 25% regardless of symptoms. Monitoring will be performed at 6 months post randomization procedure.
- c. Symptomatic AF or flutter detected on electrocardiographic monitoring regardless of AF or flutter burden. Monitoring will be performed at 6 months post randomization procedure.

#### Data to be collected during a repeat procedure will include

- a. Documentation of PV isolation: number and location of reconnected PV at the baseline of the repeat procedure.
- b. Perimitral conduction: presence or absence of perimitral block.
- c. Mechanisms of atrial flutter, if present.
- d. Documentation of other RF ablation sites
- e. Documentation of RF time, time to perimitral block (if not already achieved), fluoroscopy time, LA instrumentation time, and procedure time.
- f. Baseline and Final LA voltage map (using any commercially available electroanatomical mapping systems). Measurement of baseline and Final LA scar surface area.

### **4. Effectiveness (Treatment) Failures**

Effectiveness failures towards the primary endpoint will include the following (see Figure 8):

- e. Clinical recurrence of AF or AT after 3-months.
- f. Documented AF or AT of 30 seconds or more on EKG monitor at obtained at 6 and 12 months.
- g. Requirement of a repeat ablation procedure for recurrent AT-AF.
- h. Death.

Patients who have a recurrence after 3 months post randomization will have a repeat procedure (PVAI). Patients will be deemed to be effectiveness failure for the primary endpoint of the trial after repeat procedures. Still, subjects will:

- e. Remain in the study for the purpose of all secondary endpoints: these include quality of life, AF burden on event monitoring, success after multiple procedures.
- f. Undergo all clinically necessary procedures and treatments, including prescription of antiarrhythmic therapy and additional procedures needed to control atrial fibrillation or flutter. A crossover VOM procedure will be offered to those randomized to PVAI after 2 in-study procedures.
- g. Data on such additional procedures or treatment will be collected in the Electronic Data Capture system (EDC).
- h. An additional secondary endpoint will be created: total number of procedures performed and requirement of antiarrhythmic drugs.

#### 5. Cross-over option for of patients initially randomized to PVAI only.

If a patient is originally randomized to conventional PVAI and experiences a treatment failure after a repeat procedure he or she may undergo an additional conventional PVAI ablation procedure during the study. Crossover to VOM ethanol will only be allowed after 2 procedures are performed in the setting of study participation. This is allowed because certain recurrent flutters are particularly suited to respond to VOM ethanol. The primary and secondary endpoints will be computed following their original randomization group.

## 6.0 STATISTICAL CONSIDERATIONS

### A) Assumptions.

*Single-procedure versus multiple-procedure success.* Our initial preliminary data suggested an overall procedure success of 45% in patients undergoing PVAI and 61% for those undergoing VOM-PV (difference of 16%). This included patients with repeat procedures performed in some, but not all of the failed procedures (45% all patients in the PVAI group and 30% in the VOM-PV group). **The single-procedure success was 38% in patients undergoing PVAI and 56% in patients undergoing VOM-PV** (difference of 18%). Thus, the endpoint of single-procedure success is likely to show greater differences amongst groups.

*Mortality.* The expected mortality is low in this study as it has been in AF ablation trials. Mortality will be recorded as a safety endpoint.

*One-year follow-up time.* In previous versions of the protocol, additional follow-up time (up to 15 months) was included in the VENUS trial, in order to accommodate for appropriate follow-up of patients undergoing repeat procedures. Therefore, a trial duration of 12 months is sufficient if just single-procedure success is the primary efficacy endpoint. Procedural failures (events counted as the primary efficacy endpoint) occur mostly during the first year. Additionally, 12-month follow-up is consistent with the recommendations for clinical trials in AF by the HRS/EHRA/ECAS Catheter and Surgical Ablation consensus document.<sup>2</sup>

Unknown classification as success or failure. Patients who cannot be classified as successes or failures on the primary efficacy endpoint will be excluded from the primary analysis.

**B) VENUS Group Sequential Clinical Trial Design**

**Power and sample size determination.** Group sequential two proportions power analysis using simulation was performed using PASS V12 (Kaysville, UT). The following assumptions were made:

- Response rate in PV-VOM:  $p_1=0.56$
- Response rate in PVAI:  $p_2= 0.38$
- Hypotheses:  $H_0: p_1= p_2$ ;  $H_1: p_1 \neq p_2$
- Test Statistic: Z-Test (Unpooled)
- Zero Adjustment Method: None
- Alpha-Spending Function: O'Brien-Fleming Analog
- Beta-Spending Function: None
- Futility Boundary Type: None
- Number of Looks: 3
- Simulations: 100000

**Results.** A group sequential trial with sample sizes of  $N_1=180$  and  $N_2=156$  at the final look achieves 91% power to detect a difference of 0.18 between a treatment group success proportion of 0.56 and a control group success proportion of 0.38 at the 0.05 significance level (alpha) using a two-sided Z-Test (Unpooled). The table below lists the sample sizes required for 91% power.

**Table 5. Sample size requirements for a group sequential trial based on 100,000 iterations.**

Value	95% LCL	95% UCL	Target	Actual	95% LCL	95% UCL	Beta		
0.909	0.908	0.911	0.050	0.049	0.048	0.051	0.091		
---- Average Sample Size ----									
-- Given H0 --				-- Given H1 --					
N1	N2	Grp1	Grp2	Grp1	Grp2	Diff0	Diff1	P1 H1	P2
180	156	179	155	144	125	0.00	0.18	0.56	0.38

**Efficacy Monitoring.** We propose to monitor efficacy at two interim time points and one final time period (i.e., three “looks”) when primary outcome data (12 month follow-up) are available for 1/3, 2/3 and 3/3 of the total sample size of VENUS subjects. For the VENUS trial, these values are provide in the following table in terms of *information time*:

**Table 6. Efficacy monitoring schedule for VENUS with cumulative sample size, significance boundaries and 95%CIs, and alpha- and beta-spending.**

<i>Accumulated primary outcomes for VENUS</i>						
<b>Look</b>	<b>Accumulated Information</b>	<b>----- Accumulated Sample Size -----</b>				
	<b>Percent</b>	<b>VOM</b>	<b>PVAI</b>	<b>Total</b>		
1	33.33	60	52	112		
2	66.67	120	104	224		
3	100.00	180	156	336		

<i>Significance Boundaries with 95% Simulation Confidence Intervals</i>						
<b>Look</b>	<b>----- Z-Value Boundary -----</b>			<b>----- P-Value Boundary -----</b>		
	<b>Value</b>	<b>95% LCL</b>	<b>95% UCL</b>	<b>Value</b>	<b>95% LCL</b>	<b>95% UCL</b>
1	+/- 3.953	3.809	4.289	0.000	0.000	0.000
2	+/- 2.543	2.516	2.578	0.011	0.010	0.012
3	+/- 2.011	1.994	2.036	0.044	0.042	0.046


<i>Alpha-Spending</i>								
<b>Look</b>	<b>----- Target -----</b>		<b>----- Actual -----</b>		<b>----- Proportion -----</b>		<b>Cum.</b>	
	<b>--- Signif. Boundary ---</b>		<b>Spending</b>	<b>Spending</b>	<b>Cum.</b>	<b>H1 Sims</b>	<b>Cum.</b>	<b>H1 Sims</b>
	<b>Z-Value</b>	<b>P-Value</b>	<b>Function</b>	<b>Function</b>	<b>Alpha</b>	<b>Outside</b>	<b>Alpha</b>	<b>Outside</b>
	<b>Scale</b>	<b>Scale</b>	<b>Alpha</b>	<b>Alpha</b>	<b>Spent</b>	<b>Signif. Boundary</b>	<b>Spent</b>	<b>Signif. Boundary</b>
1	+/- 3.953	0.000	0.000	0.000	0.000	0.000	0.033	0.033
2	+/- 2.543	0.011	0.012	0.012	0.011	0.012	0.547	0.579
3	+/- 2.011	0.044	0.038	0.050	0.038	0.049	0.329	0.909

The hypothesis test applied at the  $k$ th look is a two-tailed test of equality of two independent proportions, functionally composed as

$$Z_k = \frac{\hat{p}_{1k} - \hat{p}_{2k}}{\sqrt{\frac{\hat{p}_{1k}(1-\hat{p}_{1k})}{n_{1k}} + \frac{\hat{p}_{2k}(1-\hat{p}_{2k})}{n_{2k}}}}$$

where  $\hat{p}_{1k}$  is the proportion of successful primary outcomes in the PVAI-VOM arm of VENUS at the  $k$ th look, and  $\hat{p}_{2k}$  is the proportion of successful primary outcomes within the PVAI arm of VENUS at the  $k$ th look.  $Z_k$  follows a standard normal distribution,  $N(0,1)$ . If during the first look when at least  $N=60$  VOM and  $N=52$  PVAI primary outcomes have been observed ( $N=112$  total), if  $Z_1$  exceeds 3.953, then the trial will be evaluated for early termination due to beneficial efficacy, whereas if the power is 30% or less, the trial will be evaluated for early termination for futility. However, if the power of the test falls in the “promising zone” (30-70%), we will continue the trial. The same rule applies for the 2<sup>nd</sup> look when at least  $N=120$  VOM and 104 PVAI primary outcomes (224 total) have been observed in both arms, for which the tabled critical value of  $Z_2$  is  $\pm 2.543$ . The overall efficacy of the trial will be determined when at least  $N=180$  VOM and  $N=156$  (336 total) primary outcomes have been observed, for which the critical value of  $Z_3$  is  $\pm 2.011$ .





**Figure S1. Efficacy boundaries at 33%, 66%, and 100% accrual of VENUS primary outcomes.**

**VENUS Interim Analysis - Conditional Power and Futility for Various Test Results.**

During the interim analysis, estimations of conditional power and futility will be performed, to provide information for clinical trial continuation decisions. The sample size will not be subject to any changes.

Conditional power runs were made using PASS 12 (Kaysville, UT). During the first look at 33% information time, there will be 60 VOM and 52 PVAI primary outcomes available. Using a one-sided ( $\alpha=0.025$ ) test of two proportions,  $\theta=p_2-p_1$ , where  $p_2$  is the PVAI success rate and  $p_1$  is the VOM success rate, the expectation is that the test statistic  $Z_k$  is less than zero, since  $H_a: p_2 < p_1$ . The table below list the conditional power and futility at the first look for a range of  $Z_k$  values:

**Table 7. VENUS Conditional power and futility at the first look (33% information, 60 VOM, 52 PVAI) for a range of  $Z_k$  values from a one-sided test of two independent proportions.**

Cond. Power	Pred. Power	Total Sample Size VOM/PVAI	Current Sample Size n1k n2k	Prop. Group 1 P1	Prop. Group 2 P2	Test Statistic $Z_k$	Alpha	Futility
0.99994	1	180 156	60 52	0.56	0.38	-5	0.025	0.00006
0.99974	0.99998	180 156	60 52	0.56	0.38	-4.5	0.025	0.00026
0.9991	0.99978	180 156	60 52	0.56	0.38	-4	0.025	0.0009
0.99717	0.99814	180 156	60 52	0.56	0.38	-3.5	0.025	0.00283
0.99209	0.98894	180 156	60 52	0.56	0.38	-3	0.025	0.00791
0.98027	0.95313	180 156	60 52	0.56	0.38	-2.5	0.025	0.01973
0.95597	0.85624	180 156	60 52	0.56	0.38	-2	0.025	0.04403
0.91184	0.67408	180 156	60 52	0.56	0.38	-1.5	0.025	0.08816
0.84101	0.43598	180 156	60 52	0.56	0.38	-1	0.025	0.15899
0.74056	0.2196	180 156	60 52	0.56	0.38	-0.5	0.025	0.25944
0.61467	0.08289	180 156	60 52	0.56	0.38	0	0.025	0.38533

**Table 8. VENUS Conditional power and futility at the second look (66% information, 120 VOM, 104 PVAI) for a range of  $Z_k$  values from a one-sided test of two independent proportions.**

Cond. Power	Pred. Power	Total Sample Size VOM/PVAI	Current Sample Size n1k n2k	Prop. Group 1 P1	Prop. Group 2 P2	Test Statistic $Z_k$	Alpha	Futility
1.00000	1.00000	180 156	120 104	0.56	0.38	-5.0	0.025	0
1.00000	1.00000	180 156	120 104	0.56	0.38	-4.5	0.025	0
0.99998	0.99998	180 156	120 104	0.56	0.38	-4.0	0.025	0.00002
0.99973	0.99950	180 156	120 104	0.56	0.38	-3.5	0.025	0.00027
0.99703	0.99233	180 156	120 104	0.56	0.38	-3.0	0.025	0.00297
0.97954	0.94042	180 156	120 104	0.56	0.38	-2.5	0.025	0.02046
0.90942	0.75562	180 156	120 104	0.56	0.38	-2.0	0.025	0.09058
0.73567	0.43104	180 156	120 104	0.56	0.38	-1.5	0.025	0.26433
0.46930	0.14923	180 156	120 104	0.56	0.38	-1.0	0.025	0.5307
0.21648	0.02834	180 156	120 104	0.56	0.38	-0.5	0.025	0.78352
0.06795	0.00279	180 156	120 104	0.56	0.38	0.0	0.025	0.93205

### C) Statistical Analyses.

**Pre-specified subgroup analyses:** The following subgroups are defined to assess potential impact on outcomes:

- Male vs female.
- Longstanding persistent AF (duration of more than 1 year) vs persistent AF of less than one year
- Left atrial volume strata: defined as mild or no left atrial enlargement (LA volume - up to 75 ml/m<sup>2</sup>), moderate enlargement (76-89 ml/m<sup>2</sup>), or severe enlargement -90+ ml/m<sup>2</sup>)
- Enrollment as AF or AT –for MARS-AF trial only.
- Pre-existing low voltage scar and extent of low-voltage scar after ablation procedure (divided in tertiles).

**Primary Outcome.** Hypothesis tests for the equality of two proportions (unpooled standard errors) will be employed for determining whether or not the VOM success rate is significantly greater than the success rate for PVAI. The test statistic is a z-score which is standard normal distributed and the relevant lookup critical values (percentage points) are listed in the interim analysis section for group sequential designs. From a post-hoc perspective, we may use the stratified Mantel-Haenszel odds ratio test of proportions if we learn that success rates track with a particular covariate, such as LA volume or AF duration, and the strata weights are not highly imbalanced.

**Secondary Outcomes.** The secondary outcomes are listed below along with their corresponding storage location (various tables or Excel .csv files on output after report generation). Model building strategies (MBS) will be employed using univariate and multivariable regression models for post-hoc analyses of secondary outcomes. During MBS, univariate predictors whose  $p < 0.25$  will be selected as multiple variable model candidates. MBS regression methods may include linear, logistic, Poisson, and Cox proportional hazards (PH) along with regression diagnostics using the relevant goodness-of-fit criteria, residuals, variance inflation factors (VIF), ROC-AUC, and assumption-checking techniques (e.g. normally-distributed standardized residuals for linear regression). Regression diagnostics for linear regression will include estimation and filtering of overly influential records based on residuals, standardized, residuals, deletion residuals, Cook's distance, leverage, DFFITS, DFBETAS, and VIFs. Regression diagnostics for logistic and Poisson regression will include filtering on Pearson, deviance, and leverage residuals and the Hosmer-Lemeshow test for logistic regression GOF. Cox PH regression diagnostics will include Schoenfeld and Nelson-Aalen residuals, and possible employment of stratified models when the PH assumption fails.

The table below lists the primary outcomes which are to be analyzed during each interim analysis, as well as the secondary outcomes which will be analyzed and reported prior to all DSMB review meetings.

Primary Endpoints	EDC Pages	Data Fields
1. Freedom from symptomatic AF or flutter AND reduction of AF/flutter to less than 30 seconds in a continuous 4 week monitor at 6 and 12 months	<ul style="list-style-type: none"> <li>12 month continuous ECG page- MARS</li> <li>12 month continuous ECG page- Venus</li> </ul>	<ul style="list-style-type: none"> <li>6-12 month AF/AT Burden less than 30 seconds on continuous ECG monitoring</li> </ul>
2. Safety: Acute procedural complications	<ul style="list-style-type: none"> <li>AE pages</li> <li>Day 7 Telephone FU</li> </ul>	<ul style="list-style-type: none"> <li>Acute AE's related to Day 0 procedure</li> <li>Day 7 reported complications</li> </ul>
<b>Secondary Endpoints:</b>		
1. Single vs. 2-procedure success.	<ul style="list-style-type: none"> <li>Status change page</li> </ul>	<ul style="list-style-type: none"> <li>Single: reached primary endpoint #1 after first procedure with no repeats</li> <li>Two procedure: reached primary endpoint #1 after second procedure with no 3<sup>rd</sup> procedure</li> </ul>
2. AF burden (% time) on continuous monitoring at 12 months.	<ul style="list-style-type: none"> <li>6-12 month continuous ECG page- MARS</li> <li>12 month continuous ECG page- Venus</li> </ul>	<ul style="list-style-type: none"> <li>6- 12 month AF/AT Burden (%) on continuous ECG monitoring</li> </ul>
3. Procedural parameters: total procedure, fluoroscopy, total RF ablation time (first procedure), and total extent of ablated LA tissue.	<ul style="list-style-type: none"> <li>PVAI Page</li> <li>VOM page</li> </ul>	<ul style="list-style-type: none"> <li>Total procedure time, PVAI only</li> <li>Total procedure time, VOM procedure</li> <li>Total fluoro time</li> <li>Scar measurements pre and post PVAI and VOM</li> </ul>
4. Clinical success: freedom from symptomatic AF/flutter but AF/flutter > 1 min/day < than 1% at 12 months.	<ul style="list-style-type: none"> <li>12 month continuous ECG page- MARS</li> <li>12 month continuous ECG page- Venus</li> </ul>	<ul style="list-style-type: none"> <li>12 month AF/AT Burden less than 25% continuous event monitor at 6 and 12 months from ablation procedure</li> </ul>
5 Sub-acute procedural complications (within 30 days).	<ul style="list-style-type: none"> <li>Symptoms page</li> <li>AE page</li> </ul>	Day 30 reported, procedure related complications via symptoms and/or AEs
6 Recurrence as persistent or paroxysmal AF, or flutter after 1 or 2 procedures.	<ul style="list-style-type: none"> <li>12 lead ECG page</li> <li>Evaluation for repeat procedure page</li> <li>AE page</li> </ul>	<ul style="list-style-type: none"> <li>Type of recurrence (rhythm)</li> <li>Characterization of recurrence e.g. persistent or paroxysmal for a fib; typical or atypical for a flutter.</li> </ul>
7. LA function on Doppler echocardiography (LA strain114ab) at 12 months.	Central echocardiogram page	LA Strain
8. Incidence and mechanisms of atrial flutters.	<ul style="list-style-type: none"> <li>12 lead ECG page</li> <li>AE page</li> <li>Evaluation for repeat procedure page</li> </ul>	<ul style="list-style-type: none"> <li>Date of occurrence</li> <li>Type of flutter (typical vs atypical)</li> </ul>
9. Cardiovascular hospitalizations and QOL.	<ul style="list-style-type: none"> <li>Hospitalizations</li> <li>SAEs</li> <li>QOL</li> </ul>	<ul style="list-style-type: none"> <li>Total # of CV related hospitalizations</li> <li>QOL score</li> </ul>

**Use of propensity scores in multivariate models.** An ideal goal for observational etiological

studies is to allocate randomly subjects into different treatment groups in order to guarantee on average that there are no systematic differences in covariates between groups.<sup>120</sup> After randomization, there is nevertheless a possibility for observing large differences in confounders which may lead to bias in results. The propensity score provides a scalar summary of covariate information and is defined as the propensity (probability) that a subject's covariate profile represents subjects truly assigned to a given treatment group. Propensity scores based on significantly different confounder variables can be used to create a quasi-randomized experiment with adjustment to the treatment effect. We will assess the role of propensity scores in prediction models in order to reduce the effects of baseline factors that may be significantly different among subjects in different treatment groups. Firstly, we will identify baseline covariates which are significantly different across treatment groups (using t-tests with skew-zero transformed covariates or Mann-Whitney tests). Significant covariates will be incorporated into a logistic regression model ( $y=0$  PVAI, 1-VOM-PV) to generate subject-specific logits, which are normally-distributed.<sup>121, 122</sup> Treatment-subject-specific logits will then be used for matching subjects across the treatment groups in order to construct a sample of subjects with balanced covariates. We suspect that propensity matching will not be required to tackle the problem of extreme confounder differences, but will nevertheless evaluate the effect of propensity matching prior to logistic regression to determine treatment effect possibly adjusted for age.

**Missing data.** The critical piece of data required for endpoint analysis is the electrocardiographic event monitor. Failure to comply with wearing the monitor will lead to missing data. We request patients to wear monitors for 1–month. However, only a minimum of 1-week of monitored time is required for Endpoint assessment. Patients with less than 1 –week of monitoring will be considered as missing data. Patients who die before then study end will be considered not to have a response to treatment. For patients with missing primary outcomes, we will perform multiple imputation (MI) based on Monte Carlo Markov chain (MCMC) methods (Refs 1-3). MI will only be used for dealing with missing data as a secondary analysis tool of the primary endpoint. In Stata, MI is available for many procedures, especially the regression modules (linear, logistic, Poisson, Cox PH). MI can be performed to iteratively impute central estimates of missing outcome measures based on subjects' covariate patterns. The most straightforward example can be envisioned in this study, where logistic regression with MI is employed to train a model based on primary outcome (0-failure,1-success) as the dependent variable and age, gender, baseline AF duration, and baseline LA volume as independent predictors to impute  $P(y=1|\mathbf{x})$  for subjects with missing primary outcome.

**Sensitivity analysis.** Following methods introduced in Proschan et al. (Ref 4), we simulated success rates for patients with missing 12-month outcomes in VOM and PVAI arms for VENUS and MARS at 33%, 66%, and 100% information time (looks 1-3).  $B=100,000$  iterations were used with proportions of  $P_m=0, 0.05, 0.10, 0.15,$  and  $0.2$  representing the amount of missing data in both VOM and PVAI arms. At look  $k$ , let the success rate in the VOM arm be  $p_{1k}$  and the success rate in the PVAI arm be  $p_{2k}$ ,  $n_{1k}$  and  $n_{2k}$  the number of patients accrued in the VOM and PVAI arms,  $n_{1k}^m = n_{1k}P_m$  and  $n_{2k}^m = n_{2k}P_m$  the number of patients in VOM and PVAI arms with missing outcome data, and  $n_{1k}^0 = n_{1k} - n_{1k}^m$  and  $n_{2k}^0 = n_{2k} - n_{2k}^m$  the number of patients in VOM and PVAI arms without missing outcomes. Next, for VOM patients with missing outcomes,



simulate the number of successes by taking random draws of a binomial variate with parameters  $(n_{1k}^m, p_2)$ , and the number of successes among PVAI patients with missing outcomes as  $B(n_{2k}^m, p_1)$ . Note that the random draws of binomial variates are based on the success rate in the opposing arm, which enforces a high level of conservatism. A test statistic (unpooled variance) at the  $b$ th iteration is

$$Z_k^{(b)} = \frac{\hat{p}_{1k} - \hat{p}_{2k}}{\sqrt{\frac{\hat{p}_{1k}(1-\hat{p}_{1k})}{n_{1k}} + \frac{\hat{p}_{2k}(1-\hat{p}_{2k})}{n_{2k}}}}$$

where  $\hat{p}_{1k} = [n_{1k}^0 p_{1k} + B(n_{1k}^m, p_2)]/n_{1k}$  is the unobserved success rate among VOM patients with and without missing data, and  $\hat{p}_{2k} = [n_{2k}^0 p_{2k} + B(n_{2k}^m, p_1)]/n_{2k}$ . The power of the test is equal to the proportion of rejections among the  $B$  iterations, given in the form

$$Power = \frac{\#\{b: Z_k^{(b)} > 1.96\}}{B}$$

The tables below present power as a function of VOM and PVAI success rates, and the proportion of patients with missing data for the VENUS and MARS trials.

**VENUS 33%**  
(n1=60,n2=52)

VOM Success		Missing	PVAI Success				
			0.28	0.33	0.38	0.43	0.48
<b>0.46</b>	<b>0</b>		1.000	0.000	0.000	0.000	0.000
	<b>0.05</b>		0.778	0.055	0.000	0.000	0.000
	<b>0.1</b>		0.462	0.054	0.002	0.000	0.000
	<b>0.15</b>		0.247	0.051	0.003	0.000	0.000
	<b>0.2</b>		0.197	0.052	0.007	0.001	0.000
<b>0.51</b>	<b>0</b>		1.000	1.000	0.000	0.000	0.000
	<b>0.05</b>		1.000	0.584	0.059	0.000	0.000
	<b>0.1</b>		0.855	0.461	0.045	0.001	0.000
	<b>0.15</b>		0.601	0.213	0.043	0.002	0.000
	<b>0.2</b>		0.445	0.159	0.042	0.008	0.001
<b>0.56</b>	<b>0</b>		1.000	1.000	1.000	0.000	0.000
	<b>0.05</b>		1.000	1.000	0.476	0.060	0.000
	<b>0.1</b>		1.000	0.854	0.459	0.049	0.001
	<b>0.15</b>		0.907	0.514	0.218	0.040	0.003
	<b>0.2</b>		0.709	0.397	0.154	0.045	0.011
<b>0.61</b>	<b>0</b>		1.000	1.000	1.000	1.000	0.000
	<b>0.05</b>		1.000	1.000	1.000	0.477	0.058
	<b>0.1</b>		1.000	1.000	0.860	0.452	0.053
	<b>0.15</b>		0.990	0.879	0.510	0.227	0.034
	<b>0.2</b>		0.901	0.696	0.383	0.146	0.049
<b>0.66</b>	<b>0</b>		1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>		1.000	1.000	1.000	1.000	0.478
	<b>0.1</b>		1.000	1.000	1.000	0.868	0.434

	0.15	1.000	0.991	0.866	0.513	0.233
	0.2	0.982	0.905	0.682	0.367	0.153
<b>VENUS 66%</b> (n1=120,n2=104)		<b>PVAI Success</b>				
<b>VOM Success</b>	<b>Missing</b>	<b>0.28</b>	<b>0.33</b>	<b>0.38</b>	<b>0.43</b>	<b>0.48</b>
<b>0.46</b>	<b>0</b>	1.000	1.000	0.000	0.000	0.000
	<b>0.05</b>	1.000	0.766	0.008	0.000	0.000
	<b>0.1</b>	0.976	0.473	0.024	0.000	0.000
	<b>0.15</b>	0.777	0.243	0.018	0.000	0.000
	<b>0.2</b>	0.532	0.159	0.020	0.001	0.000
<b>0.51</b>	<b>0</b>	1.000	1.000	1.000	0.000	0.000
	<b>0.05</b>	1.000	1.000	0.770	0.007	0.000
	<b>0.1</b>	1.000	0.976	0.476	0.025	0.000
	<b>0.15</b>	0.981	0.745	0.227	0.019	0.000
	<b>0.2</b>	0.860	0.487	0.148	0.020	0.001
<b>0.56</b>	<b>0</b>	1.000	1.000	1.000	1.000	0.000
	<b>0.05</b>	1.000	1.000	1.000	0.770	0.003
	<b>0.1</b>	1.000	1.000	0.971	0.429	0.022
	<b>0.15</b>	1.000	0.978	0.700	0.214	0.018
	<b>0.2</b>	0.983	0.834	0.468	0.131	0.022
<b>0.61</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	0.768
	<b>0.1</b>	1.000	1.000	1.000	0.969	0.466
	<b>0.15</b>	1.000	1.000	0.978	0.698	0.198
	<b>0.2</b>	1.000	0.981	0.812	0.483	0.129
<b>0.66</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.1</b>	1.000	1.000	1.000	1.000	0.979
	<b>0.15</b>	1.000	1.000	1.000	0.981	0.710
	<b>0.2</b>	1.000	0.999	0.980	0.821	0.479
<b>VENUS 100%</b> (n1=180,n2=156)		<b>PVAI Success</b>				
<b>VOM Success</b>	<b>Missing</b>	<b>0.28</b>	<b>0.33</b>	<b>0.38</b>	<b>0.43</b>	<b>0.48</b>
<b>0.46</b>	<b>0</b>	1.000	1.000	0.000	0.000	0.000
	<b>0.05</b>	1.000	0.994	0.086	0.000	0.000
	<b>0.1</b>	1.000	0.811	0.072	0.000	0.000
	<b>0.15</b>	0.979	0.594	0.069	0.001	0.000
	<b>0.2</b>	0.827	0.363	0.048	0.002	0.000
<b>0.51</b>	<b>0</b>	1.000	1.000	1.000	0.000	0.000
	<b>0.05</b>	1.000	1.000	0.993	0.083	0.000
	<b>0.1</b>	1.000	1.000	0.781	0.059	0.000
	<b>0.15</b>	1.000	0.973	0.572	0.061	0.001
	<b>0.2</b>	0.987	0.808	0.335	0.047	0.002

<b>0.56</b>	<b>0</b>	1.000	1.000	1.000	1.000	0.000
	<b>0.05</b>	1.000	1.000	1.000	0.992	0.081
	<b>0.1</b>	1.000	1.000	0.999	0.781	0.057
	<b>0.15</b>	1.000	1.000	0.966	0.540	0.063
	<b>0.2</b>	1.000	0.984	0.787	0.321	0.048
<b>0.61</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	0.991
	<b>0.1</b>	1.000	1.000	1.000	0.999	0.795
	<b>0.15</b>	1.000	1.000	1.000	0.966	0.552
	<b>0.2</b>	1.000	1.000	0.983	0.784	0.329
<b>0.66</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.1</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.15</b>	1.000	1.000	1.000	1.000	0.970
	<b>0.2</b>	1.000	1.000	1.000	0.985	0.800

**D) Stopping rules.** The trials will be stopped if one of the following occurs:

- a. Futility/efficacy boundaries reached. As illustrated in Figures S1 and S2, if the upper or lower boundary is reached at the 1/3 or 2/3 data assessment for beneficial efficacy or futility respectively, the trial will be evaluated for early termination.
- b. Safety. Events will be reported to FDA, NHLBI, and DSMB according to FDA/OHRP requirements and NHLBI adverse event and unanticipated problem reporting policy. Expedited reporting will occur within 7 days of initial receipt of information for fatal or life-threatening unexpected serious reactions and within 15 calendar days for non-fatal, non-life threatening unexpected events. The DSMB will otherwise evaluate overall safety events on a bi-annual basis. An excess of **procedural** adverse events attributable to study procedure will be evaluated for early termination. Procedural adverse events include those that occur within 24 hours of the procedure or those that may be delayed but procedure-related (atrio-esophageal fistula or delayed pericardial effusion). The following are expected to be rare. One event may occur by chance in either treatment groups. Two of the same events in either arm will trigger consideration for study termination after detailed case review:
  - Mortality.
  - Stroke-Transient ischemic attack or systemic embolus.
  - Pericardial effusion requiring drainage

1. Raghunathan, T. E., J. M. Lepkowski, J. Van Hoewyk, and P. Solenberger. 2001. A multivariate technique for multiply imputing missing values using a sequence of regression models. *Survey Methodology* 27: 85–95.
2. Rubin, D. B. 1987. *Multiple Imputation for Nonresponse in Surveys*. New York: Wiley.
3. van Buuren, S. 2007. Multiple imputation of discrete and continuous data by fully conditional specification. *Statistical Methods in Medical Research* 16: 219–242.
4. Proschan, MA, McMahon, RP, Shih, JH, Hunsberger, SA, Geller, NL, Knatterud, G, Wittes, J. 2001. Sensitivity analysis using an imputation method for missing binary data in clinical trials. *J. Statistical Planning and Inference*. 96: 155-165.

## 7.0 STUDY ORGANIZATION

### 7.1 SCHEDULE OF EVENTS

Visit ID	1	2	3	4	5	6	7	8	9
Procedure	screen/ baseline	procedure day 0	prior to discharge	7 days (± 3)	30 day FU (±10) 1mo	90 day FU (±30d) 3mo	180 day FU (±60d) 6mo	9 mo FU (±30d)	360 day FU (±60d) 12 mos.
<b>Informed Consent</b> (prior to study specific procedures)	X								
<b>Eligibility Checklist</b> (PMH, medications, verification of Inclusion and exclusion criteria)	X								
<b>General Medical History &amp; Cardiovascular History</b> with CHADS2-VASC Score)	X								
<b>LAA thrombus exclusion Transesophageal Echocardiogram</b> (within 48 hours) or anticoagulation/LAA exclusion)	X <sup>(l)</sup>								
<b>Cardiac MRI or CT or Echocardiogram</b> (showing structure & function within 1 year)	X <sup>(m)</sup>								
<b>Randomization</b>	X								
Targeted <b>Physical Exam</b>	X				X	X	X	X	X
12 lead <b>EKG</b>	X	X pre-procedure	X		X	X	X	X	X
<b>Laboratory:</b> CBC, Serum creatinine, and INR – (INR only if patient is taking warfarin <sup>(g)</sup> )	X								
<b>AF Quality of Life Questionnaire</b> (AFEQT)	X						X		X
Pre-procedure 3D <b>Mapping</b> <sup>(b)(j)</sup>		X							
<b>VOM Procedure</b> w/ ETOH Injection and Post ethanol map		X <sup>(i)</sup>							
<b>PVAI Procedure</b>		X							
Post Procedure 3 D <b>Mapping</b>		X <sup>(c,j)</sup>							
<b>Follow-Up Phone Call</b> <sup>(n)</sup>				X					
3-4 Week <b>EKG (Event Monitor)</b> <sup>(d,n)</sup>							X		X
<b>Echocardiogram</b> , Central Reader (Dr. Nagueh)									X <sup>(k)</sup>
<b>Repeat Procedure</b> allowed <sup>(e)</sup>						X	X	X	
<b>AAD Therapy</b>	If appl.	If appl.	If appl.	If appl.	If appl.	Stop AAD <sup>(a)</sup>			
<b>Anticoagulation</b>	X	X	X	X	X	X	X		X
<b>Adverse Events</b>	X	X	X	X	X	X	X		X

#### Footnote Key

- (a) Must be in sinus rhythm prior to stopping AAD, may stop if clinically indicated
- (b) Required for both VENUS-AF and MARS-AF groups. For subjects in VENUS-AF, there should be little to no scarring for first procedure. For subjects in MARS-AF group and study patients requiring repeat procedures, maps will assess pre-existing extent of previous ablation lesions and presence or absence of PV reconnection.
- (c) To delineate extent of scar in both PVAI alone and PVAI/VOM groups.
- (d) Continuous 4 week EKG monitoring, will take place at month 6, and 12
- (e) Repeat procedures will be allowed if certain criteria met
- (f) Seven day follow-up phone call to assess post procedure symptoms.
- (g) Baseline INR must be within 24 hours prior to procedure for patients taking warfarin;
- (h) Not applicable.
- (i) For patients randomized to receive VOM ethanol infusion, and who have a vein of Marshall that can be cannulated.
- (j) For subjects who undergo repeat on-study procedures, mapping will be done a second time
- (k) Echocardiogram for LA Strain will be performed at study end at 12 months, and read centrally by core lab.
- (l) Imaging prior to enrollment is required to rule out the presence of LA appendage thrombus. Ruling out LAA thrombus can be performed by the following: TEE within 48 hours of the procedure; at least one month of oral anticoagulation prior to the procedure; or documented prior procedures of LAA occlusion or ligation.
- (m) Imaging prior to enrollment is required to rule out structural heart disease. For ruling out structural heart disease, either a cardiac MRI or CT or transthoracic echocardiogram within 1 year prior to participation in the study is sufficient.
- (n) Options for continuous EKG monitoring include: event monitoring include: external event monitor, implanted miniaturized rhythm monitor, or implanted pacemaker.



## 7.2 PATIENT RECRUITMENT, PROCEDURES AND FOLLOW-UP

Patients will be recruited from Cardiac Electrophysiology consultation services at all sites. Qualified, trained investigators will perform the procedures at the centers. These investigators will be unblinded. Patients will be followed up by qualified and trained at each study center.

The clinicians will follow the patients and evaluate adverse events and clinical primary endpoints.

## 7.3 CLINICAL RESEARCH NURSES/COORDINATORS

Each site will have designated research nurses and/or study support staff. Coordinating center may provide research nurse and/or study support staff as needed to conduct the trial efficiently. All study staff will keep in close communication with the Project Manager at the coordinating center, in order to ensure the study process runs smoothly. The coordinating center will train all study coordinators in the same manner.

## 7.4 DATA COORDINATING CENTER (DCC)

A DCC has been set up at the Dan L. Duncan Institute for Clinical and Translational Research at Baylor College of Medicine. Coordinators at each site will use a web-based data entry and collection system, which is capable of image collection (including maps) and FISMA-compliant. Methodist coordinating center will oversee data collection, integrity, and quality. A statistician with extensive experience handling large data sets has been recruited to independently lead data analysis. He will meet periodically with DCC and lead blinded data analysis of the proposed endpoints and SAEs. Data will be reported to the DSMB with pre-specified criteria for stopping the trial if safety and futility boundaries are reached. See below in "Protection of Human Subjects."

The DCC will design, develop, and maintain the secure, web-based electronic database systems for this trial. The electronic data management system (EDC) is a secure, web-based system which will require the participants to have an internet-accessible computer/tablet with an Internet browser. This electronic data management system will have logical checks and audit logs built into the system to ensure data correctness and data integrity. All automated alerts and notifications requested by the project team will be implemented in this electronic data management system. This system will also have reports and queries that are requested by the project team and the DSMB to monitor and manage the study. Also provided will be backend access to statistical software with data connectivity to facilitate data analyses. At various time points in the study, as requested by the study team, snapshots and locking of the database will occur, and clean data sets will be provided to the study team for review and data analyses.

## 7.5 STUDY DRUG

**Investigational Product:** The VOM injections will be performed using Dehydrated Alcohol Injection, USP, (multiple manufacturers). The product is commercially available and is indicated for therapeutic neurolysis in a number of medical situations, mainly for chronic pain.

**Supply:** The alcohol will be obtained commercially by the each site, and stored in a locked, limited access area under the appropriate temperature conditions. The number of ml used in each procedure will be documented in the surgical record by the surgeon. Site specific handling and accountability procedures, if different than above, shall be approved by the sponsor and outlined in the Clinical Trial Management Plan.

**Labeling and accountability:** The supply obtained for this study will be clearly marked for Investigational use per the FDA requirements, regardless of its approval status. Records will be kept of the date, patient use, and lot # of study drug used from this supply. No unused study drug will be retained. After opening, used and unused product will be destroyed on site per institutional policy. No drug supplies shall be returned to the sponsor.

**Storage and Maintenance:** Study drug will be stored in a cool place away from a heat source, as indicated on package insert.

**Administration and Dosing:** Study drug is administered intravenously. Dosing is dependent upon the surgeon achievement of sufficient neurolysis for successful ablation (up to 4 injections of 1cc ethanol).

## 7.6 BLINDING

Patients and personnel involved in data analysis, will be blinded to the treatment provided. Upon enrollment, the operators will be informed of the randomization outcome. After the procedure is performed, data will be collected and analyzed with treatment groups as the only identifier. The DSMB will receive the data identification for their assessment.

The primary endpoint of freedom from AF as determined by electrocardiographic monitoring by either external monitors or implanted devices will be adjudicated *in an independent and blinded manner* by the external EKG monitoring laboratory, respectively.

## 7.7 CORE LABORATORIES: ECHOCARDIOGRAPHY, AND EKG MONITORING

Electrocardiographic monitoring will be performed by continuous 3-4 week monitors as described. We have secured a commitment from a qualified vendor to provide with storage of *continuous data* (i.e. e. all the heart beats) for the 3-4 week monitoring time that will allow precise determination of the AF burden (percentage of time in AF). *Data will be reviewed by technicians unaware of the treatment mode, thus AF occurrence and AF burden quantification will be blinded.* Additionally, analysis such as heart rate variability may be performed: If VOM ethanol causes effective vagal denervation, and vagal innervation modulates dynamics of heart rate variability<sup>123</sup> then we expect differences between the two treatment groups. The core echocardiographic laboratory is a national leader in echocardiography with particular expertise in LA function.<sup>114b</sup> LA volumes, ejection fraction and strain will be collected as described and reviewed and analyzed in the echocardiography core laboratory at Houston Methodist Hospital.<sup>114ab</sup>

### ***Alternate rhythm monitoring***

Certain patients may be eligible for implantation of a miniaturized subcutaneous recording device (Medtronic LinQ device) or other equivalent implanted permanent monitoring devices. These implanted devices provide continuous electrocardiographic monitoring for up to 3 years including data on atrial fibrillation or flutter burden, episode duration per day and other quantified data. For patients that choose to have this kind of monitoring, AF data will be quantified for the primary and secondary endpoints using this device as opposed to 3-4 week electrocardiographic monitoring.

Certain patients may already have an implanted pacemaker previously inserted prior to study enrollment. These devices yield interrogation reports that provide sufficient data on atrial fibrillation or flutter burden, episode duration per day and other quantified data. For patients that already undergo this kind of monitoring, AF data will be quantified for the primary and secondary endpoints using these devices as opposed to 3-4 week electrocardiographic monitoring.

## 7.8 SAFETY CONSIDERATIONS

Ethanol infusion for the treatment of hypertrophic cardiomyopathy has been used for more than a decade.<sup>124</sup> Complications derive from collateral damage (i.e. e. AV block) or spillage of ethanol in unintended arterial branches.<sup>124</sup> VOM infusion is retrograde, and spilled ethanol drains via the CS into the right atrium to be diluted to non-damaging concentrations. Ethanol passage into the systemic circulation via the LA, albeit seemingly dangerous, is necessary for its ablative effects in the atrial myocardium. In order to achieve rapid dilution and avoid systemic effects, a slow infusion rate is critical. Mixed blood ethanol concentrations have been undetectable. VOM venograms performed after VOM ethanol infusion can show varying degrees of myocardial staining, but macroscopic extravasation into the epicardial space has not occurred. Adverse events of the VOM procedure included one CS dissection, which had no clinical consequences. Two patients developed sub-acute pericardial effusion 4 and 6 weeks after the procedure, respectively. The role of VOM ethanol is unclear, since this complication is also well described in conventional ablation.<sup>56</sup> No systemic effects were

detected at the doses tested (total 4 ml). This is an FDA Investigational New Drug (IND # 105083) project, which will continue.

Added procedure and fluoroscopy times in our previous experience average 45 and 8 minutes, respectively. Reported fluoroscopy times of conventional ablation can be up to 100-120 minutes,<sup>125, 126</sup> so 8 minutes do not represent a major fluoroscopy time increase. Given that VOM ethanol may lead to ablation of otherwise targeted tissue (including LIPV isolation),<sup>1</sup> and facilitate perimitral block,<sup>3</sup> it may reduce the need of RF ablation in these areas. Thus VOM ethanol may potentially save procedure and fluoroscopy times downstream.

### **7.8.1 Adverse Event Reporting**

The adverse event reporting period for this trial begins at the time the subjects sign the informed consent form, and will continue through the final month follow-up visit or withdrawal from the study. Reportable events will be reported per institution specific IRB policy.

**Only AE's related to the catheter ablation procedure, ethanol ablation, and disease process will be captured.**

#### ***Anticipated (Expected) Adverse Events (AE's)***

Patients may experience certain clinical events that are attributable to the ablation procedure or the disease process of the patient. ***The following list of AE's are expected based on previous clinical and research experience.***

- Atrial Arrhythmias
- Chest pain or Angina
- Standard of care cardioversions for arrhythmias
- Headache
- Minor bleeding
- Hypertension or hypotension
- Vasovagal reactions
- self-limiting pericarditis attributable to the ablation procedure defined as pleuritic chest discomfort with or without pericardial rub
- pacemaker implantation for nodal dysfunction rhythms (sick sinus syndrome, sinus bradycardia, sinus arrest or AV blocks) that resulted in symptomatic bradycardia (unrelated to the ablation procedure or related to pre-existing disease state)
- Incision site pain/soreness
- Incision site infection
- Inadvertent AV block: Second or third degree heart block
- Palpitations
- Pulmonary edema
- ECG changes that did not require additional hospitalization
- Pericarditis
- Anxiety
- Hematoma

### **7.8.2 Serious Adverse Events (SAE) Reporting**

An adverse event that meets one or more of the following criteria/outcomes will be classified as serious: These events will be treated accordingly and reported per local & federal regulations and institutional policies & requirements.

- Results in a life-threatening illness or injury.
- Results in permanent impairment of a body structure or a body function.
- Requires inpatient hospitalization  $\geq$  24 hours (other than the ablation procedure) or prolongation of existing hospitalization.
- Requires a medical or surgical intervention to prevent permanent impairment to body structure.
- Death

SAE's will be reported in accordance with current institutional policies.

***NOTE: Unexpected serious adverse events deemed related, probably or possibly related to the VOM study procedure will warrant a hold on the study until further review and approval by the IRB and DSMB.***

***Screen Failure AEs will be documented as follows:*** Adverse events that occur for subjects prior to the intervention, will be documented in the study record and will not be reported to the IRB or sponsor (HMRI) unless unexpected or the PI determines the event should be reported to the IRB as non-study intervention related event. Subjects who are deemed screen failures and experience an event that meets the general SAE criteria will be followed until resolution of the event and those events will be reported to HMRI as the sponsor of the IND, and to the IRB per institutional policies for reporting SAE's.

### **7.8.3 Data Safety and Monitoring Plan**

#### **Data Safety Monitoring Board (DSMB)**

A study-specific DSMB has been created by the NHLBI (National Heart, Lung, and Blood Institute) which is funding this clinical trial (R01 HL115003). None of the members of the DSMB are listed on the protocol as sub-investigators or have conflicting interests in the trial results. The DSMB is made up of electrophysiology consultants familiar with ablation procedures that will have insights into the specific clinical scenarios that can occur in AF ablation. Additionally, the DSMB will have a dedicated statistician. The NHLBI will administer the DSMB with the assistance of the project manager and data center.

#### **Data Reports to DSMB**

Specific data reports will be supplied to the DSMB Executive Secretary at the NHLBI for reporting to the DSMB for review on a semi-annual basis or as requested. The reports



will contain un-blinded data in order to properly ascertain adverse events attributable to the VOM procedure. The DSMB reports and voting results will subsequently be provided to the IRB and the FDA as part of the IND oversight process.

#### **7.8.4 *Minimization of Other Risks***

**Procedural Risks:** There are known risks to the conventional pulmonary vein ablation procedure, and they remain present for every patient undergoing ablation of AF. Additional risks specific to the Vein of Marshall procedure are listed in the consent and expected outcomes are fully explained to each consented subject. Standard safety precautions will be taken to minimize risk. The Principal Investigator of the study is very familiar with the risks of catheter ablation procedures and is experienced in its resolution and treatment.

**Risks to PHI:** All data will be de-identified and only the research personnel will have access to subjects protected health information; all source documents will be kept onsite and stored with the principal investigator. The CRFs for this Study will be created by the PI as hard copy (paper) and as electronic CRFs. If electronic CRFs are used, the source document will be the electronic CRF, with appropriate password controls. The forms are designed to record observations and other data pertinent to the Study on each participant enrolled in the Study. The CRFs will be completed by the Investigator and/or designated staff. All data will be entered into a computer and stored in a secure database, accessible to approved personnel only. All hardcopies will be stored in a secure location and will be only accessible to approved personnel.

## **8.0 STUDY ADMINISTRATION & OVERSIGHT**

### **8.1 PI OVERSIGHT**

Principal Investigator, Dr. Miguel Valderrábano, will have general and scientific oversight of the project. Dr. Valderrábano will oversee the quality of clinical measurements obtained in the study and ensuring adherence to the protocol. Additionally, he will be responsible for patient recruitment, which includes site start-up activities and training for all site personnel.

### **8.2 COORDINATING CENTER**

Houston Methodist Research Institute d/b/a The Methodist Hospital Research Institute will serve as the coordinating center for this study, led by the project PI, Dr. Miguel Valderrábano. A trial administrator-manager at HMRI will oversee day-to-day operations of the clinical study as it relates to participant enrollment, clinical site administration, and data administration.

### **8.3 SCIENTIFIC ADVISORY BOARD**

Constituted by outside experts in clinical research, autonomic nervous system and evidence-based medicine research, or the use of ethanol ablation, this board will have the following functions:

1. Reviewing the operational conduct of the study, including adherence to the study protocol. The board will assist in facilitating resolution of problems that may arise concerning these issues.
2. Reviewing and rendering advice concerning potential changes to the protocol. Such changes would require approval by the DSMB.
3. Recommending publication policies, as well as overseeing the publications and presentations review process. This includes reviewing scientific reports, analysis, ancillary study proposals, and publications resulting from data that are obtained during the study; review and approval of any revisions to the publication guidelines for the study; and determination of data analyses, not currently included in the protocol, for the purpose of furthering scientific understanding in the field.
4. Reviewing recommendations from the DSMB and providing advice and guidance regarding potential study issues.

#### 8.4 DATA SAFETY MONITORING BOARD (DSMB)

An NIH-based, study-specific DSMB will oversee safety issues for the study as described in section 7.7.3 Data Safety Monitoring Plan.

### 9.0 TRIAL MANAGEMENT

#### 9.1 STATISTICAL MANAGEMENT

The primary functions of the individuals in the statistical core laboratory from Houston Methodist Hospital will be to contribute to data analysis and to create systems for randomization. Data from the Data Coordinating Center (see below) will be available for blinded statistical analysis for interim analysis, applicable DSMB or FDA reports, and prior to publications or presentations.

#### 9.2 DATA MANAGEMENT

##### ***Data Coordinating Center***

Data Coordinating Center (DCC) will be responsible for the integrity of data collection – blinded to the specific treatment provided. Statistical analysis will be provided by HMRI statistics team, who will have access to the DCC data. Clinical analysis will be handled by an expert EP researcher from Methodist.

##### ***Data flow From Remote Sites***

The Investigator at each investigative site is responsible for the completion and timely web-based submission of case report forms (CRFs) for each patient according to visit

requirements as detailed in the Schedule of Events. All electronic data will be stored as a HIPAA-compliant limited data set in a password-protected database. Research nurses at each site will be responsible for entering the data in the system.

### ***Data collection and record-keeping***

An electronic Case Report Form (EDC) will be completed for each subject enrolled into the clinical study. The investigator will review, approve and sign/date each completed patient case report record; the investigator's signature serving as attestation of the investigator's responsibility for ensuring that all clinical and laboratory data entered on the EDC are complete, accurate and authentic.

**Source Data** are the clinical findings and observations, laboratory and test data, and other information contained in *Source Documents*. *Source Documents* are the original records (and certified copies of original records); including, but not limited to, hospital medical records, physician or office charts, physician or nursing notes, subject diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, x-rays, etc. When applicable, information recorded on the CRF shall match the *Source Data* recorded on the *Source Documents*.

### ***Study Records Access***

The investigator will maintain all records in accordance with [Good Clinical Practice guidelines](#). Regulatory documents are maintained in a locked file cabinet in the AOCT office, with limited access. Sponsor personnel viewing any site-related PHI will follow all rules of the institution and regulations regarding protection of PHI.

Case report forms will not contain any subject identifiers and will be labeled with only subject ID numbers. Study data is recorded on a secure, limited-access electronic database constructed by the DCC, and compliant with all electronic data regulations.

Any paper records, such as consent forms, that contain direct subject identifiers (e.g., name, social security number) will be stored in a separate locked filing cabinet in the study coordinator's office. Only the study coordinator and the Investigator will have access to this information.

### ***Missing data processing plan***

Critical data fields are those variables necessary for final study analysis. They will be agreed upon by the PI and the Clinical Data Manager, and detailed within the Data Management Plan. For those critical fields that are discrepant or not completed on the case report form (CRF), a query will be issued to the investigative site. Missing or overdue patient CRFs will also be queried.

## 9.3 STUDY MONITORING

The study sponsor will provide or contract a clinical study monitor to monitor the clinical trial. Monitoring visits will begin as soon as subjects are consented and enrolled and will

continue until all subjects have been taken off of the clinical trial and the trial has been terminated. Monitoring visits will include review of informed consent process, eligibility, adherence to the clinical protocol, and adverse events. Safety issues and/or trends in data errors or deviations will be managed by the administrative study team (principal investigator, project manager, IND sponsor representative, et. al). The monitoring process is outlined in the clinical monitoring plan which will be maintained by the coordinating center.

#### 9.4 PROJECT MANAGEMENT

HMRI will have a project manager who will coordinate the sites with regard to regulatory set-up and maintenance, IRB, DSMB and other committee approvals and submissions, case report form completion, problem solving, and timeline enforcement as appropriate. Management of the trial and oversight is delineated in the Clinical Trial Management Plan.

##### **Non Local Clinical Trial Sites**

The organization of this trial is centralized at HMRI, which will act as a coordinating center for other clinical sites. Additional eligible, experienced AF treatment sites will be contracted to enroll patients and receive reimbursement on a per-patient basis. Sites will be trained on the protocol prior to initiation to minimize protocol deviations, avoid breaches of blinding procedures and other violations. Sites should be structured with 3 levels of personnel: operators, blinded clinicians that would follow the primary endpoints; and research nurses. This process and training is explained in the Clinical Trial Management Plan.

## 10.0 GUIDE TO ACRONYMS / DEFINITIONS

<b>AAD</b>	Antiarrhythmic Drug
<b>CS</b>	Coronary Sinus
<b>DCC</b>	Data Coordinating Center. This is Dan L. Duncan Institute for Clinical and Translational Research (ICTR). Will be referred to as DCC
<b>DSMB</b>	Data Safety Monitoring Board
<b>ECG/EKG</b>	Electrocardiogram
<b>EDC</b>	Electronic Data Capture (also, electronic case report form)
<b>HMRI</b>	Houston Methodist Hospital doing business as Houston Methodist Research Institute or The Methodist Hospital Research Institute (IND Sponsor)
<b>LA</b>	Left Atrium
<b>MARS</b>	Vein of <b>M</b> arshall <b>A</b> lcohol in <b>R</b> epet ablation of per <b>S</b> istent <b>A</b> trial <b>F</b> ibrillation.
<b>NIH</b>	National Institutes of Health (sponsor of this study)
<b>Persistent AF:</b>	continuous AF that is sustained beyond seven days. Episodes of AF in which a decision is made to electrically or pharmacologically cardiovert the patient after 48 hours of AF, but prior to 7 days, should also be classified as persistent AF episodes.
<b>PMF</b>	Perimitral Flutter
<b>PVAI</b>	Pulmonary Vein Antrum Isolation (traditional A. Fib. Procedure)
<b>RF</b>	Radiofrequency
<b>VENUS</b>	<b>VENUS-AF. Vein of Marshall Ethanol iNfusion in Untreated perSistent Atrial Fibrillation.</b>
<b>VOM</b>	Vein of Marshall
<b>VOM-PV</b>	Vein of Marshall infusion plus conventional PVAI. Also VOM+PVAI



## 11.0 CLASSES OF ANTI-ARRHYTHMIC DRUGS (VAUGHN-WILLIAMS CLASSIFICATION)<sup>127</sup>

Class	Known as	Examples	Mechanism	Clinical uses in cardiology <sup>[2]</sup>
Ia	fast-channel blockers- affect QRS complex	<ul style="list-style-type: none"> <li>Quinidine</li> <li>Procainamide</li> <li>Disopyramide</li> </ul>	(Na <sup>+</sup> ) channel block (intermediate association/dissociation)	<ul style="list-style-type: none"> <li>Ventricular arrhythmias</li> <li>prevention of paroxysmal recurrent atrial fibrillation (triggered by vagal over activity)</li> <li>procainamide in Wolff-Parkinson-White syndrome</li> </ul>
Ib	Do not affect QRS complex	<ul style="list-style-type: none"> <li>Lidocaine</li> <li>Phenytoin</li> <li>Mexiletine</li> <li>Tocainide</li> </ul>	(Na <sup>+</sup> ) channel block (fast association/dissociation)	<ul style="list-style-type: none"> <li>treatment and prevention during and immediately after myocardial infarction, though this practice is now discouraged given the increased risk of systole</li> <li>ventricular tachycardia</li> </ul>
Ic		<ul style="list-style-type: none"> <li>Encainide</li> <li>Flecainide</li> <li>Propafenone</li> <li>Moricizine</li> </ul>	(Na <sup>+</sup> ) channel block (slow association/dissociation)	<ul style="list-style-type: none"> <li>prevents paroxysmal atrial fibrillation</li> <li>treats recurrent tachyarrhythmias of abnormal conduction system.</li> <li>contraindicated immediately post-myocardial infarction.</li> </ul>
II	Beta-blockers	<ul style="list-style-type: none"> <li>Propranolol</li> <li>Esmolol</li> <li>Timolol</li> <li>Metoprolol</li> <li>Atenolol</li> <li>Bisoprolol</li> </ul>	beta blocking Propranolol also shows some class I action	<ul style="list-style-type: none"> <li>decrease myocardial infarction mortality</li> <li>prevent recurrence of tachyarrhythmias</li> </ul>
III		<ul style="list-style-type: none"> <li>Amiodarone</li> <li>Sotalol</li> <li>Ibutilide</li> <li>Dofetilide</li> <li>Dronedarone</li> <li>E-4031</li> </ul>	K <sup>+</sup> channel blocker  Sotalol is also a beta blocker <sup>[3]</sup> Amiodarone has Class I, II, III & IV activity	<ul style="list-style-type: none"> <li>In Wolff-Parkinson-White syndrome</li> <li>(sotalol:) ventricular tachycardias and atrial fibrillation</li> <li>(Ibutilide:) atrial flutter and atrial fibrillation</li> </ul>
IV	slow-channel blockers	<ul style="list-style-type: none"> <li>Verapamil</li> <li>Diltiazem</li> </ul>	Ca <sub>2+</sub> channel blocker	<ul style="list-style-type: none"> <li>prevent recurrence of paroxysmal supraventricular tachycardia</li> <li>reduce ventricular rate in patients with atrial fibrillation</li> </ul>
V		<ul style="list-style-type: none"> <li>Adenosine</li> <li>Digoxin</li> <li>Magnesium Sulfate</li> </ul>	Work by other or unknown mechanisms (Direct nodal inhibition).	Used in supraventricular arrhythmias, especially in Heart Failure with Atrial Fibrillation, contraindicated in ventricular arrhythmias. Or in the case of Magnesium Sulfate, used in Torsades de Pointes.

## 12.0 LITERATURE CITED

1. Dave AS, Baez-Escudero JL, Sasaridis C, Hong TE, Rami T, Valderrabano M. Role of the vein of marshall in atrial fibrillation recurrences after catheter ablation: Therapeutic effect of ethanol infusion. *Journal of cardiovascular electrophysiology*. 2012;23 (6) :583-591.
2. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ, Jr. , Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 hrs/ehra/ecas expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: A report of the heart rhythm society (hrs) task force on catheter and surgical ablation of atrial fibrillation. Developed in partnership with the european heart rhythm association (ehra) , a registered branch of the european society of cardiology (esc) and the european cardiac arrhythmia society (ecas) ; and in collaboration with the american college of cardiology (acc) , american heart association (aha) , the asia pacific heart rhythm society (aphrs) , and the society of thoracic surgeons (sts). Endorsed by the governing bodies of the american college of cardiology foundation, the american heart association, the european cardiac arrhythmia society, the european heart rhythm association, the society of thoracic surgeons, the asia pacific heart rhythm society, and the heart rhythm society. *Heart Rhythm*. 2012;9 (4) :632-696 e621.
3. Baez-Escudero JL, Morales PF, Dave AS, Sasaridis CM, Kim YH, Okishige K, Valderrabano M. Ethanol infusion in the vein of marshall facilitates mitral isthmus ablation. *Heart Rhythm*. 2012 In press.
- 3b Morales PF, Dave AS, Sasaridis CM, Valderrabano M. Anatomical variations of the vein of Marshall and its implications to atrial fibrillation ablation. *Heart Rhythm*. 2012;9(5): S78.
4. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TS, Van Wagoner DR, Waldo AL, Wyse DG. Prevention of atrial fibrillation: Report from a national heart, lung, and blood institute workshop. *Circulation*. 2009;119 (4) :606-618.
5. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ, Jr. , Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ. Hrs/ehra/ecas expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up. A report of the heart rhythm society (hrs) task force on catheter and surgical ablation of atrial fibrillation developed in partnership with the european heart rhythm association (ehra) and the european cardiac arrhythmia

society (ecas) ; in collaboration with the american college of cardiology (acc) , american heart association (aha) , and the society of thoracic surgeons (sts). Endorsed and approved by the governing bodies of the american college of cardiology, the american heart association, the european cardiac arrhythmia society, the european heart rhythm association, the society of thoracic surgeons, and the heart rhythm society. *Europace*. 2007;9 (6) :335-379.

6. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *The New England journal of medicine*. 1998;339 (10) :659-666.

7. Katriotis D, Merchant FM, Mela T, Singh JP, Heist EK, Aroundas AA. Catheter ablation of atrial fibrillation the search for substrate-driven end points. *Journal of the American College of Cardiology*. 2010;55 (21) :2293-2298.

8. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Turov A, Shirokova N, Karaskov A. Ablation of paroxysmal and persistent atrial fibrillation: 1-year follow-up through continuous subcutaneous monitoring. *Journal of cardiovascular electrophysiology*. 2011;22 (4) :369-375.

9. Tan AY, Zhou S, Ogawa M, Song J, Chu M, Li H, Fishbein MC, Lin SF, Chen LS, Chen PS. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. *Circulation*. 2008;118 (9) :916-925.

10. Choi EK, Shen MJ, Han S, Kim D, Hwang S, Sayfo S, Piccirillo G, Frick K, Fishbein MC, Hwang C, Lin SF, Chen PS. Intrinsic cardiac nerve activity and paroxysmal atrial tachyarrhythmia in ambulatory dogs. *Circulation*. 2010;121 (24) :2615-2623.

11. Oral H, Knight BP, Tada H, Ozaydin M, Chugh A, Hassan S, Scharf C, Lai SW, Greenstein R, Pelosi F, Jr. , Strickberger SA, Morady F. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. *Circulation*. 2002;105 (9) :1077-1081.

12. O'Neill MD, Wright M, Knecht S, Jais P, Hocini M, Takahashi Y, Jonsson A, Sacher F, Matsuo S, Lim KT, Arantes L, Derval N, Lellouche N, Nault I, Bordachar P, Clementy J, Haissaguerre M. Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint. *Eur Heart J*. 2009;30 (9) :1105-1112.

13. Knecht S, Hocini M, Wright M, Lellouche N, O'Neill MD, Matsuo S, Nault I, Chauhan VS, Makati KJ, Bevilacqua M, Lim KT, Sacher F, Deplagne A, Derval N, Bordachar P, Jais P, Clementy J, Haissaguerre M. Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation. *Eur Heart J*. 2008;29 (19) :2359-2366.

14. Rostock T, Steven D, Hoffmann B, Servatius H, Drewitz I, Sydow K, Mullerleile K, Ventura R, Wegscheider K, Meinertz T, Willems S. Chronic atrial fibrillation is a biatrial arrhythmia: Data from catheter ablation of chronic atrial fibrillation aiming arrhythmia termination using a sequential ablation approach. *Circ Arrhythm Electrophysiol*. 2008;1 (5) :344-353.

15. Oral H, Chugh A, Good E, Wimmer A, Dey S, Gadeela N, Sankaran S, Crawford T, Sarrazin JF, Kuhne M, Chalfoun N, Wells D, Frederick M, Fortino J, Benloucif-Moore S, Jongnarangsin K, Pelosi F, Jr. , Bogun F, Morady F. Radiofrequency catheter ablation of chronic atrial fibrillation guided by complex electrograms. *Circulation*. 2007;115 (20) :2606-2612.
16. Elayi CS, Verma A, Di Biase L, Ching CK, Patel D, Barrett C, Martin D, Rong B, Fahmy TS, Khaykin Y, Hongo R, Hao S, Pelargonio G, Dello Russo A, Casella M, Santarelli P, Potenza D, Fanelli R, Massaro R, Arruda M, Schweikert RA, Natale A. Ablation for longstanding permanent atrial fibrillation: Results from a randomized study comparing three different strategies. *Heart Rhythm*. 2008;5 (12) :1658-1664.
17. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jr. , Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. Acc/aha/esc 2006 guidelines for the management of patients with atrial fibrillation: A report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) : Developed in collaboration with the european heart rhythm association and the heart rhythm society. *Circulation*. 2006;114 (7) :e257-354.
18. Valderrabano M, Chen HR, Sidhu J, Rao L, Ling Y, Khoury DS. Retrograde ethanol infusion in the vein of marshall: Regional left atrial ablation, vagal denervation and feasibility in humans. *Circ Arrhythm Electrophysiol*. 2009;2 (1) :50-56.
19. Valderrabano M, Liu X, Sasaridis C, Sidhu J, Little S, Khoury DS. Ethanol infusion in the vein of marshall: Adjunctive effects during ablation of atrial fibrillation. *Heart Rhythm*. 2009;6 (11) :1552-1558.
20. Baez-Escudero JLD, A. S. ;Sasaridis, C. M. ; Valderrabano, M. Regional vagal denervation of the human left atrium following ethanol infusion in the vein of marshall *Heart Rhythm*. 2011;8:s77.
21. Wolf PA, Dawber TR, Thomas HE, Jr. , Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The framingham study. *Neurology*. 1978;28 (10) :973-977.
22. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the manitoba follow-up study. *Am J Med*. 1995;98 (5) :476-484.
23. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The rotterdam study. *Stroke*. 1997;28 (2) :316-321.
24. Miyasaka Y, Barnes ME, Petersen RC, Cha SS, Bailey KR, Gersh BJ, Casacang-Verzosa G, Abhayaratna WP, Seward JB, Iwasaka T, Tsang TS. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: Data from a community-based cohort. *Eur Heart J*. 2007;28 (16) :1962-1967.

25. Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: A systematic review and meta-analysis. *Neurology*. 2011;76 (10) :914-922.
26. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The framingham heart study. *Circulation*. 1998;98 (10) :946-952.
27. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators. *Journal of the American College of Cardiology*. 2000;35 (1) :183-187.
28. Goudevenos JA, Vakalis JN, Giogiakas V, Lathridou P, Katsouras C, Michalis LK, Sideris DA. An epidemiological study of symptomatic paroxysmal atrial fibrillation in northwest greece. *Europace*. 1999;1 (4) :226-233.
29. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (atria) study. *Jama*. 2001;285 (18) :2370-2375.
30. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the united states. *Am J Cardiol*. 2009;104 (11) :1534-1539.
31. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in olmsted county, minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation*. 2006;114 (2) :119-125.
32. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y. Heart disease and stroke statistics--2009 update: A report from the american heart association statistics committee and stroke statistics subcommittee. *Circulation*. 2009;119 (3) :e21-181.
33. Kim MH, Johnston SS, Chu B-C, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the united states. *Circ Cardiovasc Qual Outcomes*. 2011;4 (3) :313-320.
34. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. *The New England journal of medicine*. 2002;347 (23) :1825-1833.
35. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL. Rhythm



control versus rate control for atrial fibrillation and heart failure. *The New England journal of medicine*. 2008;358 (25) :2667-2677.

36. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG. Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (affirm) study. *Circulation*. 2004;109 (12) :1509-1513.

37. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. *The New England journal of medicine*. 2009;360 (7) :668-678.

38. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanan F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH. Dronedarone in high-risk permanent atrial fibrillation. *The New England journal of medicine*. 2011;365 (24) :2268-2276.

39. Verma A, Marrouche NF, Natale A. Pulmonary vein antrum isolation: Intracardiac echocardiography-guided technique. *Journal of cardiovascular electrophysiology*. 2004;15 (11) :1335-1340.

40. Arentz T, Weber R, Burkle G, Herrera C, Blum T, Stockinger J, Minners J, Neumann FJ, Kalusche D. Small or large isolation areas around the pulmonary veins for the treatment of atrial fibrillation? Results from a prospective randomized study. *Circulation*. 2007;115 (24) :3057-3063.

41. Lin WS, Tai CT, Hsieh MH, Tsai CF, Lin YK, Tsao HM, Huang JL, Yu WC, Yang SP, Ding YA, Chang MS, Chen SA. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. *Circulation*. 2003;107 (25) :3176-3183.

42. Tanaka K, Zlochiver S, Vikstrom KL, Yamazaki M, Moreno J, Klos M, Zaitsev AV, Vaidyanathan R, Auerbach DS, Landas S, Guiraudon G, Jalife J, Berenfeld O, Kalifa J. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. *Circ Res*. 2007;101 (8) :839-847.

43. Haissaguerre M, Hocini M, Sanders P, Sacher F, Rotter M, Takahashi Y, Rostock T, Hsu LF, Bordachar P, Reuter S, Roudaut R, Clementy J, Jais P. Catheter ablation of long-lasting persistent atrial fibrillation: Clinical outcome and mechanisms of subsequent arrhythmias. *Journal of cardiovascular electrophysiology*. 2005;16 (11) :1138-1147.

44. Rostock T, Drewitz I, Steven D, Hoffmann BA, Salukhe TV, Bock K, Servatius H, Aydin MA, Meinertz T, Willems S. Characterization, mapping, and catheter ablation of recurrent atrial tachycardias after

stepwise ablation of long-lasting persistent atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2010;3 (2) :160-169.

45. Rostock T, Salukhe TV, Steven D, Drewitz I, Hoffmann BA, Bock K, Servatius H, Mullerleile K, Sultan A, Gosau N, Meinertz T, Wegscheider K, Willems S. Long-term single- and multiple-procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation. *Heart Rhythm*. 2011;8 (9) :1391-1397.

46. Hocini M, Jais P, Sanders P, Takahashi Y, Rotter M, Rostock T, Hsu LF, Sacher F, Reuter S, Clementy J, Haissaguerre M. Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: A prospective randomized study. *Circulation*. 2005;112 (24) :3688-3696.

47. Takahashi Y, O'Neill MD, Hocini M, Reant P, Jonsson A, Jais P, Sanders P, Rostock T, Rotter M, Sacher F, Laffite S, Roudaut R, Clementy J, Haissaguerre M. Effects of stepwise ablation of chronic atrial fibrillation on atrial electrical and mechanical properties. *Journal of the American College of Cardiology*. 2007;49 (12) :1306-1314.

48. Jais P, Hocini M, Hsu LF, Sanders P, Scavee C, Weerasooriya R, Macle L, Raybaud F, Garrigue S, Shah DC, Le Metayer P, Clementy J, Haissaguerre M. Technique and results of linear ablation at the mitral isthmus. *Circulation*. 2004;110 (19) :2996-3002.

49. Arruda M, Mlcochova H, Prasad SK, Kilicaslan F, Saliba W, Patel D, Fahmy T, Morales LS, Schweikert R, Martin D, Burkhardt D, Cummings J, Bhargava M, Dresing T, Wazni O, Kanj M, Natale A. Electrical isolation of the superior vena cava: An adjunctive strategy to pulmonary vein antrum isolation improving the outcome of af ablation. *Journal of cardiovascular electrophysiology*. 2007;18 (12) :1261-1266.

50. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Mohanty S, Horton R, Gallingshouse GJ, Bailey SM, Zagrodzky JD, Santangeli P, Hao S, Hongo R, Beheiry S, Themistoclakis S, Bonso A, Rossillo A, Corrado A, Raviele A, Al-Ahmad A, Wang P, Cummings JE, Schweikert RA, Pelargonio G, Dello Russo A, Casella M, Santarelli P, Lewis WR, Natale A. Left atrial appendage: An underrecognized trigger site of atrial fibrillation. *Circulation*. 2010;122 (2) :109-118.

51. Hocini M, Shah AJ, Nault I, Sanders P, Wright M, Narayan SM, Takahashi Y, Jais P, Matsuo S, Knecht S, Sacher F, Lim KT, Clementy J, Haissaguerre M. Localized reentry within the left atrial appendage: Arrhythmogenic role in patients undergoing ablation of persistent atrial fibrillation. *Heart Rhythm*. 2011.

52. Elayi CS, L DIB, Bai R, Burkhardt JD, Mohanty P, Sanchez J, Santangeli P, Hongo R, Gallingshouse GJ, Horton R, Bailey S, Zagrodzky J, Beheiry S, Natale A. Identifying the relationship between the non-pv triggers and the critical cfae sites post-pvai to curtail the extent of atrial ablation in longstanding persistent af. *Journal of cardiovascular electrophysiology*. 2011.

53. Narayan SM, Krummen DE, Rappel WJ. Clinical mapping approach to diagnose electrical rotors and focal impulse sources for human atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2012;23 (5) :447-454.

54. Yamazaki M, Vaquero LM, Hou L, Campbell K, Zlochiver S, Klos M, Mironov S, Berenfeld O, Honjo H, Kodama I, Jalife J, Kalifa J. Mechanisms of stretch-induced atrial fibrillation in the presence and the absence of adrenergic stimulation: Interplay between rotors and focal discharges. *Heart Rhythm*. 2009;6 (7) :1009-1017.
55. Valderrabano M. Atrial fibrillation: The mother rotor and its rebellious offspring take turns sustaining the family. *Heart Rhythm*. 2009;6 (7) :1018-1019.
56. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2010;3 (1) :32-38.
57. Earley MJ, Abrams DJ, Staniforth AD, Sporton SC, Schilling RJ. Catheter ablation of permanent atrial fibrillation: Medium term results. *Heart*. 2006;92 (2) :233-238.
58. Mulder AA, Wijffels MC, Wever EF, Boersma LV. Pulmonary vein isolation and left atrial complex-fractionated atrial electrograms ablation for persistent atrial fibrillation with phased radio frequency energy and multi-electrode catheters: Efficacy and safety during 12 months follow-up. *Europace*. 2011.
59. Bhargava M, Di Biase L, Mohanty P, Prasad S, Martin DO, Williams-Andrews M, Wazni OM, Burkhardt JD, Cummings JE, Khaykin Y, Verma A, Hao S, Beheiry S, Hongo R, Rossillo A, Raviele A, Bonso A, Themistoclakis S, Stewart K, Saliba WJ, Schweikert RA, Natale A. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: Results from a multicenter study. *Heart Rhythm*. 2009;6 (10) :1403-1412.
60. Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen J, Crijns HJ. Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. *Journal of the American College of Cardiology*. 2012;60 (1) :54-61.
61. Gersak B, Pernat A, Robic B, Sinkovec M. Low rate of atrial fibrillation recurrence verified by implantable loop recorder monitoring following a convergent epicardial and endocardial ablation of atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2012.
62. Deisenhofer I, Estner H, Zrenner B, Schreieck J, Weyerbrock S, Hessling G, Scharf K, Karch MR, Schmitt C. Left atrial tachycardia after circumferential pulmonary vein ablation for atrial fibrillation: Incidence, electrophysiological characteristics, and results of radiofrequency ablation. *Europace*. 2006;8 (8) :573-582.
63. Haissaguerre M, Sanders P, Hocini M, Takahashi Y, Rotter M, Sacher F, Rostock T, Hsu LF, Bordachar P, Reuter S, Roudaut R, Clementy J, Jais P. Catheter ablation of long-lasting persistent atrial fibrillation: Critical structures for termination. *Journal of cardiovascular electrophysiology*. 2005;16 (11) :1125-1137.
64. Chugh A, Oral H, Good E, Han J, Tamirisa K, Lemola K, Elmouchi D, Tschopp D, Reich S, Igic P, Bogun F, Pelosi F, Jr. , Morady F. Catheter ablation of atypical atrial flutter and atrial tachycardia within the

coronary sinus after left atrial ablation for atrial fibrillation. *Journal of the American College of Cardiology*. 2005;46 (1) :83-91.

65. Ammar S, Hessling G, Reents T, Fichtner S, Wu J, Zhu P, Kathan S, Estner HL, Jilek C, Kolb C, Haller B, Deisenhofer I. Arrhythmia type after persistent atrial fibrillation ablation predicts success of the repeat procedure. *Circ Arrhythm Electrophysiol*. 2011.

66. Chugh A, Oral H, Lemola K, Hall B, Cheung P, Good E, Tamirisa K, Han J, Bogun F, Pelosi F, Jr. , Morady F. Prevalence, mechanisms, and clinical significance of macroreentrant atrial tachycardia during and following left atrial ablation for atrial fibrillation. *Heart Rhythm*. 2005;2 (5) :464-471.

67. Pappone C, Manguso F, Vicedomini G, Gugliotta F, Santinelli O, Ferro A, Gulletta S, Sala S, Sora N, Paglino G, Augello G, Agricola E, Zangrillo A, Alfieri O, Santinelli V. Prevention of iatrogenic atrial tachycardia after ablation of atrial fibrillation: A prospective randomized study comparing circumferential pulmonary vein ablation with a modified approach. *Circulation*. 2004;110 (19) :3036-3042.

68. Knecht S, Wright M, Sacher F, Lim KT, Matsuo S, O'Neill MD, Hocini M, Jais P, Clementy J, Haissaguerre M. Relationship between perimitral and peritricuspid conduction times. *Heart Rhythm*. 2008;5 (3) :400-405.

69. Pak HN, Oh YS, Lim HE, Kim YH, Hwang C. Comparison of voltage map-guided left atrial anterior wall ablation versus left lateral mitral isthmus ablation in patients with persistent atrial fibrillation. *Heart Rhythm*. 2011;8 (2) :199-206.

70. Yokokawa M, Sundaram B, Garg A, Stojanovska J, Oral H, Morady F, Chugh A. Impact of mitral isthmus anatomy on the likelihood of achieving linear block in patients undergoing catheter ablation of persistent atrial fibrillation. *Heart Rhythm*. 2011;8 (9) :1404-1410.

71. Mountantonakis S, Frankel DS, Hutchinson MD, Dixit S, Riley M, Callans DJ, Garcia F, Lin D, Tzou W, Bala R, Marchlinski FE, Gerstenfeld EP. Feasibility of catheter ablation of mitral annular flutter in patients with prior mitral valve surgery. *Heart Rhythm*. 2011;8 (6) :809-814.

72. Anousheh R, Sawhney NS, Panutich M, Tate C, Chen WC, Feld GK. Effect of mitral isthmus block on development of atrial tachycardia following ablation for atrial fibrillation. *Pacing Clin Electrophysiol*. 2011;33 (4) :460-468.

73. Matsuo S, Yamane T, Hioki M, Ito K, Tanigawa S, Yamashita S, Inada K, Date T, Yoshimura M. Recurrent atrial arrhythmia in patients with atrial fibrillation following pulmonary vein isolation. *Journal of cardiovascular electrophysiology*. 2011;22 (9) :1080-1082.

74. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. *Circulation*. 1997;95 (8) :2075-2081.

75. Sacher F, Sobieszczyk P, Tedrow U, Eisenhauer AC, Field ME, Selwyn A, Raymond JM, Koplan B, Epstein LM, Stevenson WG. Transcoronary ethanol ventricular tachycardia ablation in the modern electrophysiology era. *Heart Rhythm*. 2008;5 (1) :62-68.
76. Chen PS, Douglas p. Zipes lecture. Neural mechanisms of atrial fibrillation. *Heart Rhythm*. 2006;3 (11) :1373-1377.
77. Ardell JL. Structure and function of mammalian intrinsic cardiac neurons. In: Armour JAA, J. L. , ed. *Neurocardiology*. New York: Oxford University Press; 1994:95-114.
78. Ardell JL. Intrathoracic neuronal regulation of cardiac function. In: Armour JAA, J. L. , ed. *Basic and clinical neurocardiology*. New York: Oxford University Press; 2004:118-152.
79. Pauza DH, Skripkiene G, Skripka V, Pauziene N, Stropus R. Morphological study of neurons in the nerve plexus on heart base of rats and guinea pigs. *J Auton Nerv Syst*. 1997;62 (1-2) :1-12.
80. Pauza DH, Skripka V, Pauziene N, Stropus R. Morphology, distribution, and variability of the epicardiac neural ganglionated subplexuses in the human heart. *Anat Rec*. 2000;259 (4) :353-382.
81. Smith FM. Extrinsic inputs to intrinsic neurons in the porcine heart in vitro. *Am J Physiol*. 1999;276 (2 Pt 2) :R455-467.
82. Adams DJC, J. Electrophysiological properties of intrinsic cardiac neurons. In: Armour JAA, J. L. , ed. *Basic and clinical neurocardiology*. New York: Oxford University Press; 2004:1-60.
83. Parsons RL. Mammalian cardiac ganglia as local integration centers: Histochemical and electrophysiological evidence. In: Dun NJM, B. H. ;Pilowsky, P. M. , ed. *Neural mechanisms of cardiovascular regulation*. Boston: Kluwer Academic Publishers; 2004:335-356.
84. Lin J, Scherlag BJ, Zhou J, Lu Z, Patterson E, Jackman WM, Lazzara R, Po SS. Autonomic mechanism to explain complex fractionated atrial electrograms (cfae). *Journal of cardiovascular electrophysiology*. 2007;18 (11) :1197-1205.
85. Patterson E, Jackman WM, Beckman KJ, Lazzara R, Lockwood D, Scherlag BJ, Wu R, Po S. Spontaneous pulmonary vein firing in man: Relationship to tachycardia-pause early afterdepolarizations and triggered arrhythmia in canine pulmonary veins in vitro. *Journal of cardiovascular electrophysiology*. 2007;18 (10) :1067-1075.
86. Chen PS, Chou CC, Tan AY, Zhou S, Fishbein MC, Hwang C, Karagueuzian HS, Lin SF. The mechanisms of atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2006;17 Suppl 3:S2-7.
87. Schauerte P, Scherlag BJ, Pitha J, Scherlag MA, Reynolds D, Lazzara R, Jackman WM. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. *Circulation*. 2000;102 (22) :2774-2780.

88. Scanavacca M, Pisani CF, Hachul D, Lara S, Hardy C, Darrieux F, Trombetta I, Negrao CE, Sosa E. Selective atrial vagal denervation guided by evoked vagal reflex to treat patients with paroxysmal atrial fibrillation. *Circulation*. 2006;114 (9) :876-885.
89. Katritsis D, Giazitzoglou E, Sougiannis D, Goumas N, Paxinos G, Camm AJ. Anatomic approach for ganglionic plexi ablation in patients with paroxysmal atrial fibrillation. *Am J Cardiol*. 2008;102 (3) :330-334.
90. Danik S, Neuzil P, d'Avila A, Malchano ZJ, Kralovec S, Ruskin JN, Reddy VY. Evaluation of catheter ablation of periatrial ganglionic plexi in patients with atrial fibrillation. *Am J Cardiol*. 2008;102 (5) :578-583.
91. Pokushalov E, Romanov A, Shugayev P, Artyomenko S, Shirokova N, Turov A, Katritsis DG. Selective ganglionated plexi ablation for paroxysmal atrial fibrillation. *Heart Rhythm*. 2009;6 (9) :1257-1264.
92. Marshall J. On the development of the great anterior veins in man and mammalia: Including an account of certain remnants of foetal structure found in the adult, a comparative view of these great veins in the different mammalia, and an analysis of their occasional peculiarities in the human subject. *Philos Trans R Soc Lond*. 1850;140:133-169.
93. Hwang C, Wu TJ, Doshi RN, Peter CT, Chen PS. Vein of marshall cannulation for the analysis of electrical activity in patients with focal atrial fibrillation. *Circulation*. 2000;101 (13) :1503-1505.
94. Cabrera JA, Ho SY, Climent V, Sanchez-Quintana D. The architecture of the left lateral atrial wall: A particular anatomic region with implications for ablation of atrial fibrillation. *Eur Heart J*. 2008;29 (3) :356-362.
95. Ulphani JS, Arora R, Cain JH, Villuendas R, Shen S, Gordon D, Inderyas F, Harvey LA, Morris A, Goldberger JJ, Kadish AH. The ligament of marshall as a parasympathetic conduit. *American journal of physiology*. 2007;293 (3) :H1629-1635.
96. Kim DT, Lai AC, Hwang C, Fan LT, Karagueuzian HS, Chen PS, Fishbein MC. The ligament of marshall: A structural analysis in human hearts with implications for atrial arrhythmias. *Journal of the American College of Cardiology*. 2000;36 (4) :1324-1327.
97. Makino M, Inoue S, Matsuyama TA, Ogawa G, Sakai T, Kobayashi Y, Katagiri T, Ota H. Diverse myocardial extension and autonomic innervation on ligament of marshall in humans. *Journal of cardiovascular electrophysiology*. 2006;17 (6) :594-599.
98. Lin J, Scherlag BJ, Niu G, Lu Z, Patterson E, Liu S, Lazzara R, Jackman WM, Po SS. Autonomic elements within the ligament of marshall and inferior left ganglionated plexus mediate functions of the atrial neural network. *Journal of cardiovascular electrophysiology*. 2009;20 (3) :318-324.
99. Scherlag BJ, Yeh BK, Robinson MJ. Inferior interatrial pathway in the dog. *Circ Res*. 1972;31 (1) :18-35.



100. Doshi RN, Wu TJ, Yashima M, Kim YH, Ong JJ, Cao JM, Hwang C, Yashar P, Fishbein MC, Karagueuzian HS, Chen PS. Relation between ligament of marshall and adrenergic atrial tachyarrhythmia. *Circulation*. 1999;100 (8) :876-883.
101. Lin J, Scherlag BJ, Lu Z, Zhang Y, Liu S, Patterson E, Jackman WM, Lazzara R, Po SS. Inducibility of atrial and ventricular arrhythmias along the ligament of marshall: Role of autonomic factors. *Journal of cardiovascular electrophysiology*. 2008;19 (9) :955-962.
102. Han S, Joung B, Scanavacca M, Sosa E, Chen PS, Hwang C. Electrophysiological characteristics of the marshall bundle in humans. *Heart Rhythm*. 2010;7 (6) :786-793.
103. Hwang C, Karagueuzian HS, Chen PS. Idiopathic paroxysmal atrial fibrillation induced by a focal discharge mechanism in the left superior pulmonary vein: Possible roles of the ligament of marshall. *Journal of cardiovascular electrophysiology*. 1999;10 (5) :636-648.
104. Katritsis D, Ioannidis JP, Anagnostopoulos CE, Sarris GE, Giazitzoglou E, Korovesis S, Camm AJ. Identification and catheter ablation of extracardiac and intracardiac components of ligament of marshall tissue for treatment of paroxysmal atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2001;12 (7) :750-758.
105. Polymeropoulos KP, Rodriguez LM, Timmermans C, Wellens HJ. Images in cardiovascular medicine. Radiofrequency ablation of a focal atrial tachycardia originating from the marshall ligament as a trigger for atrial fibrillation. *Circulation*. 2002;105 (17) :2112-2113.
106. Katritsis D, Giazitzoglou E, Korovesis S, Paxinos G, Anagnostopoulos CE, Camm AJ. Epicardial foci of atrial arrhythmias apparently originating in the left pulmonary veins. *Journal of cardiovascular electrophysiology*. 2002;13 (4) :319-323.
107. Kurotobi T, Ito H, Inoue K, Iwakura K, Kawano S, Okamura A, Date M, Fujii K. Marshall vein as arrhythmogenic source in patients with atrial fibrillation: Correlation between its anatomy and electrophysiological findings. *Journal of cardiovascular electrophysiology*. 2006;17 (10) :1062-1067.
108. Wu TJ, Ong JJ, Chang CM, Doshi RN, Yashima M, Huang HL, Fishbein MC, Ting CT, Karagueuzian HS, Chen PS. Pulmonary veins and ligament of marshall as sources of rapid activations in a canine model of sustained atrial fibrillation. *Circulation*. 2001;103 (8) :1157-1163.
109. Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M, Sandoval E, Calvo N, Brugada J, Kelder J, Wijffels M, Mont L. Atrial fibrillation catheter ablation versus surgical ablation treatment (fast) : A 2-center randomized clinical trial. *Circulation*. 2011;125 (1) :23-30.
110. Vaitkevicius R, Saburkina I, Rysevaite K, Vaitkeviciene I, Pauziene N, Zaliunas R, Schauerte P, Jalife J, Pauza DH. Nerve supply of the human pulmonary veins: An anatomical study. *Heart Rhythm*. 2009;6 (2) :221-228.

111. Mischke K, Zarse M, Schmid M, Gemein C, Hatam N, Spillner J, Dohmen G, Rana O, Saygili E, Knackstedt C, Weis J, Pauza D, Bianchi S, Schauerte P. Chronic augmentation of the parasympathetic tone to the atrioventricular node: A nonthoracotomy neurostimulation technique for ventricular rate control during atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2010;21 (2) :193-199.
112. Baez-Escudero JLD, A. S. ;Sasaridis, C. M. ; Valderrabano, M. Ethanol injection in the vein of marshall facilitates bidirectional mitral isthmus block. *Europace*. 2011;13:Abstract 830.
113. Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development and validation of the atrial fibrillation effect on quality-of-life (afeqt) questionnaire in patients with atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2011;4 (1) :15-25.
- 114a. Munger TM, Dong YX, Masaki M, Oh JK, Mankad SV, Borlaug BA, Asirvatham SJ, Shen WK, Lee HC, Bielinski SJ, Hodge DO, Herges RM, Buescher TL, Wu JH, Ma C, Zhang Y, Chen PS, Packer DL, Cha YM. Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation. *Journal of the American College of Cardiology*. 2012.
- 114b. Kurt M, Wang J, Torre-Amione G, Nagueh S. Left atrial function in diastolic heart failure. *Circ Cardiovasc Imaging*. 2009;2:10-5.
115. Leong-Sit P, Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, Bala R, Dixit S, Riley M, Hutchinson MD, Cooper J, Russo AM, Verdino R, Gerstenfeld EP. Antiarrhythmics after ablation of atrial fibrillation (5a study) : Six-month follow-up study. *Circ Arrhythm Electrophysiol*. 2011;4 (1) :11-14.
116. Piantadosi S. *Clinical trials - a methodological perspective*. New Jersey: Wiley & Sons; 2005.
117. Pocock S. *Clinical trials - a practical approach*. New York: Wiley & Sons; 1983.
118. Rosenberger WFL, J. M. *Randomization in clinical trials - theory and practice*. New York: Wiley & Sons; 2002.
119. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. *J Cardiovasc Magn Reson*. 2005;7 (5) :775-782.
120. Rubin DB. On principles for modeling propensity scores in medical research. *Pharmacoepidemiol Drug Saf*. 2004;13 (12) :855-857.
121. Peterson LEA, S;Divakaran, V. ;Deswal, A. ;Bozkurt, B. ; Mann, D. L. Improved propensity matching for heart failure using neural gas and self-organizing maps. Proceedings of the international joint conference on neural networks (ijcnn'09). . Piscataway (NJ) : IEEE Press; 2009.
122. Chylack LT, Jr. , Peterson LE, Feiveson AH, Wear ML, Manuel FK, Tung WH, Hardy DS, Marak LJ, Cucinotta FA. Nasa study of cataract in astronauts (nasca). Report 1: Cross-sectional study of the relationship of exposure to space radiation and risk of lens opacity. *Radiat Res*. 2009;172 (1) :10-20.

123. Malik M, Camm AJ. Heart rate variability: From facts to fancies. *Journal of the American College of Cardiology*. 1993;22 (2) :566-568.
124. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, Hodge DO, Schaff HV, Holmes DR, Jr. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. *Circulation*. 2008;118 (2) :131-139.
125. Dixit S, Marchlinski FE, Lin D, Callans DJ, Bala R, Riley MP, Garcia FC, Hutchinson MD, Ratcliffe SJ, Cooper JM, Verdino RJ, Patel VV, Zado ES, Cash NR, Killian T, Tomson TT, Gerstenfeld EP. Randomized ablation strategies for the treatment of persistent atrial fibrillation: Rasta study. *Circ Arrhythm Electrophysiol*. 2012;5 (2) :287-294.
126. Chao TF, Tsao HM, Lin YJ, Tsai CF, Lin WS, Chang SL, Lo LW, Hu YF, Tuan TC, Suenari K, Li CH, Hartono B, Chang HY, Ambrose K, Wu TJ, Chen SA. Clinical outcome of catheter ablation in patients with nonparoxysmal atrial fibrillation: Results of 3-year follow-up. *Circ Arrhythm Electrophysiol*. 2012;5 (3) :514-520.
127. Vaughan Williams EM. "Classification of anti-arrhythmic drugs." In: *Symposium on Cardiac Arrhythmias*, Sandfte E, Flensted-Jensen E, Olesen KH eds. Sweden, AB ASTRA, Södertälje, 1970;449-472.

## PROTOCOL MODIFICATIONS

### Version 1 to version 5.

Protocol Entitled “Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation”

Added time-windows to scheduled visits and monitoring.

Page, Section Changes and Rationale

16 Randomization Removed phrase “...using a validated method provided by statistician...”

Randomization will be handled via the Data Coordinating Center web-based study management system, and will be performed via the site personnel. In case this changes again, we will leave the method of randomization off.

17 VOM procedure, letter “d” Added one step, “A one time 10cc sample of whole blood will be drawn after this procedure in order to determine if there is residual alcohol in the blood as a result of the injected ETOH”

Neglected to include in original protocol: 6, 9, and 12 month follow-up

Clarification added re: echocardiography stating that echo will be performed “at the end of the patient’s participation in the study as it was in the pre-procedure visit”. Clarification of final echo timepoint

Schedule of Events Removed TEE at month 6-15 Error

Schedule of Events Separated events VOM and PVAI procedure, and added “injection of ETOH” for the VOM group. Clarifying the study treatment and timepoint when given.

31 Data Management Removed parenthetical phrase “Treatment A or B” Confusing as there are no groups named A or B. It is a redundant statement, the one preceding it is clear enough

Corrections to "Protocol Summary" which were inconsistent with the revision of the body of the last protocol.

Corrections to the "Schedule of Events" which contained errors.

Addition of 10ml blood sample to be taken from VOM patients to detect any ETOH levels post procedure.

## SUMMARY OF PROTOCOL MODIFICATIONS Versions 5 to 7

The changes summarized below follow discussions held during DSMB meetings in the preceding months and respond to needs to enhance enrollment and facilitate the conduct of the trial. This was implemented early in 2016, when 87 of the total 343 patients had been enrolled.

### A. PROTOCOL MODIFICATIONS

#### 1. Clarification of the primary endpoint in VENUS .

The primary endpoint is single-procedure success in VENUS, defined as *freedom from symptomatic atrial fibrillation (AF) or atrial tachycardia (AT) AND reduction of AF/AT to less than 30 seconds in a continuous monitor at 6 and 12 months after a single procedure.* This has significant implications:

- a. Eliminates the need to account for repeat procedures for the purposes of primary endpoint determination, and allows for a trial duration of 12 months for both VENUS and MARS, consistent with the recommendations for clinical trials in AF by the HRS/EHRA/ECAS Catheter and Surgical Ablation consensus document.<sup>1</sup>
- b. New power calculations are included

**2. Addition of mortality to primary safety endpoint.**

As documented in prior clinical trials using similar patient populations, mortality is expected to be low in both groups. Zero mortality was found in the RASTA study<sup>2</sup> and in one patient out of 589 patients in the STAR-AF2 study.<sup>3</sup> Nevertheless, it will be recorded as part of the primary safety endpoint that includes procedural complications. Per DSMB recommendations, mortalities will be considered as “effectiveness failures” for the purpose of the primary endpoint.

**3. Follow-up duration of 12 months for all patients.**


Both VENUS will have the same follow-up duration of 12 months.

**4. Definition of clinical/partial success as secondary endpoint to follow HRS consensus.**


The 2012 consensus document defines it as follows: Clinical/partial success is defined as a 75% or greater reduction in the number of AF episodes, the duration of AF episodes, or the % time a patient is in AF as assessed with a device capable of measuring AF burden in the presence or absence of previously ineffective antiarrhythmic drug therapy. Patients with persistent AF are assumed to have 100% AF over a 1-week period –definition of persistent AF. We will define clinical/partial success as less than 25% AF burden on a continuous event monitor at 6 and 12 months from ablation procedure.

**5. Repeat procedures will qualify as effectiveness failures for the primary endpoint.**

A secondary endpoint of freedom from AT/AF after more than one procedure has been included. There will be no blanking period for repeat procedures.



**Patient Flow of Protocol 7.** The primary endpoint became freedom from AF or flutter (tachycardia) *after a single procedure*. Patients follow-up duration will be 12 months. Patients will be followed clinically every 3 months and monitored (1 month monitor) at 6 months and at 12 months. Recurrences of AF/AT clinically or during EKG monitoring will be considered effectiveness failures. Repeat procedures will constitute in effectiveness failures. This was a change from the original protocol shown below, in which the time interval from 3 to 9 months was allowed for repeat procedures and the primary endpoint included freedom from AF after 1 or 2 procedures, with a total follow-up of 15 months. **Previous patient flow:**



**6. Clarification of the indications for repeat procedures.**

Indications for repeat procedures will include:

- a. procedure failures –recurrent persistent AF or flutter on clinical follow-up;
- b. less than clinical/partial success – AF or flutter burden of >25%;
- c. symptomatic AF or flutter regardless of burden

**7. Clarification of the definitions of effectiveness failures. Per DSMB recommendations:**

- a. Clinical recurrence of AF or flutter after 3-months.
- b. Documented AF or flutter of 30 seconds or more on EKG monitor at either 6- or 12 months post randomization procedure.
- c. Repeat procedures.
- d. Mortality.

**8. Stratification by LA size or AF duration removed.**

This required LA volume to be measured on CT or MRI prior to the procedure and constituted an obstacle to early randomization after patient screening. VENUS patients will no longer be stratified by AF duration or LA volume. Degrees of LA enlargement and AF duration added to pre-specified subgroup analyses.

**9. Elimination of required cardiac CT or MRI to assess LA volume.**

This created the need to perform either of these tests prior to randomization and was an unnecessary obstacle in patient flow. This eliminates the exclusion criterion of contraindication for CT or MR.

**10. Clarification of continuous EKG monitoring times:**

Continuous EKG monitoring will be performed at 6 months for all patients and at end of the study (12 months). Both 6- and 12-month monitoring sessions will have a window of  $\pm 60$  days.

**11. Re-done statistical analysis plan.** To accommodate single-procedural endpoint in VENUS.

Sequential trial design as described. No plans for sample-size modification. Multiple imputation



will only be used for dealing with missing data as a secondary analysis tool of the primary endpoint.

12. **Clarification of voltage maps to be obtained**
13. **Clarification of the PVAI ablation lesions.**
14. **Clarification of the angioplasty balloons to be used in VOM procedure, and clarification of possible approaches to CS cannulation (jugular or femoral).**
15. **No recording of AF recurrences in the blanking period required, since they do not constitute effectiveness failures.**
16. **Clarification of the data to be collected in repeat procedures.**
17. **Eliminate post procedure labs (CBC, troponin, ethanol level).**
18. **Specify no restrictions in data collection sites.**

*Post-procedure data collection - Patients may receive follow-up standard of care procedures (ECG, physical exam, review of medical history and concomitant medications (limited to AAD and anticoagulants)) at the study site or at a provider of their choice. If an investigator at a study site does not perform the visit, the study staff will have the patient sign a Release of Medical Information and request the applicable medical records from the patient's provider. All ECG tracings must be reviewed and interpreted by a study investigator. The AFEQT questionnaire may be conducted by telephone call with the patient.*

19. **Concomitant medications to be tracked limited to antiarrhythmic drugs and anticoagulants.**
20. **Methods to rule-out left atrium appendage (LAA) thrombus by pre-procedural imaging have been expanded to additionally include CT or MRI. Documentation by exception (no LAA thrombus documented on imaging reports) is permitted for determination of eligibility.**
21. **Elimination of 6-month history of AF in the definition of persistent AF, to accommodate to the AF consensus definitions of minimum documentation of AF:**  
physician's note indicating continuous AF 7 days.
22. **Broadening of the follow-up 1-month ECG monitor window at 6 and 12 months to 6 months (+/- 60 days) and 12 months (+/- 60 days).**
23. **Requirement of INR testing pre-procedure only on patients taking warfarin.**
24. **Consent: more explicitly detailed coverage of monitoring data.** Only external monitors provided by the study. Data can be extracted from implanted devices that are present due to other clinical indications but the study does not constitute an indication for such implanted devices and will not cover their associated costs.

1. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ, Jr., Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 hrs/ehra/ecas expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: A report of the heart rhythm society

(hrs) task force on catheter and surgical ablation of atrial fibrillation. Developed in partnership with the european heart rhythm association (ehra), a registered branch of the european society of cardiology (esc) and the european cardiac arrhythmia society (ecas); and in collaboration with the american college of cardiology (acc), american heart association (aha), the asia pacific heart rhythm society (aphrs), and the society of thoracic surgeons (sts). Endorsed by the governing bodies of the american college of cardiology foundation, the american heart association, the european cardiac arrhythmia society, the european heart rhythm association, the society of thoracic surgeons, the asia pacific heart rhythm society, and the heart rhythm society. *Heart Rhythm*. 2012;9:632-696 e621

2. Dixit S, Marchlinski FE, Lin D, Callans DJ, Bala R, Riley MP, Garcia FC, Hutchinson MD, Ratcliffe SJ, Cooper JM, Verdino RJ, Patel VV, Zado ES, Cash NR, Killian T, Tomson TT, Gerstenfeld EP. Randomized ablation strategies for the treatment of persistent atrial fibrillation: Rasta study. *Circ Arrhythm Electrophysiol*. 2012;5:287-294
3. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P. Approaches to catheter ablation for persistent atrial fibrillation. *N Engl J Med*. 2015;372:1812-1822

## ORIGINAL STATISTICAL PLAN

### VENUS STATISTICAL PLAN

#### a) VENUS Group Sequential Design

**VENUS Preliminary Data.** In patients undergoing their first ablation for persistent AF (original VENUS trial sample size calculations), the pilot data showed a response rate of  $p_1=45\%$  for  $n=174$  patients receiving PVAI and  $p_2=61\%$  for  $n=66$  patients receiving VOM-PV.

**VENUS Power and sample size determination.** Group sequential two proportions power analysis using simulation was performed using PASS V12 (Kaysville, UT). The following assumptions were made:

- Response rate in PV-VOM:  $p_1=0.61$
- Response rate in PVAI:  $p_2= 0.45$
- Hypotheses:  $H_0: p_1= p_2$ ;  $H_1: p_1 \neq p_2$
- Test Statistic: Z-Test (Pooled)
- Zero Adjustment Method: None
- Alpha-Spending Function: O'Brien-Fleming Analog
- Beta-Spending Function: None
- Futility Boundary Type: None
- Number of Looks: 3
- Simulations: 100000

**Results.** Group sequential trials with sample sizes of  $N_1=156$  and  $N_2=156$  at the final look achieve 80% power to detect a difference of 0.16 between a treatment group proportion of 0.61 and a control group proportion of 0.45 at the 0.050 significance level (alpha) using a two-sided Z-Test (Pooled). The table below lists the sample sizes required for 80% power.

**Table S1.** Sample size requirements for a group sequential trial looks based on 100,000 iterations.

Power			Alpha				Beta		
Value	95% LCL	95% UCL	Target	Actual	95% LCL	95% UCL			
0.806	0.803	0.808	0.050	0.049	0.047	0.050	0.194		
----- Average Sample Size -----									
-- Given H0 --			-- Given H1 --						
N1	N2	Grp1	Grp2	Grp1	Grp2	Diff0	Diff1	P1 H1	P2
156	156	155	155	134	134	0.00	0.16	0.61	0.45


**Total VENUS Sample Size due to Technical Feasibility.** Because there is a technical feasibility rate of 85% for the VOM procedure, the total sample size for the VOM-PV arm in VENUS needs to be increased by 1.15 for an intention-to-treat approach to lead to enough on-treatment patients in the VOM group. Therefore, this results in  $N_1=156*1.15=180$ , so that the total sample size of MARS patients to be enrolled is  $N=156 + 180 = 336$ .

**VENUS Efficacy Monitoring.** We propose to monitor efficacy at two interim time points and one final time period (i.e., three “looks”) when primary outcome data (at first AF/AT recurrence or up 12 month follow-up) are available for 1/3, 2/3 and 3/3 of the total sample size of VENUS subjects. For the VENUS trial, these values are provide in the following table in terms of *information time*:

**Table S2.** Efficacy monitoring schedule for VENUS with cumulative sample size, significance boundaries and 95% CIs, and alpha- and beta-spending.

Look	Accumulated Information	----- Accumulated Primary Outcomes -----		
	Percent	Group 1	Group 2	Total
1	33.33	52	52	104
2	66.67	104	104	208
3	100.00	156	156	312

**Figure S1.** Group sequential trial efficacy boundaries for the VENUS trial at three looks (1/3, 2/3, and 3/3 of total sample size based on primary outcomes).



**Table S3.** Significance Boundaries with 95% Simulation Confidence Intervals

Look	----- Z-Value Boundary -----			----- P-Value Boundary -----		
	Value	95% LCL	95% UCL	Value	95% LCL	95% UCL
1	+/- 3.727	3.554	3.744	0.000	0.000	0.000
2	+/- 2.519	2.508	2.534	0.012	0.011	0.012
3	+/- 2.038	1.954	2.041	0.042	0.041	0.051

**Table S4.** Alpha-Spending and Null Hypothesis Simulation Details

----- Target -----	----- Actual -----	----- Proportion -----	Cum.
Cum.	Cum.	H1 Sims	H1 Sims

Look	--- Signif. Boundary---		Spending	Spending	Alpha	Cum.	Outside	Outside
	Z-Value	P-Value	Function	Function				
	Scale	Scale	Alpha	Alpha	Spent	Spent	Boundary	Boundary
1	+/- 3.727	0.000	0.000	0.000	0.000	0.000	0.019	0.019
2	+/- 2.519	0.012	0.012	0.012	0.011	0.011	0.383	0.403
3	+/- 2.038	0.042	0.038	0.050	0.038	0.049	0.403	0.806

The hypothesis test applied at the  $k$ th look is a two-tailed test of equality of two independent proportions, functionally composed as:

$$Z_k = \frac{\hat{p}_{1k} - \hat{p}_{2k}}{\sqrt{\hat{p}_{1k}(1 - \hat{p}_{1k}) + \hat{p}_{2k}(1 - \hat{p}_{2k})}}$$

where  $\hat{p}_{1k}$  is the proportion of successful primary outcomes in the PVAI-VOM arm of VENUS at the  $k$ th look, and  $\hat{p}_{2k}$  is the proportion of successful primary outcomes within the PVAI arm of VENUS at the  $k$ th look.  $Z_k$  follows a standard normal distribution,  $\mathcal{N}(0,1)$ . If during the first look when at least N=52 primary outcomes have been observed in both arms (N=104 total), if  $Z_1$  exceeds 3.727, then the trial will be evaluated for early termination due to beneficial efficacy, whereas if  $Z_1$  is less than -3.727, the trial will be evaluated for early termination for non-beneficial efficacy. However, for the “inner wedge,” when  $-3.727 \leq Z_1 \leq 3.727$ , we will consider completing the trial in order to reject the null hypothesis. The same rule applies for the 2<sup>nd</sup> look when at least N=104 primary outcomes have been observed in both arms (208 total), for which the tabled critical value of  $Z$  is  $\pm 2.519$ . The overall efficacy of the trial will be determined when at least N=156 primary outcomes have been observed in both arms (312 total), for which the critical value of  $Z$  is  $\pm 2.038$ .

**Subject randomization.** Patients will be randomized to treatment groups by the EDC system at a 1:1.15 ratio (PVAI : VOM-PV). Stratified block-randomization (to ensure balance of strata –de novo ablation vs repeat ablation) will be performed in an attempt to remove treatment preference based on risk, prognostic factors, and subject choice.<sup>116-118</sup> The N=405 planned enrollees will be block-randomized into the 2 treatment groups (PVAI or VOM-PV), with stratification by their prior AF ablation history: De novo AF ablation vs Prior AF ablation failures.

**Data quality.** All study data will be evaluated on a periodic basis by the study staff at the data coordinating center (see below). Meetings will consist of review of enrollment progress, recruitment sample size summaries, review of potential problems, holes reports for existing data (missing data), progress with data collection, and summary statistics of subjects enrolled.

**Statistical analysis.** All major treatment comparisons between the two randomized groups in this study will be performed according to the principle of “intention-to-treat”, that is, subjects will be analyzed according to the treatment arm to which patients were randomized, regardless of compliance to assigned treatment. Summary statistics (age, race, gender, BMI, smoking, AF duration, medical history coronary artery disease, diabetes mellitus, hypertension, chronic obstructive pulmonary disease, sleep apnea, prior stroke), will be determined by treatment arm. Regarding demographic and host factors, Chi-square or

Fisher's exact test for categorical variables and the t-test or Wilcoxon Rank Sum test will be employed for identifying significant group-wise differences for continuous variables. The crude difference between treatment arms will be compared by tests of two independent proportions, whereas treatment differences for stratified data (AF duration, LA volume) will be performed using the Mantel-Haenszel odds-ratio. In spite of the smaller sample sizes, we will nevertheless employ logistic regression modeling ( $y=0$  for success  $y=1$  for failure) to assess confounding effects of age, race, gender, and AF ablation history. A pre-specified subgroup analysis will be performed to compare effectiveness of VOM ethanol in patients with de novo vs repeat ablations at the time of study entry.

**Use of propensity scores in multivariate models.** An ideal goal for observational etiological studies is to allocate randomly subjects into different treatment groups in order to guarantee on average that there are no systematic differences in covariates between groups.<sup>120</sup> After randomization, there is nevertheless a possibility for observing large differences in confounders which may lead to bias in results. The propensity score provides a scalar summary of covariate information and is defined as the propensity (probability) that a subject's covariate profile represents subjects truly assigned to a given treatment group. Propensity scores based on significantly different confounder variables can be used to create a quasi-randomized experiment with adjustment to the treatment effect. We will assess the role of propensity scores in prediction models in order to reduce the effects of baseline factors that may be significantly different among subjects in different treatment groups. Firstly, we will identify baseline covariates which are significantly different across treatment groups (using t-tests with skew-zero transformed covariates or Mann-Whitney tests). Significant covariates will be incorporated into a logistic regression model ( $y=0$  PVAI, 1-VOM-PV) to generate subject-specific logits, which are normally-distributed.<sup>121, 122</sup> Treatment-subject-specific logits will then be used for matching subjects across the treatment groups in order to construct a sample of subjects with balanced covariates. We suspect that propensity matching will not be required to tackle the problem of extreme confounder differences, but will nevertheless evaluate the effect of propensity matching prior to logistic regression to determine treatment effect possibly adjusted for age.

**Missing data.** The critical piece of data required for endpoint analysis is the electrocardiographic event monitor. Failure to comply with wearing the monitor will lead to missing data. We request patients to wear monitors for 1 –month. However, only a minimum of 1-week of monitored time is required for Endpoint assessment. Patients with less than 1 – week of monitoring will be considered as missing data. Patients who die before then study end will be considered not to have a response to treatment. For patients with missing primary outcomes, we will perform multiple imputation based on Monte Carlo Markov chain (MCMC) methods (Refs 1-3).

1. Raghunathan, T. E., J. M. Lepkowski, J. Van Hoewyk, and P. Solenberger. 2001. A multivariate technique for multiply imputing missing values using a sequence of regression models. *Survey Methodology* 27: 85–95.
2. Rubin, D. B. 1987. *Multiple Imputation for Nonresponse in Surveys*. New York: Wiley.
3. van Buuren, S. 2007. Multiple imputation of discrete and continuous data by fully conditional specification. *Statistical Methods in Medical Research* 16: 219–242.





# STATISTICAL ANALYSIS PLAN

24 April 2018 DRAFT

## **Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation IND 115,060**

PROTOCOL NUMBER 1212-0235

SPONSORED BY

NHLBI

Principal Investigator: Miguel Valderrabano, M.D.

PREPARED BY

Leif Peterson, Ph.D., M.P.H.  
Professor of Healthcare Policy and Research  
Dept. of Healthcare Policy and Research  
Weill Cornell Medical College  
and  
Director, Center for Biostatistics  
Houston Methodist Research Institute  
6565 Fannin Street, Suite MGJ6-031  
Houston, Texas 77030

Telephone: (713) 441-6121  
E-mail: [lepeterson@houstonmethodist.org](mailto:lepeterson@houstonmethodist.org)

*This document is confidential and proprietary to HMRI. Acceptance of this document constitutes agreement by the recipient that no unpublished information contained herein will be reproduced, published, or otherwise disclosed without the prior written approval of HRMI, except that this document may be disclosed to appropriate Institutional Review Boards under the condition that they keep the information confidential.*

**DOCUMENT VERSION CONTROL**

<b>Version Number</b>	<b>Date</b>	<b>Comments/Changes</b>
0.1	Feb 17, 2015	
0.2	Apr 24, 2018	

**APPROVALS**

Approved:	_____	Date:	_____
	Name		
	Title		
	_____	Date:	_____
	Name		
	Title		
	_____	Date:	_____
	Name		
	Title		
	_____	Date:	_____
	Name		
	Title		
	_____	Date:	_____
	Name		
	Title		

## TABLE OF CONTENTS

### CONTENTS

<b>1. THE STATISTICAL ANALYSIS PLAN.....</b>	<b>8</b>
<b>2. PROTOCOL SUMMARY.....</b>	<b>8</b>
2.1 Study Objectives.....	8
2.2 Sub-Studies.....	8
2.3 VENUS Group Sequential Clinical Trial Design.....	8
2.4 MARS Group Sequential Clinical Trial Design.....	10
2.5 Pre-Study Sensitivity Analysis for Varying Levels of Missingness.....	12
<b>3. STATISTICAL ANALYSIS OVERVIEW.....</b>	<b>17</b>
3.1 Primary and Secondary Analyses.....	17
3.2 Analysis populations.....	18
3.2.1 Enrolled Population.....	18
3.2.2 Analysis Population.....	18
3.3 General Analysis and Reporting Conventions.....	18
<b>4. PRIMARY ANALYSIS FOR EFFICACY.....</b>	<b>18</b>
4.1 Primary Outcome for Interim Efficacy Monitoring.....	18
4.2 VENUS Interim Efficacy Analysis.....	20
4.3 MARS Interim Efficacy Monitoring.....	22
4.4 Intention to Treat Analysis (ITT).....	23
<b>5. SECONDARY ANALYSES FOR EFFICACY.....</b>	<b>25</b>
5.1 Sensitivity Analysis of Primary Outcome.....	25
5.1.1 Non-Compliance or Protocol Deviations.....	25
5.1.2 Missing Data.....	25
5.1.3 Missing Imputation.....	26
5.1.4 Baseline Imbalance (Model Building Strategies).....	26
5.1.5 Center Imbalance (Random Effects Modeling).....	26
5.1.1 Use of Propensity Scores in Multivariate Models.....	27
5.1.1 Cluster Discovery.....	27
5.2 Secondary Outcomes.....	27
5.2.1 Demographic and Other Baseline Characteristics.....	29
5.2.2 Tests of Association and Dependency for Secondary Outcomes.....	30
5.2.1 Time-To-Event Analysis of Loss-of-Rhythm and QOL data.....	30
<b>6. SAFETY EVALUATION AND ANALYSIS.....</b>	<b>30</b>
<b>7. REFERENCES.....</b>	<b>33</b>



## LIST OF ABBREVIATIONS

AE	Adverse event
AF	Atrial fibrillation
AT	As treated
CI	Confidence interval
CRF	Case report form
CS	Coronary sinus
DCC	Data Coordinating Center
IA	Interim analysis
ITT	Intent to treat
LA	Left atrial
MARS-AF	Vein of <b>M</b> arshall <b>A</b> lcohol in <b>R</b> epeat ablation of <b>p</b> er <b>S</b> istent <b>A</b> trial <b>F</b> ibrillation
NHLBI	National Heart, Lung, and Blood Institute
NIH	National Institutes of Health
PP	Per protocol
PMF	Particularly perimitral flutter
ROC	Receiver operating characteristics
SAE	Serious adverse event
SAP	Statistical Analysis Plan
VOM	Vein of Marshall
VENUS-AF	<b>V</b> ein of Marshall <b>E</b> thanol <b>i</b> n <b>f</b> usion in <b>U</b> ntreated <b>p</b> er <b>S</b> istent <b>A</b> trial <b>F</b> ibrillation

## LIST OF SYMBOLS

aOR	Adjusted odds ratio
$\alpha$	Type I error rate (significance level)
$\beta$	Type II error rate (1-Power)
$\beta_j$	Regression coefficient for $j$ th variable
$n$	Sample size
$p$	Number of variables
$x_i$	Covariate value for $i$ th subject
$P$	Tail probability (p-value)
$N(\mu, \sigma^2)$	Normal distribution
$\chi_v^2$	Chi-squared variate with $v$ d.f.
$F(v, \omega)$	F-ratio variate with $v, \omega$ d.f.
$t(v)$	t-variate with $v$ d.f.
OR	Odds ratio
PV-	Negative predictive value
PV+	Positive predictive value
$ran$	Random number
ROC	Receiver operating characteristics
AUC	Area under the ROC curve
$U(0,1)$	Uniform random variate
$Z$	Z-score

## 1. THE STATISTICAL ANALYSIS PLAN

The Statistical Analysis Plan (SAP) is not a stand-alone document but expands in further detail the statistical analysis and considerations already outlined the protocol. The protocol background information, objectives, design, and procedures are fully described in the study protocol.

## 2. PROTOCOL SUMMARY

A brief summary of protocol objectives and study design are described below. For further details refer to the protocol.

### 2.1 Study Objectives

This is a Phase III blinded stratified randomized clinical trial to assess safety and efficacy of Vein of Marshall (VOM) ethanol infusion in *de novo* catheter ablation of persistent AF. This objective is termed “VENUS,” which represents **V**ein of Marshall **E**thanol **i**nfusion in **U**ntreated **p**ersistent **A**trial **F**ibrillation.

### 2.2 Sub-Studies

**VENUS** - This sub-study focuses on *de novo* patients with newly diagnosed AF.

**MARS** – This sub-study focuses on subjects having recurrent AF at the time of enrollment.

Patient enrollment will occur in several centers, and Houston Methodist Hospital will serve as the Coordinating Center. Data collection will involve assessment of data quality, data completeness, missing data, and primary and secondary outcomes.

### 2.3 VENUS Group Sequential Clinical Trial Design

**Power and sample size determination.** Group sequential two proportions power analysis using simulation was performed using PASS V12 (Kaysville, UT). The following assumptions were made:

- Response rate in PV-VOM:  $p_1=0.56$
- Response rate in PVAI:  $p_2= 0.38$
- Hypotheses:  $H_0: p_1= p_2$ ;  $H_1: p_1 \neq p_2$
- Test Statistic: Z-Test (Unpooled)
- Zero Adjustment Method: None
- Alpha-Spending Function: O'Brien-Fleming Analog
- Beta-Spending Function: None
- Futility Boundary Type: None
- Number of Looks: 3
- Simulations: 100000

**Results.** A group sequential trial with sample sizes of  $N_1=180$  and  $N_2=156$  at

the final look achieves 91% power to detect a difference of 0.18 between a treatment group success proportion of 0.56 and a control group success proportion of 0.38 at the 0.05 significance level (alpha) using a two-sided Z-Test (Unpooled). The table below lists the sample sizes required for 91% power.

**Table 5. Sample size requirements for a group sequential trial based on 100,000 iterations.**

<b>Value</b>	<b>95% LCL</b>	<b>95% UCL</b>	<b>Target</b>	<b>Actual</b>	<b>95% LCL</b>	<b>95% UCL</b>			
0.909	0.908	0.911	0.050	0.049	0.048	0.051			
----- Average Sample Size -----									
-- Given H0 --    -- Given H1 --									
<b>N1</b>	<b>N2</b>	<b>Grp1</b>	<b>Grp2</b>	<b>Grp1</b>	<b>Grp2</b>	<b>Diff0</b>	<b>Diff1</b>	<b>P1 H1</b>	<b>P2</b>
180	156	179	155	144	125	0.00	0.18	0.56	0.38

**VENUS Interim Analysis - Conditional Power and Futility For Various Test Results.** Conditional power runs were made using PASS 12 (Kaysville, UT). During the first look at 33% information time, there will be 60 VOM and 52 PVAI primary outcomes available. Using a one-sided ( $\alpha=0.025$ ) test of two proportions,  $\theta=p_2-p_1$ , where  $p_2$  is the PVAI success rate and  $p_1$  is the VOM success rate, the expectation is that the test statistic  $Z_k$  is less than zero, since  $H_a: p_2 < p_1$ . The table below list the conditional power and futility at the first look for a range of  $Z_k$  values:

**Table 10. VENUS Conditional power and futility at the first look (33% information, 60 VOM, 52 PVAI) for a range of  $Z_k$  values from a one-sided test of two independent proportions.**

<b>Cond. Power</b>	<b>Pred. Power</b>	<b>Total Sample Size VOM/PVAI</b>	<b>Current Sample Size n1k n2k</b>	<b>Prop. Group 1 P1</b>	<b>Prop. Group 2 P2</b>	<b>Test Statistic <math>Z_k</math></b>	<b>Alpha</b>	<b>Futility</b>
0.99994	1	180 156	60 52	0.56	0.38	-5	0.025	0.00006
0.99974	0.99998	180 156	60 52	0.56	0.38	-4.5	0.025	0.00026
0.9991	0.99978	180 156	60 52	0.56	0.38	-4	0.025	0.0009
0.99717	0.99814	180 156	60 52	0.56	0.38	-3.5	0.025	0.00283
0.99209	0.98894	180 156	60 52	0.56	0.38	-3	0.025	0.00791
0.98027	0.95313	180 156	60 52	0.56	0.38	-2.5	0.025	0.01973
0.95597	0.85624	180 156	60 52	0.56	0.38	-2	0.025	0.04403
0.91184	0.67408	180 156	60 52	0.56	0.38	-1.5	0.025	0.08816
0.84101	0.43598	180 156	60 52	0.56	0.38	-1	0.025	0.15899
0.74056	0.2196	180 156	60 52	0.56	0.38	-0.5	0.025	0.25944
0.61467	0.08289	180 156	60 52	0.56	0.38	0	0.025	0.38533

**Table 11. VENUS Conditional power and futility at the second look (66% information, 120 VOM, 104 PVAI) for a range of  $Z_k$  values from a one-sided test of two independent proportions.**

Cond. Power	Pred. Power	Total Sample Size VOM/PVAI	Current Sample Size n1k n2k	Prop. Group 1 P1	Prop. Group 2 P2	Test Statistic $Z_k$	Alpha	Futility
1.00000	1.00000	180 156	120 104	0.56	0.38	-5.0	0.025	0
1.00000	1.00000	180 156	120 104	0.56	0.38	-4.5	0.025	0
0.99998	0.99998	180 156	120 104	0.56	0.38	-4.0	0.025	0.00002
0.99973	0.99950	180 156	120 104	0.56	0.38	-3.5	0.025	0.00027
0.99703	0.99233	180 156	120 104	0.56	0.38	-3.0	0.025	0.00297
0.97954	0.94042	180 156	120 104	0.56	0.38	-2.5	0.025	0.02046
0.90942	0.75562	180 156	120 104	0.56	0.38	-2.0	0.025	0.09058
0.73567	0.43104	180 156	120 104	0.56	0.38	-1.5	0.025	0.26433
0.46930	0.14923	180 156	120 104	0.56	0.38	-1.0	0.025	0.5307
0.21648	0.02834	180 156	120 104	0.56	0.38	-0.5	0.025	0.78352
0.06795	0.00279	180 156	120 104	0.56	0.38	0.0	0.025	0.93205

## 2.4 MARS Group Sequential Clinical Trial Design

**Power and sample size determination.** Group sequential two proportions power analysis using simulation was performed using PASS V12 (Kaysville, UT). The following assumptions were made:

- Response rate in PV-VOM:  $p_1=0.76$
- Response rate in PVAI:  $p_2= 0.42$
- Hypotheses:  $H_0: p_1= p_2$ ;  $H_1: p_1 \neq p_2$
- Test Statistic: Z-Test (Unpooled)
- Zero Adjustment Method: None
- Alpha-Spending Function: O'Brien-Fleming Analog
- Beta-Spending Function: None
- Futility Boundary Type: None
- Number of Looks: 3
- Simulations: 100000

**Table 7. Sample size requirements for a group sequential trial based on 100,000 iterations.**

Value	Power		Target	Alpha			Beta
	95% LCL	95% UCL		Actual	95% LCL	95% UCL	
0.810	0.807	0.812	0.050	0.049	0.047	0.050	0.1
----- Average Sample Size -----							

		-- Given H0 --		-- Given H1 --					
N1	N2	Grp1	Grp2	Grp1	Grp2	Diff0	Diff1	P1 H1	P2
33	33	33	33	28	28	0.00	0.34	0.76	0.42

**Results.** Group sequential trials with sample sizes of 33 and 33 at the final look achieve 81% power to detect a difference of 0.34 between a treatment group proportion of 0.76 and a control group proportion of 0.42 at the 0.05 significance level (alpha) using a two-sided Z-Test (Unpooled).

**Table 12. MARS Conditional power and futility at the first look (33% information, 11 VOM, 11 PVAI) for a range of  $Z_k$  values from a one-sided test of two independent proportions.**

Cond. Power	Pred. Power	Total Sample Size VOM/PVAI	Current Sample Size n1k n2k	Prop. Group 1 P1	Prop. Group 2 P2	Test Statistic $Z_k$	Alpha	Futility
0.9997	1	33 33	11 11	0.76	0.42	-5	0.025	0.0003
0.99894	0.99998	33 33	11 11	0.76	0.42	-4.5	0.025	0.00106
0.99674	0.99978	33 33	11 11	0.76	0.42	-4	0.025	0.00326
0.99104	0.99814	33 33	11 11	0.76	0.42	-3.5	0.025	0.00896
0.97798	0.98894	33 33	11 11	0.76	0.42	-3	0.025	0.02202
0.95155	0.95313	33 33	11 11	0.76	0.42	-2.5	0.025	0.04845
0.90431	0.85624	33 33	11 11	0.76	0.42	-2	0.025	0.09569
0.82969	0.67408	33 33	11 11	0.76	0.42	-1.5	0.025	0.17031
0.72555	0.43598	33 33	11 11	0.76	0.42	-1	0.025	0.27445
0.5971	0.2196	33 33	11 11	0.76	0.42	-0.5	0.025	0.4029
0.45712	0.08289	33 33	11 11	0.76	0.42	0	0.025	0.54288

**Table 13. MARS Conditional power and futility at the second look (66% information, 22 VOM, 22 PVAI) for a range of  $Z_k$  values from a one-sided test of two independent proportions.**

Cond. Power	Pred. Power	Total Sample Size VOM/PVAI	Current Sample Size n1k n2k	Prop. Group 1 P1	Prop. Group 2 P2	Test Statistic $Z_k$	Alpha	Futility
1.0000 0	1.0000 0	33 33	22 22	0.76	0.42	-5	0.025	0
1.0000 0	1.0000 0	33 33	22 22	0.76	0.42	-4.5	0.025	0
0.9999	0.9999	33 33	22 22	0.76	0.42	-4	0.025	0.0000



5	8							5
0.9992								0.0007
5	0.9995	33 33	22 22	0.76	0.42	-3.5	0.025	5
0.9932	0.9923							0.0067
3	3	33 33	22 22	0.76	0.42	-3	0.025	7
0.9609	0.9404							0.0390
7	2	33 33	22 22	0.76	0.42	-2.5	0.025	3
0.8542	0.7556							0.1457
6	2	33 33	22 22	0.76	0.42	-2	0.025	4
	0.4310							
0.636	4	33 33	22 22	0.76	0.42	-1.5	0.025	0.364
0.3596	0.1492							0.6403
8	3	33 33	22 22	0.76	0.42	-1	0.025	2
0.1431	0.0283							0.8568
1	4	33 33	22 22	0.76	0.42	-0.5	0.025	9
0.0380	0.0027							0.9619
7	9	33 33	22 22	0.76	0.42	0	0.025	3

## 2.5 Pre-Study Sensitivity Analysis for Varying Levels of Missingness

Following methods introduced in Proschan et al. (Ref 4), we simulated success rates for patients with missing primary outcomes in VOM and PVAI arms for VENUS and MARS at 33%, 66%, and 100% information time (looks 1-3).  $B=100,000$  iterations were used with proportions of  $P_m=0, 0.05, 0.10, 0.15,$  and  $0.2$  representing the amount of missing data in both VOM and PVAI arms. At look  $k$ , let the success rate in the VOM arm be  $p_{1k}$  and the success rate in the PVAI arm be  $p_{2k}$ ,  $n_{1k}$  and  $n_{2k}$  the number of patients accrued in the VOM and PVAI arms,  $n_{1k}^m = n_{1k}P_m$  and  $n_{2k}^m = n_{2k}P_m$  the number of patients in VOM and PVAI arms with missing outcome data, and  $n_{1k}^0 = n_{1k} - n_{1k}^m$  and  $n_{2k}^0 = n_{2k} - n_{2k}^m$  the number of patients in VOM and PVAI arms without missing outcomes. Next, for VOM patients with missing outcomes, simulate the number of successes by taking random draws of a binomial variate with parameters  $(n_{1k}^m, p_2)$ , and the number of successes among PVAI patients with missing outcomes as  $B(n_{2k}^m, p_1)$ . Note that the random draws of binomial variates are based on the success rate in the opposing arm, which enforces a high level of conservatism. A test statistic (unpooled variance) at the  $b$ th iteration is

$$Z_k^{(b)} = \frac{\hat{p}_{1k} - \hat{p}_{2k}}{\sqrt{\frac{\hat{p}_{1k}(1 - \hat{p}_{1k})}{n_{1k}} + \frac{\hat{p}_{2k}(1 - \hat{p}_{2k})}{n_{2k}}}}$$

where  $\hat{p}_{1k} = [n_{1k}^0 p_{1k} + B(n_{1k}^m, p_2)]/n_{1k}$  is the unobserved success rate among VOM patients with and without missing data, and  $\hat{p}_{2k} = [n_{2k}^0 p_{2k} + B(n_{2k}^m, p_1)]/n_{2k}$ . The power of the test is equal to the proportion of rejections among the  $B$  iterations, given in the form

$$Power = \frac{\#\{b: Z_k^{(b)} > 1.96\}}{B}$$

The tables below present power as a function of VOM and PVAI success rates, and the proportion of patients with missing data for the VENUS and MARS trials.

<b>VENUS 33%</b> (n1=60,n2=52)		<b>PVAI Success</b>				
<b>VOM Success</b>	<b>Missing</b>	<b>0.28</b>	<b>0.33</b>	<b>0.38</b>	<b>0.43</b>	<b>0.48</b>
<b>0.46</b>	<b>0</b>	1.000	0.000	0.000	0.000	0.000
	<b>0.05</b>	0.778	0.055	0.000	0.000	0.000
	<b>0.1</b>	0.462	0.054	0.002	0.000	0.000
	<b>0.15</b>	0.247	0.051	0.003	0.000	0.000
	<b>0.2</b>	0.197	0.052	0.007	0.001	0.000
<b>0.51</b>	<b>0</b>	1.000	1.000	0.000	0.000	0.000
	<b>0.05</b>	1.000	0.584	0.059	0.000	0.000
	<b>0.1</b>	0.855	0.461	0.045	0.001	0.000
	<b>0.15</b>	0.601	0.213	0.043	0.002	0.000
	<b>0.2</b>	0.445	0.159	0.042	0.008	0.001
<b>0.56</b>	<b>0</b>	1.000	1.000	1.000	0.000	0.000
	<b>0.05</b>	1.000	1.000	0.476	0.060	0.000
	<b>0.1</b>	1.000	0.854	0.459	0.049	0.001
	<b>0.15</b>	0.907	0.514	0.218	0.040	0.003
	<b>0.2</b>	0.709	0.397	0.154	0.045	0.011
<b>0.61</b>	<b>0</b>	1.000	1.000	1.000	1.000	0.000
	<b>0.05</b>	1.000	1.000	1.000	0.477	0.058
	<b>0.1</b>	1.000	1.000	0.860	0.452	0.053
	<b>0.15</b>	0.990	0.879	0.510	0.227	0.034
	<b>0.2</b>	0.901	0.696	0.383	0.146	0.049
<b>0.66</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	0.478
	<b>0.1</b>	1.000	1.000	1.000	0.868	0.434
	<b>0.15</b>	1.000	0.991	0.866	0.513	0.233
	<b>0.2</b>	0.982	0.905	0.682	0.367	0.153
<b>VENUS 66%</b> (n1=120,n2=104)		<b>PVAI Success</b>				
<b>VOM Success</b>	<b>Missing</b>	<b>0.28</b>	<b>0.33</b>	<b>0.38</b>	<b>0.43</b>	<b>0.48</b>
<b>0.46</b>	<b>0</b>	1.000	1.000	0.000	0.000	0.000
	<b>0.05</b>	1.000	0.766	0.008	0.000	0.000
	<b>0.1</b>	0.976	0.473	0.024	0.000	0.000
	<b>0.15</b>	0.777	0.243	0.018	0.000	0.000

	<b>0.2</b>	0.532	0.159	0.020	0.001	0.000
<b>0.51</b>	<b>0</b>	1.000	1.000	1.000	0.000	0.000
	<b>0.05</b>	1.000	1.000	0.770	0.007	0.000
	<b>0.1</b>	1.000	0.976	0.476	0.025	0.000
	<b>0.15</b>	0.981	0.745	0.227	0.019	0.000
	<b>0.2</b>	0.860	0.487	0.148	0.020	0.001
<b>0.56</b>	<b>0</b>	1.000	1.000	1.000	1.000	0.000
	<b>0.05</b>	1.000	1.000	1.000	0.770	0.003
	<b>0.1</b>	1.000	1.000	0.971	0.429	0.022
	<b>0.15</b>	1.000	0.978	0.700	0.214	0.018
	<b>0.2</b>	0.983	0.834	0.468	0.131	0.022
<b>0.61</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	0.768
	<b>0.1</b>	1.000	1.000	1.000	0.969	0.466
	<b>0.15</b>	1.000	1.000	0.978	0.698	0.198
	<b>0.2</b>	1.000	0.981	0.812	0.483	0.129
<b>0.66</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.1</b>	1.000	1.000	1.000	1.000	0.979
	<b>0.15</b>	1.000	1.000	1.000	0.981	0.710
	<b>0.2</b>	1.000	0.999	0.980	0.821	0.479
<b>VENUS 100%</b>						
<b>(n1=180,n2=156)</b>						
<b>VOM Success</b>	<b>Missing</b>	<b>PVAI Success</b>				
<b>0.46</b>	<b>0</b>	<b>0.28</b>	<b>0.33</b>	<b>0.38</b>	<b>0.43</b>	<b>0.48</b>
	<b>0.05</b>	1.000	1.000	0.000	0.000	0.000
	<b>0.1</b>	1.000	0.994	0.086	0.000	0.000
	<b>0.15</b>	1.000	0.811	0.072	0.000	0.000
	<b>0.2</b>	0.979	0.594	0.069	0.001	0.000
<b>0.51</b>	<b>0</b>	0.827	0.363	0.048	0.002	0.000
	<b>0.05</b>	1.000	1.000	1.000	0.000	0.000
	<b>0.1</b>	1.000	1.000	0.993	0.083	0.000
	<b>0.15</b>	1.000	1.000	0.781	0.059	0.000
	<b>0.2</b>	1.000	0.973	0.572	0.061	0.001
<b>0.56</b>	<b>0</b>	0.987	0.808	0.335	0.047	0.002
	<b>0.05</b>	1.000	1.000	1.000	1.000	0.000
	<b>0.1</b>	1.000	1.000	1.000	0.992	0.081
	<b>0.15</b>	1.000	1.000	0.999	0.781	0.057
	<b>0.2</b>	1.000	1.000	0.966	0.540	0.063
<b>0.61</b>	<b>0</b>	1.000	0.984	0.787	0.321	0.048
	<b>0.05</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.1</b>	1.000	1.000	1.000	1.000	0.991
	<b>0.15</b>	1.000	1.000	1.000	0.999	0.795
	<b>0.2</b>	1.000	1.000	1.000	0.966	0.552
	<b>0.2</b>	1.000	1.000	0.983	0.784	0.329

<b>0.66</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.1</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.15</b>	1.000	1.000	1.000	1.000	0.970
	<b>0.2</b>	1.000	1.000	1.000	0.985	0.800
<b>MARS 33% (n1=11,n2=11) VOM Success</b>		<b>PVAI Success</b>				
<b>0.66</b>	<b>Missing</b>	<b>0.32</b>	<b>0.37</b>	<b>0.42</b>	<b>0.47</b>	<b>0.52</b>
<b>0</b>	<b>0</b>	1.000	0.000	0.000	0.000	0.000
<b>0.05</b>	<b>0.05</b>	0.109	0.127	0.000	0.000	0.000
<b>0.1</b>	<b>0.1</b>	0.108	0.126	0.000	0.000	0.000
<b>0.15</b>	<b>0.15</b>	0.107	0.132	0.020	0.026	0.000
<b>0.2</b>	<b>0.2</b>	0.108	0.015	0.021	0.026	0.000
<b>0.71</b>	<b>0</b>	1.000	1.000	0.000	0.000	0.000
<b>0.05</b>	<b>0.05</b>	0.518	0.108	0.124	0.000	0.000
<b>0.1</b>	<b>0.1</b>	0.517	0.108	0.121	0.000	0.000
<b>0.15</b>	<b>0.15</b>	0.357	0.108	0.129	0.018	0.023
<b>0.2</b>	<b>0.2</b>	0.087	0.107	0.015	0.019	0.024
<b>0.76</b>	<b>0</b>	1.000	1.000	1.000	0.000	0.000
<b>0.05</b>	<b>0.05</b>	0.483	0.521	0.420	0.113	0.124
<b>0.1</b>	<b>0.1</b>	0.482	0.522	0.102	0.113	0.000
<b>0.15</b>	<b>0.15</b>	0.314	0.356	0.102	0.121	0.015
<b>0.2</b>	<b>0.2</b>	0.312	0.084	0.103	0.093	0.015
<b>0.81</b>	<b>0</b>	1.000	1.000	1.000	1.000	0.000
<b>0.05</b>	<b>0.05</b>	1.000	1.000	0.530	0.472	0.097
<b>0.1</b>	<b>0.1</b>	1.000	0.489	0.529	0.089	0.098
<b>0.15</b>	<b>0.15</b>	0.554	0.311	0.357	0.094	0.111
<b>0.2</b>	<b>0.2</b>	0.270	0.313	0.194	0.095	0.092
<b>0.86</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
<b>0.05</b>	<b>0.05</b>	1.000	1.000	1.000	0.545	0.588
<b>0.1</b>	<b>0.1</b>	1.000	1.000	0.499	0.544	0.517
<b>0.15</b>	<b>0.15</b>	0.659	0.613	0.309	0.358	0.277
<b>0.2</b>	<b>0.2</b>	0.660	0.265	0.310	0.232	0.080
<b>MARS 66% (n1=22,n2=22) VOM Success</b>		<b>PVAI Success</b>				
<b>0.66</b>	<b>Missing</b>	<b>0.32</b>	<b>0.37</b>	<b>0.42</b>	<b>0.47</b>	<b>0.52</b>
<b>0</b>	<b>0</b>	1.000	1.000	1.000	0.000	0.000
<b>0.05</b>	<b>0.05</b>	1.000	0.584	0.141	0.000	0.000
<b>0.1</b>	<b>0.1</b>	0.799	0.445	0.154	0.026	0.000
<b>0.15</b>	<b>0.15</b>	0.643	0.363	0.152	0.042	0.006
<b>0.2</b>	<b>0.2</b>	0.252	0.112	0.050	0.052	0.012
<b>0.71</b>	<b>0</b>	1.000	1.000	1.000	1.000	0.000
<b>0.05</b>	<b>0.05</b>	1.000	1.000	0.588	0.134	0.000
<b>0.1</b>	<b>0.1</b>	1.000	0.799	0.448	0.151	0.023

	<b>0.15</b>	0.887	0.642	0.362	0.147	0.038
	<b>0.2</b>	0.461	0.251	0.119	0.114	0.046
<b>0.76</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	0.603	0.128
	<b>0.1</b>	1.000	1.000	0.805	0.447	0.141
	<b>0.15</b>	0.859	0.890	0.647	0.359	0.140
	<b>0.2</b>	0.702	0.459	0.248	0.120	0.116
<b>0.81</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.1</b>	1.000	1.000	1.000	0.815	0.449
	<b>0.15</b>	1.000	0.868	0.897	0.655	0.359
	<b>0.2</b>	0.908	0.710	0.464	0.336	0.235
<b>0.86</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.1</b>	1.000	1.000	1.000	1.000	0.830
	<b>0.15</b>	1.000	1.000	1.000	0.906	0.667
	<b>0.2</b>	1.000	0.914	0.718	0.465	0.380
<b>MARS 100%</b> <b>(n1=33,n2=33)</b> <b>VOM Success</b>	<b>Missing</b>	<b>PVAI Success</b>				
<b>0.66</b>	<b>0</b>	<b>0.32</b>	<b>0.37</b>	<b>0.42</b>	<b>0.47</b>	<b>0.52</b>
	<b>0.05</b>	1.000	1.000	1.000	0.000	0.000
	<b>0.1</b>	1.000	1.000	0.703	0.181	0.000
	<b>0.15</b>	1.000	0.928	0.414	0.183	0.005
	<b>0.2</b>	0.742	0.501	0.319	0.056	0.019
	<b>0</b>	0.515	0.371	0.115	0.061	0.028
<b>0.71</b>	<b>0</b>	1.000	1.000	1.000	1.000	0.000
	<b>0.05</b>	1.000	1.000	1.000	0.859	0.177
	<b>0.1</b>	1.000	1.000	0.931	0.414	0.179
	<b>0.15</b>	0.973	0.863	0.499	0.316	0.118
	<b>0.2</b>	0.661	0.513	0.372	0.126	0.056
<b>0.76</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	0.867
	<b>0.1</b>	1.000	1.000	1.000	0.934	0.414
	<b>0.15</b>	1.000	0.975	0.896	0.502	0.315
	<b>0.2</b>	0.934	0.660	0.517	0.372	0.231
<b>0.81</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.1</b>	1.000	1.000	1.000	1.000	0.941
	<b>0.15</b>	1.000	1.000	0.977	0.903	0.619
	<b>0.2</b>	0.984	0.939	0.734	0.516	0.369
<b>0.86</b>	<b>0</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.05</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.1</b>	1.000	1.000	1.000	1.000	1.000
	<b>0.15</b>	1.000	1.000	1.000	0.981	0.913

0.2      1.000   0.986   0.944   0.852   0.619

### 3. STATISTICAL ANALYSIS OVERVIEW

#### 3.1 Primary and Secondary Analyses

The data analytic components are divided into primary and secondary analysis. The main objectives of these analyses are summarized as follows:

Analysis	Outcomes assessed	Analysis/Subjects	Timing
Primary	Primary, SAEs	Intention to Treat with varying levels of missingness	Performed during interim efficacy analysis (DSMB reviews)
Secondary	Primary, SAEs	Complete records analysis (“per-protocol”)	Performed during post-study analysis phase
		Sensitivity analysis (effects of outliers, subject clustering, covariates)	Performed during post-study analysis phase
	Secondary, AEs	Complete records analysis	Performed during post-study analysis phase

A brief summary of the types of analysis to be performed is provided below.

**Intention to Treat analysis (ITT).** The primary analysis will be Intent to Treat (ITT) analysis, which will be based on a Z-score based test of two proportions ( $p_{bar}$ ) with varying levels of missingness. ITT analysis will be performed during interim efficacy monitoring at each “look,” and will be reported to the DSMB prior to and during review meetings.

**Complete Records Analysis (CRA).** Analysis involving only subjects with complete data and use of the actual treatment received, i.e., “per protocol.” CRA analysis will be performed during the post-study phase.

**Sensitivity Analysis (SA).** Involves a determination of robustness of results using various analytic methods, models, or assumptions, with an aim to develop results which are dependent on questionable or unsupported assumptions. SA will be performed during the post-study phase.



## 3.2 Analysis populations

### 3.2.1 Enrolled Population

The enrolled population will include all subjects who meet the study's inclusion and exclusion criteria and sign their informed consent.

### 3.2.2 Analysis Population

The analysis population will include all subjects of the enrolled population, including all consented and randomized subjects, and subjects for whom at least safety (AE, SAE) and secondary/primary outcome results are available.

## 3.3 General Analysis and Reporting Conventions

The following is a list of general analysis and reporting conventions to be applied for this study. These are general guidelines and reporting conventions may deviate from this guideline for publication and presentation purposes.

- Categorical variables will be summarized using counts (n) and percentage (%) and will be presented in the form n (%).
- Mean, bias, standard deviation, and precision will be reported at 1 more significant digit than the precision of the data.
- Order statistics including median, min and max will be reported to the same level of precision as the original observations. If any values are calculated to have more significant digits than the value should be rounded so that it is the same level of precision as the original data.
- The median will be reported as the average of the two middle numbers if the dataset contains even numbers.
- P-values will be reported to 3 decimal places if greater than 0.001. If less than 0.001 then report '<0.001'. Report p-values and significant levels as 0.05 rather than .05.
- No preliminary rounding should be performed; rounding should only occur after analysis. To round, consider digit to right of last significant digit: if < 5 then round down, if >=5 then round up.

## 4. PRIMARY ANALYSIS FOR EFFICACY

### 4.1 Primary Outcome for Interim Efficacy Monitoring

The primary outcome for interim efficacy monitoring will be **success from treatment**. Treatment success is defined as not experiencing any of the following failures within 12 months of follow-up.

1. **Effectiveness failure:** Can be determined by the PI any time after the “washout” period 3-months after initial treatment. This is typically confirmed by presenting signs and symptoms of AF/Flutter confirmed via 12-lead EKG during a patient visit to the ED, in-patient admission, or scheduled follow-up office visit.
2. **Clinical failure at 6 or 12 months:** Having >30 sec of AF/Flutter during the 30-day continuous ECG monitoring at 6 months or 12 months of follow-up time. Subjects with a successful 12-month continuous ECG result with a missing 6-month ECG are assumed to be a success.
3. **Early exit or withdrawal of consent:** Exiting the study or withdrawing consent for any reason will be considered a failure.
4. **Death:** Any death of a subject is considered a failure.

The table below lists the primary endpoints which will be employed during interim efficacy analysis and reported prior to all DSMB review meetings:

<b>Primary Endpoints</b>	<b>EDC Pages</b>	<b>Data Fields</b>
<b>Effectiveness failure:</b> Early exit, withdrawn consent, death (any of the codes in far right column denote failure)	Statuschange Table	<b>Exitreason</b> (failure codes are below) 2-Patient Withdrew Consent 3-Patient was unable to complete the ablation procedure as randomized 4-Patient was considered an “ <b>effectiveness failure</b> ” (unable to remain symptom free for protocol period) 5-Patient expired 6-Subject had other priority medical issue requiring that they stop participation 7-Investigator decision 8-Other 9-Screen Failure 10-Subject lost to follow up
<b>Clinical failure:</b> Freedom from AF/flutter >30 sec during one-month continual ECG at 6 and 12 month follow-up periods	ContinuousECG Table	<b>AtrialFibrillationGreaterThan30Sec</b> (1-Yes, 2-No)
<b>Safety:</b> <ul style="list-style-type: none"> <li>• Acute procedural complications</li> <li>• Incidence of AEs</li> <li>• Severity of AEs</li> <li>• Death</li> </ul>	SevenDayPhoneFollowUp AdverseEvents AdverseEvents AdverseEvents StatusChange	<b>PostProcedureHospitalizationOrSAE</b> (1-Yes,2-No) <b>AdverseEventCategory, AdverseEventType, AdverseEventGrade</b>  <b>ExitReason</b> (code=5 for death)

**Definition of Success (Primary Outcome).** Efficacy in this clinical trial is based on treatment success. During interim analysis, there will be several components of success determined from the combination of ECG results at 6 and 12 months, and lack of failing due to early exit, withdrawal, or death. Overall success is defined as demonstrating success during the 6 and 12 month continuous ECGs by not exhibiting AF or flutter > 30 seconds, and not failing due to effectiveness

failure, exiting the study early, withdrawing consent, or death. Four success variables will be used during each interim analysis, which are described in the table below.

<b>Success component</b>	<b>Variable name</b>
Success at the 6m continuous ECG	success6m (1-Yes, 0-No)
Success at the 12m continuous ECG	success12m (1-Yes, 0-No)
Success from not exiting early, withdrawing consent, death, etc.	success6m12meff (1-Yes, 0-No)
Overall success (“primary outcome”) based on product of above 3 success components. Example: 1*0*1=0, 1*1*1=1)	success6m12meff (1-Yes, 0-No)

Any failure caused by having AF/flutter > 30 seconds at the 6 month or 12 month ECG, or early exit or death constitutes an overall failure, leading to no overall success.

#### 4.2 VENUS Interim Efficacy Analysis

For VENUS, we propose to monitor efficacy at two interim time points and one final time period (i.e., three “looks”) when primary outcome data (12 month follow-up) are available for 1/3, 2/3 and 3/3 of the total sample size of VENUS subjects. For the VENUS trial, these values are provide in the following table in terms of information time:

**Table 6. Efficacy monitoring schedule for VENUS with cumulative sample size, significance boundaries and 95%CIs, and alpha- and beta-spending.**

<i>Accumulated primary outcomes for VENUS</i>						
<b>Look</b>	<b>Accumulated Information</b>		<b>----- Accumulated Sample Size -----</b>			
	<b>Percent</b>	<b>VOM</b>	<b>PVAI</b>	<b>Total</b>		
1	33.33	60	52	112		
2	66.67	120	104	224		
3	100.00	180	156	336		


<i>Significance Boundaries with 95% Simulation Confidence Intervals</i>						
<b>Look</b>	<b>----- Z-Value Boundary -----</b>			<b>----- P-Value Boundary -----</b>		
	<b>Value</b>	<b>95% LCL</b>	<b>95% UCL</b>	<b>Value</b>	<b>95% LCL</b>	<b>95% UCL</b>
1	+/- 3.953	3.809	4.289	0.000	0.000	0.000
2	+/- 2.543	2.516	2.578	0.011	0.010	0.012
3	+/- 2.011	1.994	2.036	0.044	0.042	0.046

Look	----- Target -----		----- Actual -----		----- Proportion	Cum.	H1 Sims Outside Signif. Boundary	H1 Sims Outside Signif. Boundary
	--- Signif. Z-Value Scale	Boundary--- P-Value Scale	Spending Function Alpha	Spending Function Alpha	Alpha Spent	Cum. Alpha Spent		
1	+/- 3.953	0.000	0.000	0.000	0.000	0.000	0.033	0.033
2	+/- 2.543	0.011	0.012	0.012	0.011	0.012	0.547	0.579
3	+/- 2.011	0.044	0.038	0.050	0.038	0.049	0.329	0.909

The hypothesis test applied at the  $k$ th look is a two-tailed test of equality of two independent proportions, functionally composed as

$$Z_k = \frac{\hat{p}_{1k} - \hat{p}_{2k}}{\sqrt{\frac{\hat{p}_{1k}(1 - \hat{p}_{1k})}{n_{1k}} + \frac{\hat{p}_{2k}(1 - \hat{p}_{2k})}{n_{2k}}}}$$

where  $\hat{p}_{1k}$  is the proportion of successful primary outcomes in the PVAI-VOM arm of VENUS at the  $k$ th look, and  $\hat{p}_{2k}$  is the proportion of successful primary outcomes within the PVAI arm of VENUS at the  $k$ th look.  $Z_k$  follows a standard normal distribution,  $N(0,1)$ . If during the first look when at least  $N=60$  VOM and  $N=52$  PVAI primary outcomes have been observed ( $N=112$  total), if  $Z_1$  exceeds 3.953, then the trial will be evaluated for early termination due to beneficial efficacy, whereas if the power is 30% or less, the trial will be evaluated for early termination for futility. However, if the power of the test falls in the “promising zone” (30-70%), we will consider re-determination of sample size for successfully completing the trial in order to reject the null hypothesis with power  $1-\beta$ . The same rule applies for the 2<sup>nd</sup> look when at least  $N=120$  VOM and 104 PVAI primary outcomes (224 total) have been observed in both arms, for which the tabled critical value of  $Z_2$  is  $\pm 2.543$ . The overall efficacy of the trial will be determined when at least  $N=180$  VOM and  $N=156$  (336 total) primary outcomes have been observed, for which the critical value of  $Z_3$  is  $\pm 2.011$ .



**Figure 1. Efficacy boundaries at 33%, 66%, and 100% accrual of VENUS primary outcomes.**

**4.3 MARS Interim Efficacy Monitoring**

For MARS, we also propose to monitor efficacy at two interim time points and one final time period (i.e., three “looks”) when primary outcome data (12-15 month follow-up) are available for 1/3, 2/3 and 3/3 of the total sample size of MARS subjects. For the MARS trial, these values are provide in the following table in terms of *information time*:

**Table 8. Efficacy monitoring schedule for MARS with cumulative sample size, significance boundaries and 95% CIs, and alpha- and beta-spending.**

<i>Accumulated primary outcomes for MARS</i>						
Look	Accumulated Information		----- Accumulated Sample Size -----			
	Percent		Group 1	Group 2	Total	
1	33.33		11	11	22	
2	66.67		22	22	44	
3	100.00		33	33	66	


  

<i>Significance Boundaries with 95% Simulation Confidence Intervals for Scenario 1</i>						
Look	----- Z-Value Boundary -----			----- P-Value Boundary -----		
	Value	95% LCL	95% UCL	Value	95% LCL	95% UCL
1	+/- 5.014	5.014	6.675	0.000	0.000	0.000
2	+/- 2.708	2.640	2.708	0.007	0.007	0.008
3	+/- 2.055	2.055	2.080	0.040	0.037	0.040

<i>Alpha-Spending</i>						
--- Signif. Boundary ---	----- Target -----	----- Actual -----	----- Proportion -----	Cum.	H1 Sims	H1 Sim
	Spending	Cum. Spending		Cum.	Outside	Outsid

Look	Z-Value Scale	P-Value Scale	Function Alpha	Function Alpha	Alpha Spent	Alpha Spent	Signif. Boundary	Signi Boundar
1	+/- 5.014	0.000	0.000	0.000	0.000	0.000	0.017	0.01
2	+/- 2.708	0.007	0.012	0.012	0.010	0.011	0.404	0.42
3	+/- 2.055	0.040	0.038	0.050	0.038	0.049	0.388	0.81



**Figure 2. Efficacy boundaries at 33%, 66%, and 100% accrual of MARS primary outcomes.**

#### 4.4 Intention to Treat Analysis (ITT)

The primary analysis will include interim efficacy analysis (IA) for both VENUS and MARS immediately prior to each DSMB meeting, after recent follow-up data have been locked and disseminated by the EDC. The primary analysis will be based on **Intention to Treat** analysis, with varying levels of missingness. Naturally, this will entail incorporation of varying levels of missing outcomes for subjects who exited early or withdrew consent, and who are missing primary outcome measurements, i.e., the 6- and/or 12-month continuous ECG results. The primary analysis will not include sensitivity analysis.

**Hypothesis test for efficacy.** Once the success components for efficacy are determined for all subjects, hypothesis tests for the equality of two proportions (pooled standard errors) will be employed for determining whether or not the success rate in blinded groups A and B are significantly different. The test statistic is a Z-score, which is standard normal distributed. Relevant lookup critical values (percentage points) are listed in the interim analysis section for group sequential designs. Specific test procedures are listed in the following sections.



**Withdrawn subjects.** The ITT primary analysis which will occur during interim efficacy monitoring will include withdrawn subjects, who lack primary outcome data (6 month and 12 month continuous ECG measurement results). Accordingly, these patients will predominantly serve as the bulk of subjects having missing primary outcome. Patients who die before the 12-month study end will also be considered not to have a response to treatment.

**Missing continuous ECG results.** The critical piece of data required for endpoint analysis is the electrocardiographic event monitor. Failure to comply with wearing the monitor will lead to missing data. We request patients to wear monitors for 1-month. However, only a minimum of 1-week of monitored time is required for Endpoint assessment. Patients with less than 1-week of monitoring will be considered as missing primary outcome data.

**Resampling analysis.** The ITT analysis will be carried out using iterative resampling methods. Let  $B=500$  represent the number of iterations,  $U(0,1)$  a random uniform variate, and  $\pi=0.1, 0.2, 0.4, 0.6, 0.8, 0.9, 1$  represent the average sampling fraction of records with missing data. The algorithm **RESAMPZ** below describes a resampling approach for determining a range of Z-scores for the test of two proportions as a function of levels of missingness.

#### **Algorithm RESAMPZ for Varying Levels of Missingness**

1. Set the sampling fraction to  $\pi=0.1$ .
2. Set  $ran=0$  for all records with complete outcomes (success and failure records).
3. For each record with missing outcomes, draw a random uniform variate,  $ran=U(0,1)$ .
4. Perform a test of two proportions for treatment groups A and B using all records for which  $ran \leq \pi$ . (in this fashion, on average, the fraction  $\pi$  of records with missing will be used for the test).
5. Repeat steps 3 and 4  $B=500$  times, storing the Z-score for each  $b$ th test of proportions.
6. Repeats steps 1 to 5 using values of  $\pi=0.2, 0.4, 0.6, 0.8, 0.9, 1$ .

Next, for each value of  $\pi=0.1, 0.2, 0.4, 0.6, 0.8, 0.9, 1$ , sort the  $B$  Z-scores in ascending order, and plot as a series versus indices 1-500. The final X-Y scatter plot will have 7 series, one series for each value of  $\pi$ . The seven series of Z-scores should

converge together near one value on the x-axis value of  $Z$ , termed  $Z^*$ , which is used as the test statistic.

The maximum likelihood-based  $Z$ -score from running a test of two proportions on complete (only) data should be plotted as a reference point.

**Decision rule.** Compare the resampling-based  $Z^*$  obtained from the RESAMPZ algorithm described above with the efficacy boundaries for VENUS and MARS in Figures 1 and 2, and make a recommendation to the DSMB on what has been observed for the specific look being considered.

## 5. SECONDARY ANALYSES FOR EFFICACY

### 5.1 Sensitivity Analysis of Primary Outcome

Sensitivity analysis for the primary outcome will be performed using complete records to assess the effect of outliers, within-subject clustering and correlation, baseline imbalances, distributional assumptions (parametric, non-parametric), and non-compliance/protocol violations on the primary outcome. Results of sensitivity analyses will only be used for assessing the robustness of the primary analysis, and not to modify conclusions of the study.

#### 5.1.1 Non-Compliance or Protocol Deviations

Protocol deviations are common in clinical trials, so it is imperative to assess the robustness of results to protocol deviations. A **per-protocol** (PP) analysis of primary outcomes will be performed by excluding subjects with protocol deviations. After the PP analysis, we will perform an **as-treated** (AT) analysis in which subjects are analyzed according to the treatment they actually received.

#### 5.1.2 Missing Data

Missing data can bias the results of an RCT by reducing validity and efficiency. During the statistical data analysis, the presence of missing data requires an assumption about the probability of missing data and the underlying values of the variables involved in the analysis. There are three broad mechanisms associated with the cause of missing data:

**Missing completely at random (MCAR).** Data are missing completely at random (MCAR) if the probability of missingness is independent of the observed and unobserved data. Generally speaking, MCAR is often viewed as a very restrictive assumption which is unlikely to hold in many investigations.

**Missing at random (MAR).** It is commonly more plausible for missing data to be missing at random (MAR), where the probability of missingness is dependent on

the observed data. This also implies that the probability of missing data is not dependent on unobserved data as well.

**Missing not at random (MNAR).** If the data are missing not at random (MNAR), then the probability of missing data is dependent on both the observed and unobserved data.

In RCTs, another common plausible assumption is that missing outcomes depend on baseline covariates, but not on the outcomes. This is called covariate dependent missingness which falls under MAR when baseline covariates are fully observed. For this investigation, we will assume that the binary success outcomes are partially observed, and assume that all baseline covariates are fully observed.

### 5.1.3 Missing Imputation

For patients with missing primary outcomes, we will perform multiple imputation (MI) based on Monte Carlo Markov chain (MCMC) methods (Refs 1-3). In Stata, MI is available for many procedures, especially the regression modules (linear, logistic, Poisson, Cox PH). MI can be performed to iteratively impute central estimates of missing outcome measures based on subjects' covariate patterns. The most straightforward example can be envisioned in this study, where logistic regression with MI is employed to train a model based on primary outcome (0-failure, 1-success) as the dependent variable and age, gender, baseline AF duration, and baseline LA volume as independent predictors to impute  $P(y=1|\mathbf{x})$  for subjects with missing primary outcome.

### 5.1.4 Baseline Imbalance (Model Building Strategies)

Although randomization helps to minimize confounder influences of results, there nevertheless can be imbalances in baseline covariates or confounders across treatment arms. We will therefore identify covariate heterogeneity over arms and include significant variables in univariate and multiple logistic models of success (0,1) to generate crude and adjusted odds ratios (OR, aOR) and 95% confidence intervals (CI) of the A-group treatment effect. Univariate logistic models of success whose p-values are less than 0.25 will be included in the multivariable model. Regression diagnostics to determine overly influential observations (outliers) and goodness-of-fit (Hosmer-Lemeshow, Pearson) will also be assessed for each multivariable model.

### 5.1.5 Center Imbalance (Random Effects Modeling)

It is possible for confounder patterns to exist which vary over the centers which enroll patients. To identify whether this imbalance over centers is present, baseline covariate values will be compared across centers, and a random effects term for centers will be employed in model building strategies.

### **5.1.1 Use of Propensity Scores in Multivariate Models**

An ideal goal for observational etiological studies is to allocate randomly subjects into different treatment groups in order to guarantee on average that there are no systematic differences in covariates between groups.(1) After randomization, there is nevertheless a possibility for observing large differences in confounders which may lead to bias in results. The propensity score provides a scalar summary of covariate information and is defined as the propensity (probability) that a subject's covariate profile represents subjects truly assigned to a given treatment group. Propensity scores based on significantly different confounder variables can be used to create a quasi-randomized experiment with adjustment to the treatment effect. We will assess the role of propensity scores in prediction models in order to reduce the effects of baseline factors that may be significantly different among subjects in different treatment groups. Firstly, we will identify baseline covariates which are significantly different across treatment groups (using t-tests with skew-zero transformed covariates or Mann-Whitney tests). Significant covariates will be incorporated into a logistic regression model ( $y=0$  PVAI, 1-VOM-PV) to generate subject-specific logits, which are normally-distributed.(2, 3) Treatment-subject-specific logits will then be used for matching subjects across the treatment groups in order to construct a sample of subjects with balanced covariates. We suspect that propensity matching will not be required to tackle the problem of extreme confounder differences, but will nevertheless evaluate the effect of propensity matching prior to logistic regression to determine treatment effect possibly adjusted for age.

### **5.1.1 Cluster Discovery**

The cluster structure of the baseline data will be evaluated using a variety of unsupervised methods (K-means, self-organizing maps, neural gas, random forests, hierarchical cluster analysis, Gaussian mixture models, etc.) as well as non-linear manifold learning methods (local linear embedding, Laplacian eigenmaps, locality preserving projections, etc.), as well as linear methods (PCA). Cluster validity analysis using cross-validation will be employed to determine the optimal number of clusters. Potential clusters of patients will be partitioned to determine the effect of clustering on primary outcomes. Complete record analysis will only be performed.

## **5.2 Secondary Outcomes**

The secondary analysis will include comparisons of secondary outcomes between treatment arms (VOM, PVAI) for VENUS and MARS. Regarding the schedule of events, it is typically not possible to perform all secondary analyses prior to a DSMB meeting, mostly because of the lack of adequate time when preparing for a DSMB meeting.

The secondary outcomes are listed below along with their corresponding storage location (various tables or Excel .csv files on output after report generation). Model building strategies (MBS) will be employed using univariate and multivariable regression models for post-hoc analyses of secondary outcomes. During MBS, univariate predictors whose  $p < 0.25$  will be selected as multiple variable model candidates. MBS regression methods may include linear, logistic, Poisson, and Cox proportional hazards (PH) along with regression diagnostics using the relevant goodness-of-fit criteria, residuals, variance inflation factors (VIF), ROC-AUC, and assumption-checking techniques (e.g. normally-distributed standardized residuals for linear regression). Regression diagnostics for linear regression will include estimation and filtering of overly influential records based on residuals, standardized, residuals, deletion residuals, Cook's distance, leverage, DFFITS, DFBETAS, and VIFs. Regression diagnostics for logistic and Poisson regression will include filtering on Pearson, deviance, and leverage residuals and the Hosmer-Lemeshow test for logistic regression GOF. Cox PH regression diagnostics will include Schoenfeld and Nelson-Aalen residuals, and possible employment of stratified models when the PH assumption fails.

The table below lists the secondary endpoints which are to be analyzed during the post-study phase:

<b>Secondary Endpoints:</b>		
1. Single vs. 2-procedure success.	<ul style="list-style-type: none"> <li>Status change page</li> </ul>	<ul style="list-style-type: none"> <li>Single: reached primary endpoint #1 after first procedure with no repeats</li> <li>Two procedure: reached primary endpoint #1 after second procedure with no 3<sup>rd</sup> procedure</li> </ul>
2. AF burden (% time) on continuous monitoring at 12 months.	<ul style="list-style-type: none"> <li>12 month continuous ECG page</li> </ul>	<ul style="list-style-type: none"> <li>12 month AF/Flutter (Total Time) Burden on continuous ECG monitoring</li> </ul>
3. Procedural parameters: total procedure, fluoroscopy, total RF ablation time (first procedure), and total extent of ablated LA tissue.	<ul style="list-style-type: none"> <li>PVAI Page</li> <li>VOM page</li> </ul>	<ul style="list-style-type: none"> <li>Total procedure time, PVAI only</li> <li>Total procedure time, VOM procedure</li> <li>Total fluoro time</li> <li>Scar measurements pre and post PVAI and VOM</li> </ul>
4. Clinical success:	<ul style="list-style-type: none"> <li>12 month continuous</li> </ul>	<ul style="list-style-type: none"> <li>12 month AF/Flutter</li> </ul>

freedom from ECG symptomatic AF/flutter but AF/flutter > 30 sec/day < than 1% at 12 months.	ECG page	Burden <b>greater than one minute/day but less than 1%</b> on continuous ECG monitoring
5 Sub-acute procedural complications (within 30 days).	<ul style="list-style-type: none"> <li>• Symptoms page</li> <li>• AE page</li> </ul>	Day 30 reported, procedure related complications via symptoms and/or AEs
6 Recurrence as persistent or paroxysmal AF, or flutter after 1 or 2 procedures.	<ul style="list-style-type: none"> <li>• 12 lead ECG page</li> <li>• Evaluation for repeat procedure page</li> <li>• AE page</li> </ul>	<ul style="list-style-type: none"> <li>• Type of recurrence (rhythm)</li> <li>• Characterization of recurrence e.g. persistent or paroxysmal for a fib; typical or atypical for a flutter.</li> </ul>
7. LA function on Doppler echocardiography (LA strain <sup>114ab</sup> ) at 12.	Central echocardiogram page	LA Strain
8. Incidence and mechanisms of atrial flutters.	<ul style="list-style-type: none"> <li>• 12 lead ECG page</li> <li>• AE page</li> <li>• Evaluation for repeat procedure page</li> </ul>	<ul style="list-style-type: none"> <li>• Date of occurrence</li> <li>• Type of flutter (typical vs atypical)</li> </ul>
9. Cardiovascular hospitalizations and QOL.	<ul style="list-style-type: none"> <li>• Hospitalizations</li> <li>• SAEs</li> <li>• QOL</li> </ul>	<ul style="list-style-type: none"> <li>• Total # of CV related hospitalizations</li> <li>• QOL score</li> </ul>

### 5.2.1 Demographic and Other Baseline Characteristics

The demographic variables of the analysis population include age, gender, ethnicity, race, level of education, etc. Baseline characteristics include demographic variables, cardiovascular history, medications, AF duration, LA volume, etc. Continuously-scaled baseline characteristics will be summarized by treatment arm using the number of observations, mean, standard deviation, mode, median, minimum, maximum, range, 10<sup>th</sup> and 90<sup>th</sup> percentiles, quartiles, skewness, and kurtosis. Frequencies by treatment arm will be reported for ordinal and nominal variables. Ordinal variables will also be summarized using mode, median, minimum, maximum, 10<sup>th</sup> and 90<sup>th</sup> percentiles, quartiles by treatment arm. P-values for hypothesis tests for inequality will be reported using t-tests for continuous outcomes, Wilcoxon-rank sum tests for ordinal outcomes, and chi-square tests with continuity corrections for the nominal outcomes. These p-values will be considered of an exploratory nature and no corrections will be made for multiple comparisons.



In addition, baseline characteristics will be summarized for those subjects of the enrolled population who lack follow-up data. If data are sufficiently rich, we will investigate patterns of data availability by exploring the association between the frequency of non-missing demographic, baseline, and follow-up data.

## 5.2.2 Tests of Association and Dependency for Secondary Outcomes

Continuously-scaled cross-sectional baseline data will be evaluated for association using Pearson and Spearman rank correlation tests. We will also use multiple linear regression to identify predictors of various secondary outcomes such as fluoroscopy times, scarring, and signal-processing characteristics of continuous ECG data.

(Note: from a post-hoc perspective, we may use the stratified Mantel-Haenszel odds ratio test of proportions if we learn that success rates track with a particular covariate, such as LA volume or AF *duration*, and the strata weights are not highly imbalanced).

## 5.2.1 Time-To-Event Analysis of Loss-of-Rhythm and QOL data

*Repeated measures ANOVA* will also be employed to determine significant within-group (W) and between-group differences in QOL data and other secondary outcomes, as well as the B\*W interaction for a change in response across treatment. We will also employ GEE and/or mixed model regression to adjust for within-subject covariance of QOL data (secondary outcomes) to identify a significant time\*treatment interaction.

## 6. SAFETY EVALUATION AND ANALYSIS

The procedures for catheter ablation study for AF may expose subjects to greater than minimal risks. Patient risks in this trial include:

- Additional catheter placement for injecting alcohol into the vein of Marshall.
- Dissection or tearing of the vein of Marshall during alcohol injection.
- Pericarditis from alcohol injection in the vein of Marshall.
- Atrioesophageal fistula.

Safety monitoring in this trial adopts the NCI Common Terminology Criteria for Adverse Events (CTCAE, V4.0, 2010), which is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term.

**System Organ Class (SOC).** System Organ Class, the highest level of the MedDRA hierarchy, is identified by anatomical or physiological system, etiology, or purpose (e.g., SOC Investigations for laboratory test results). CTCAE terms are grouped by MedDRA Primary SOCs. Within each SOC, AEs are listed and accompanied by descriptions of severity (Grade).

**CTCAE Terms.** An Adverse Event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may *not* be considered related to the medical treatment or procedure. An AE is a term that is a unique

representation of a specific event used for medical documentation and scientific analyses. Each CTCAE v4.0 term is a MedDRA LLT (Lowest Level Term).

**Grades.** Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline:

<b>Grade of AE</b>	<b>Description</b>
Grade 1 – Mild	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 - Moderate	Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL)*.
Grade 3 - Severe	Medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL**.
Grade 4 – Life Threatening	Urgent intervention indicated.
Grade 5 - Death	Related to AE

\*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.

\*\*Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.

**Incidence of AEs.** Incidence reports of AEs will be generated for each DSMB meeting. Reports will arrange AEs by SOC and treatment arm. Tests of inequality of incidence rates will be performed between arms for each SOC, and p-values will be reported in the tables.

**Severity of AEs.** Severity of AEs will also be reported by SOC and treatment arm.

**Death.** A death report will also be generated for each DSMB meeting, and significance (P-value) for a test of equality of the death rates will be provided.

### 6.1 Risk-Benefit Analysis

A risk-benefit analysis will be performed by partitioning all subjects into quartiles of the CHAD2VASC score, and running Poisson regression of the SAE and failure rates and person-time (time-to-fail, time-to-SAE) for each arm (A,B) within each quartile. The result of each Poisson regression model is the number of expected failures or SAEs.

The table below lists the predicted number of failures and SAEs in each CHAD2VASC score for the VOM trial subjects (VENUS or MARS):

<b>Outcome</b>	<b>Arm</b>	<b>Quartile 1</b>	<b>Quartile 2</b>	<b>Quartile 3</b>	<b>Quartile 4</b>
SAEs	Trt A	$\hat{d}_{SAE,A,1}$	$\hat{d}_{SAE,A,2}$	$\hat{d}_{SAE,A,3}$	$\hat{d}_{SAE,A,4}$
	Trt B	$\hat{d}_{SAE,B,1}$	$\hat{d}_{SAE,B,2}$	$\hat{d}_{SAE,B,3}$	$\hat{d}_{SAE,B,4}$
Failures	Trt A	$\hat{d}_{Fail,A,1}$	$\hat{d}_{Fail,A,2}$	$\hat{d}_{Fail,A,3}$	$\hat{d}_{Fail,A,4}$

	Trt B	$\hat{d}_{Fail,B,1}$	$\hat{d}_{Fail,B,2}$	$\hat{d}_{Fail,B,3}$	$\hat{d}_{Fail,B,4}$
--	-------	----------------------	----------------------	----------------------	----------------------

Within each quartile, we will first determine the risk-benefit ratio

$$\frac{\Delta_{Fail,1}}{\Delta_{SAE,1}} = \frac{|\hat{d}_{Fail,A,1} - \hat{d}_{Fail,B,1}|}{|\hat{d}_{SAE,A,1} - \hat{d}_{SAE,B,1}|}$$

If there is a risk-benefit from treatment, the ratio  $\Delta_{Fail} / \Delta_{SAE}$  should be less than 1 in quartiles 1 and 2, and greater than 1 in quartiles 3 and 4. This is because, for an effective treatment, the difference in predicted failure events (successes) between arms should increase with baseline risk, while the difference in predicted SAEs between arms should decrease.

## 7. REFERENCES

1. Raghunathan, T. E., J. M. Lepkowski, J. Van Hoewyk, and P. Solenberger. 2001. A multivariate technique for multiply imputing missing values using a sequence of regression models. *Survey Methodology* 27: 85–95.
2. Rubin, D. B. 1987. *Multiple Imputation for Nonresponse in Surveys*. New York: Wiley.
3. van Buuren, S. 2007. Multiple imputation of discrete and continuous data by fully conditional specification. *Statistical Methods in Medical Research* 16: 219–242.
4. Proschan, MA, McMahon, RP, Shih, JH, Hunsberger, SA, Geller, NL, Knatterud, G, Wittes, J. 2001. Sensitivity analysis using an imputation method for missing binary data in clinical trials. *J. Statistical Planning and Inference*. 96: 155-165.

## **SUMMARY OF STATISTICAL PLAN MODIFICATIONS**

**Change in primary endpoint.** Since the primary endpoint became single-procedure success, and not success after up to 2 procedures, new sample-size calculations were required, based on pilot data on single-procedure success.

**More detailed description of stopping rules.**

**More detailed description of plans to handle missing data.**